{"protocolSection":{"identificationModule":{"nctId":"NCT04816643","orgStudyIdInfo":{"id":"C4591007"},"secondaryIdInfos":[{"id":"2020-005442-42","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"BioNTech SE","class":"INDUSTRY"},"briefTitle":"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children","officialTitle":"A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN"},"statusModule":{"statusVerifiedDate":"2026-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-03-24","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-10-04","type":"ACTUAL"},"completionDateStruct":{"date":"2023-12-08","type":"ACTUAL"},"studyFirstSubmitDate":"2021-03-19","studyFirstSubmitQcDate":"2021-03-24","studyFirstPostDateStruct":{"date":"2021-03-25","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-10-02","resultsFirstSubmitQcDate":"2026-05-26","resultsFirstPostDateStruct":{"date":"2026-05-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-05-26","lastUpdatePostDateStruct":{"date":"2026-05-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"BioNTech SE","class":"INDUSTRY"},"collaborators":[{"name":"Pfizer","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase 1/2/3 study in healthy children.\n\nDependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants \\<6 months of age may subsequently be evaluated.","detailedDescription":"Phase 1 Dose-Finding\n\nIs the open-label dose-finding portion of the study that will evaluate safety, tolerability, and immunogenicity of BNT162b2 administered on a 2-dose (separated by approximately 21 days) schedule in up to 3 age groups (participants ≥5 to \\<12 years, ≥2 to \\<5 years, and ≥6 months to \\<2 years of age).\n\nDose finding is being initiated in this study in participants ≥5 to \\<12 years of age based on the acceptable blinded safety assessment of the 30-µg dose in 12- to 15-year-olds in the C4591001 study.\n\nThe purpose of Phase 1 is to identify preferred dose level(s) of BNT162b2 from up to 3 different dose levels in each age group.\n\nDependent upon safety and/or immunogenicity data generated during the course of this study, it is possible that dose levels may not be started, may be terminated early, and/or may be added with dose levels below the lowest stated dose.\n\nUpdate as part of protocol amendment 6: All participants will receive a third dose of BNT162b2. For participants ≥6 months to \\<5 years, the third dose will occur at least 8 weeks after the second dose. In participants ≥5 to \\<12 years, the third dose will occur at least 6 months after the second dose. The interval between the second and third doses will be based on the participant's age at the time of enrollment. The dose level of the third dose of BNT162b2 will be based on age at the time of vaccination: participants \\<5 years of age at the time of the third dose will receive the 3-µg dose level, participants ≥5 to \\<12 years of age at the time of the third dose will receive the 10-µg dose level, and participants ≥12 years of age at the time of the third dose will receive the 30-µg dose level.\n\nParticipants will have blood drawn prior to both Dose 1 and Dose 2 and 7 days after Dose 2 to assess immunogenicity to determine the selected BNT162b2 dose level for Phase 2/3. Participants will also have blood drawn prior to Dose 3 and 1, 6, and 12 months after Dose 3.\n\nPhase 2/3 Selected-Dose\n\nIs the portion of the study that will evaluate the safety, tolerability, and immunogenicity in each age group at the selected dose level from the Phase 1 dose-finding portion of the study. Efficacy will be evaluated within or across age groups in which immunobridging is successful, depending on accrual of a sufficient number of cases in those age groups.\n\nParticipants will have blood drawn at baseline prior to Dose 1 and 6 months after Dose 2. Immunobridging to participants 16 to 25 years of age in the C4591001 study will be based on immunogenicity data collected at (1) baseline and 1 month after Dose 2 and (2) baseline and 1 month after Dose 3. The persistence of the immune response will be based on immunogenicity data collected in participants at (1) baseline and 1 and 6 months after Dose 2 and (2) baseline and 1, 6, 12, and 18 months after Dose 3. In addition, efficacy against confirmed COVID-19 and against asymptomatic infection will also be assessed in participants ≥5 to \\<12 years of age.\n\nAt designated US sites, an additional optional whole blood sample of approximately 10 mL will be obtained prior to Dose 1 and at 7 days and 6 months after Dose 2 from up to approximately 60 participants ≥10 years of age. Additional samples will be obtained prior to Dose 3 and 1 month after Dose 3 (original BNT162b2 group only). These samples will be used on an exploratory basis to investigate the postvaccination cell-mediated immune response at these time points.\n\nAt the 6-month follow-up visit, all participants will be unblinded. Participants who originally received placebo will be offered the opportunity to receive BNT162b2 as part of the study. Participants who originally received placebo and become eligible for receipt of BNT162b2 or another COVID-19 vaccine according to local or national recommendations prior to the 6 month follow-up visit (Visit 5 or 405) (detailed separately and available in the electronic study reference portal) will have the opportunity to receive BNT162b2 (10 µg or 3 µg) based on age at the time of vaccination.\n\nUpdate as part of protocol amendment 6: All participants will receive a third dose of BNT162b2. For participants ≥6 months to \\<5 years, the third dose will occur at least 8 weeks after the second dose. In participants ≥5 to \\<12 years, the third dose will occur at least 6 months after the second dose. The interval between the second and third doses will be based on the participant's age at the time of enrollment. The dose level of the second and third doses of BNT162b2 will be based on age at the time of vaccination: participants \\<5 years of age at the time of the second/third dose will receive the 3-µg dose level, participants ≥5 to \\<12 years of age at the time of the second/third dose will receive the 10-µg dose level, and participants ≥12 years of age at the time of the second/third dose will receive the 30-µg dose level.\n\nPhase 2/3 Obtaining Serum Samples for Potential Troponin I Testing\n\nIf testing of troponin I levels in individuals who did not receive BNT162b2 indicates that troponin I level could be a reliable indicator of potential subclinical myocarditis, obtaining serum samples for potential troponin I testing during the period of increased risk of clinical myocarditis may help characterize the absence/presence and frequency of subclinical myocarditis. To assess, an additional group of participants will be included: ≥5 to \\<12 years: randomized 2:1 to receive BNT162b2 10 µg or placebo, and ≥12 to \\<16 years of age: open-label receipt of BNT162b2 30 µg.\n\nUpdate as part of protocol amendment 7: All participants will receive a third dose of BNT162b2. For all participants (≥5 to \\<12 and ≥12 to \\<16 years of age), the third dose will occur at least 5 months after Dose 2.\n\nThe dose level of the second and third doses of BNT162b2 will be based on age at the time of vaccination: participants ≥5 to \\<12 years of age at the time of the second/third dose will receive the 10-µg dose level, and participants ≥12 years of age at the time of the second/third dose will receive the 30-µg dose level.\n\nUpdate as part of protocol amendment 8: The Lower-Dose Evaluation portion of the protocol has been removed.\n\nParticipation in the study will cease 6 months after the third dose of BNT162b2."},"conditionsModule":{"conditions":["SARS-CoV-2 Infection, COVID-19"],"keywords":["COVID-19","Coronavirus Vaccine","SARS-CoV-2","RNA Vaccine","mRNA Vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":11837,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Low/Mid-Dose, ≥5 to <12 Years","type":"EXPERIMENTAL","description":"Low/Mid-Dose (10mcg), 2 doses 21 days apart","interventionNames":["Biological: Biological/Vaccine: BNT162b2 10mcg"]},{"label":"Mid-Dose, ≥5 to <12 Years","type":"EXPERIMENTAL","description":"Mid-Dose, (20mcg), 2 doses 21 days apart","interventionNames":["Biological: BNT162b2 20mcg"]},{"label":"High-Dose, ≥5 to <12 Years","type":"EXPERIMENTAL","description":"High-Dose (30mcg), 2 doses 21 days apart","interventionNames":["Biological: BNT162b2 30mcg"]},{"label":"Low/Mid-Dose, ≥2 to < 5 Years","type":"EXPERIMENTAL","description":"Low/Mid-Dose (10mcg), 2 doses 21 days apart","interventionNames":["Biological: Biological/Vaccine: BNT162b2 10mcg"]},{"label":"Mid-Dose, ≥2 to <5 Years","type":"EXPERIMENTAL","description":"Mid-Dose, (20mcg), 2 doses 21 days apart","interventionNames":["Biological: BNT162b2 20mcg"]},{"label":"High-Dose, ≥2 to <5 Years","type":"EXPERIMENTAL","description":"High-Dose, (30mcg), 2 doses 21 days apart","interventionNames":["Biological: BNT162b2 30mcg"]},{"label":"Low/Mid-Dose, ≥6 Months to <2 Years","type":"EXPERIMENTAL","description":"Low/Mid-Dose, (10mcg), 2 doses 21 days apart","interventionNames":["Biological: Biological/Vaccine: BNT162b2 10mcg"]},{"label":"Mid-Dose, ≥6 Months to <2 Years","type":"EXPERIMENTAL","description":"Mid-Dose, (20mcg), 2 doses 21 days apart","interventionNames":["Biological: BNT162b2 20mcg"]},{"label":"High-Dose, ≥6 Months to <2 Years","type":"EXPERIMENTAL","description":"High-Dose, (30mcg), 2 doses 21 days apart","interventionNames":["Biological: BNT162b2 30mcg"]},{"label":"Placebo, ≥6 Months to <2 Years","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"Placebo, ≥2 to <5 Years","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"Placebo, ≥5 to <12 Years","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"Low-Dose, ≥6 Months to <2 Years","type":"EXPERIMENTAL","description":"Low-Dose (3mcg), 2 doses 21 doses apart","interventionNames":["Biological: Biological/Vaccine: BNT162b2 3mcg"]},{"label":"Low-Dose, ≥2 to <5 Years","type":"EXPERIMENTAL","description":"Low-Dose (3mcg), 2 doses 21 days apart","interventionNames":["Biological: Biological/Vaccine: BNT162b2 3mcg"]},{"label":"High-Dose, 12 to <16 Years (Troponin I Testing)","type":"EXPERIMENTAL","description":"High-Dose (30mcg), 3 doses","interventionNames":["Biological: BNT162b2 30mcg"]},{"label":"Low/Mid-Dose, ≥5 to <12 Years (Troponin I Testing)","type":"EXPERIMENTAL","description":"Low/Mid-Dose (10mcg), 3 doses","interventionNames":["Biological: Biological/Vaccine: BNT162b2 10mcg"]},{"label":"Placebo, ≥5 to <12 Years (Troponin I Testing)","type":"EXPERIMENTAL","interventionNames":["Other: Placebo"]},{"label":"Low-Dose, ≥6 Months to <2 Years (3-dose regimen)","type":"EXPERIMENTAL","description":"Low-Dose (3mcg), 3 doses","interventionNames":["Biological: Biological/Vaccine: BNT162b2 3mcg"]},{"label":"Low-Dose, ≥2 to <5 Years (3-dose regimen)","type":"EXPERIMENTAL","description":"Low-Dose (3mcg), 3 doses","interventionNames":["Biological: Biological/Vaccine: BNT162b2 3mcg"]},{"label":"Placebo, ≥6 Months to <2 Years (3-dose regimen)","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"Placebo, ≥2 to <5 Years (3-dose regimen)","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Biological/Vaccine: BNT162b2 10mcg","description":"BNT162b2 Low/Mid-Dose (10mcg) level","armGroupLabels":["Low/Mid-Dose, ≥2 to < 5 Years","Low/Mid-Dose, ≥5 to <12 Years","Low/Mid-Dose, ≥5 to <12 Years (Troponin I Testing)","Low/Mid-Dose, ≥6 Months to <2 Years"]},{"type":"BIOLOGICAL","name":"BNT162b2 20mcg","description":"BNT162b2 Mid-Dose (20mcg) level","armGroupLabels":["Mid-Dose, ≥2 to <5 Years","Mid-Dose, ≥5 to <12 Years","Mid-Dose, ≥6 Months to <2 Years"]},{"type":"BIOLOGICAL","name":"BNT162b2 30mcg","description":"BNT162b2 High-Dose (30mcg) level","armGroupLabels":["High-Dose, 12 to <16 Years (Troponin I Testing)","High-Dose, ≥2 to <5 Years","High-Dose, ≥5 to <12 Years","High-Dose, ≥6 Months to <2 Years"]},{"type":"OTHER","name":"Placebo","description":"Intramuscular injection","armGroupLabels":["Placebo, ≥2 to <5 Years","Placebo, ≥2 to <5 Years (3-dose regimen)","Placebo, ≥5 to <12 Years","Placebo, ≥5 to <12 Years (Troponin I Testing)","Placebo, ≥6 Months to <2 Years","Placebo, ≥6 Months to <2 Years (3-dose regimen)"]},{"type":"BIOLOGICAL","name":"Biological/Vaccine: BNT162b2 3mcg","description":"BNT162b2 Low-Dose (3mcg) level","armGroupLabels":["Low-Dose, ≥2 to <5 Years","Low-Dose, ≥2 to <5 Years (3-dose regimen)","Low-Dose, ≥6 Months to <2 Years","Low-Dose, ≥6 Months to <2 Years (3-dose regimen)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age","description":"Local reactions were collected in electronic diary (e-diary) or during unscheduled clinical assessments from Day 1 to 7 after Dose 1. Redness and swelling were measured and recorded in measuring device unit (mdu) where, 1 mdu = 0.5 centimeter (cm) and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 Emergency room (ER) visit or hospitalization). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% confidence interval was based on Clopper and Pearson method.","timeFrame":"Phase 1: From Day 1 to Day 7 after Dose 1"},{"measure":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 2"},{"measure":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4(necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 3"},{"measure":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 degree Celsius (deg C); categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 1"},{"measure":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 2"},{"measure":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3:>=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 3"},{"measure":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 1"},{"measure":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 2"},{"measure":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 3"},{"measure":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 1"},{"measure":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 2"},{"measure":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 3"},{"measure":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 1"},{"measure":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 2"},{"measure":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization for severe tenderness at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 3"},{"measure":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of Age","description":"Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 1. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 1"},{"measure":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of Age","description":"Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 2.Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake),severe (refusal to feed).Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted).Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 2"},{"measure":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of Age","description":"Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 3. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity).Irritability: mild (easily consolable), moderate (requiring increased attention), severe(Inconsolable; crying cannot be comforted).Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 3"},{"measure":"Phase 1: Percentage of Participants Reporting Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 1: From Dose 1 to 1 Month after Dose 2"},{"measure":"Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method.","timeFrame":"Phase 1: From Dose 3 to 1 Month after Dose 3"},{"measure":"Phase 1: Percentage of Participants Reporting Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 2: >=5 to <12 Years of Age","description":"A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.","timeFrame":"Phase 1: From Dose 1 to 6 Months after Dose 2"},{"measure":"Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic Exact 2-sided 95% CI based on the Clopper and Pearson method.","timeFrame":"Phase 1: From Dose 3 to 6 Months after Dose 3"},{"measure":"Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 1: From Dose 1 to 1 Month after Dose 2"},{"measure":"Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=2 to <5 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI based on the Clopper and Pearson method. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 1: From Dose 3 to 1 Month after Dose 3"},{"measure":"Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.","timeFrame":"Phase 1: From Dose 1 to 6 Months after Dose 2"},{"measure":"Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=2 to <5 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.","timeFrame":"Phase 1: From Dose 3 to 6 Months after Dose 3"},{"measure":"Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=6 Months to <2 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 1: From Dose 1 to 1 Month after Dose 2"},{"measure":"Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=6 Months to <2 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method.Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 1: From Dose 3 to 1 Month after Dose 3"},{"measure":"Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=6 Months to <2 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.Exact 2-sided 95% CI based on the Clopper and Pearson method.","timeFrame":"Phase 1: From Dose 1 to 6 Months after Dose 2"},{"measure":"Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.","timeFrame":"Phase 1: From Dose 3 to 6 Months after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \\>2.0 to 5.0 cm), moderate (\\>5.0 to 10.0), severe \\>10.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \\>2.0 to 5.0 cm), moderate (\\>5.0 to 10.0), severe \\>10.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \\>2.0 to 5.0 cm),moderate (\\>5.0 to 10.0), severe \\>10.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \\>2.0 to 5.0 cm), moderate (\\>5.0 to 10.0), severe \\>10.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1:Troponin Group: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=5 to <12 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 2/3: From Dose 1 to 1 Month after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=12 to <16 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 2/3: From Dose 1 to 1 Month after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group: >=5 to <12 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 2/3: From Dose 3 to 1 Month after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group:>=12 to <16 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 3 to 1 month from dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 2/3: From Dose 3 to 1 Month after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : Troponin Group: >=5 to <12 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"Phase 2/3: From Dose 1 to 6 Months after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Troponin Group: >=12 to <16 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"Phase 2/3: From Dose 1 to 6 Months after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: Troponin Group: >=5 to <12 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"Phase 2/3: From Dose 3 to 6 Months after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3 : Troponin Group:>=12 to <16 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"Phase 2/3: From Dose 3 to 6 Months after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity),severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(\\>=0.5 to 2.0 cm),moderate (\\>2.0 to 7.0 cm),severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe(prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 deg C; categorized as \\>=38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C,\\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 deg C; categorized as \\>=38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C,\\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis\\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity),severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 deg C; categorized as \\>=38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C,\\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate(hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of Age","description":"Systemic events recorded in an e-diary \\& at unscheduled clinical assessments up to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 deg C; categorised as \\>=38.0 to 38.4 deg C,\\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Decreased appetite: mild (decreased interest in eating),moderate (decreased oral intake),severe(refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of Age","description":"Systemic events recorded in an e-diary \\& at unscheduled clinical assessments up to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 deg C; categorised as \\>=38.0 to 38.4 deg C,\\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of Age","description":"Systemic events recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 deg C; categorised as \\>=38.0 to 38.4 deg C,\\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe(disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 2/3: From Dose 1 to 1 Month after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 2/3: From Dose 3 to 1 Month after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=5 to <12 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"Phase 2/3: From Dose 1 to 6 Months after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"Phase 2/3: From Dose 3 to 6 Months after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month from dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 2/3: From Dose 1 to 1 Month after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3:>=2 to <5 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 2/3: From Dose 3 to 1 Month after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"Phase 2/3: From Dose 1 to 6 Months after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3:>=2 to <5 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"Phase 2/3: From Dose 3 to 6 Months after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2 : >=6 Months to <2 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 2/3: From Dose 1 to 1 Month after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3 : >=6 Months to <2 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Phase 2/3: From Dose 3 to 1 Month after Dose 3"},{"measure":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=6 Months to <2 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"Phase 2/3: From Dose 1 to 6 Months after Dose 2"},{"measure":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","timeFrame":"Phase 2/3: From Dose 3 to 6 Months after Dose 3"},{"measure":"Phase2/3:Geometric Mean Ratio(GMR)Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants>=5 to<12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort:1 Month After Dose 2:Participants Without Evidence of Infection","description":"GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of the titers and the corresponding CIs (based on student t distribution). GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\\*LLOQ. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants of the age 16 to 25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section and GMR is reported under statistical analysis.","timeFrame":"C4591007 (>=5 to <12 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2"},{"measure":"Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=5 to <12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection","description":"Seroresponse is defined as achieving a \\>=4 fold rise from baseline (before Dose 1). Assay result below a postvaccination \\>=4\\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","timeFrame":"C4591007 (>=5 to <12 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2"},{"measure":"Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection","description":"GMRs \\& corresponding 2-sided CIs were calculated by exponentiating mean difference of logarithm of titers \\& corresponding CIs(based on student t distribution).GMTs \\& 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs(based on the Student t distribution).Assay results below LLOQ were set to 0.5\\*LLOQ.Results include those from comparator group of C4591001(NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\\& had no medical history of COVID-19 were also included.GMT is reported in descriptive analysis section \\& GMR is reported under statistical analysis.EIP included all eligible randomized participants who received study intervention to which they were randomized,had a valid\\&determinate immunogenicity result within 28-42 days after study vaccination,had no other important protocol deviations as determined by clinician.","timeFrame":"C4591007 (>=2 to <5 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2"},{"measure":"Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection","description":"Seroresponse is defined as achieving a \\>=4-fold rise from baseline (before Dose 1). Assay result below a postvaccination \\>=4\\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","timeFrame":"C4591007 (>=2 to <5 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2"},{"measure":"Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection","description":"GMRs \\& corresponding 2-sided CIs were calculated by exponentiating mean difference of logarithm of titers \\& corresponding CIs(based on student t distribution).GMTs \\& 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs(based on the Student t distribution).Assay results below LLOQ were set to 0.5\\*LLOQ.Results include those from comparator group of C4591001(NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\\& had no medical history of COVID-19 were also included.GMT is reported in descriptive analysis section \\& GMR is reported under statistical analysis.EIP included all eligible randomized participants who received study intervention to which they were randomized,had a valid\\&determinate immunogenicity result within 28-42 days after study vaccination,had no other important protocol deviations as determined by clinician.","timeFrame":"C4591007 (>=6 Months to <2 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2"},{"measure":"Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort : 1 Month After Dose 2: Participants Without Evidence of Infection","description":"Seroresponse is defined as achieving a \\>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \\>=4\\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","timeFrame":"C4591007 (>=6 Months to <2 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2"},{"measure":"Phase 2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 3 in Participants Aged>=2 to<5Years Compared With Study C4591001 Phase2/3 16 to 25 Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection","description":"GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of logarithm of the titers and the corresponding CIs(based on student t distribution).GMTs \\& 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5\\*LLOQ. Results include those from comparator group of C4591001 (NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection \\& had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section \\& GMR is reported under statistical analysis.","timeFrame":"C4591007 (>=2 to <5 years):1 Month after Dose 2 and C4591001 Historical cohort (16-25 years):1 Month after Dose 2"},{"measure":"Phase 2/3:Difference in Percentage of Participants With Seroresponse in 2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years of Age Historical Cohort: Participants Without Evidence of Infection","description":"Seroresponse is defined as achieving a \\>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \\>=4\\*LLOQ is considered a seroresponse.Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","timeFrame":"C4591007 (>=2 to <5 years): 1 Month after Dose 3 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2"},{"measure":"Phase2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose3 in Participants Aged 6Month to 2Year Compared With Study C4591001 Phase2/3 16 to 25Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection","description":"GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of titers and the corresponding CIs (based on student t distribution). GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5\\*LLOQ. Results include those from comparator group of C4591001 (NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\\& had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section \\& GMR is reported under statistical analysis.","timeFrame":"C4591007 (>=6 months to <2 years):1 Month after Dose 3 and C4591001 Historical cohort (16-25 years):1 Month after Dose 2"},{"measure":"Phase 2/3:Difference in Percentage of Participants With Seroresponse in 6 Months to <2 Years (1 Month After Dose 3) Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort (1 Month After Dose 2): Participants Without Evidence of Infection","description":"Seroresponse is defined as achieving a \\>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \\>=4\\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","timeFrame":"C4591007 (>=6 Months to <2 years):1 Month after Dose 3 and C4591001 Historical cohort (16-25 years):1 month after Dose 2"}],"secondaryOutcomes":[{"measure":"Phase 1: Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=6 Months to <2 Years of Age: Participants Without Evidence of Infection","description":"GMT of SARS-CoV-2 neutralizing titer after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.","timeFrame":"Phase 1: 7 days post Dose 2"},{"measure":"Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=2 to <5 Years of Age: Participants Without Evidence of Infection","description":"GMT of SARS-CoV-2 neutralizing titers after the study vaccination was reported in this outcome measure. GMT and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution).Assay results below the LLOQ were set to 0.5\\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.","timeFrame":"Phase 1: 7 days post Dose 2"},{"measure":"Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=5 to <12 Years of Age: Participants Without Evidence of Infection","description":"GMT of SARS-CoV-2 neutralizing titer after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.","timeFrame":"Phase 1: 7 days post Dose 2"},{"measure":"Phase 2/3: Geometric Mean Titer - Neutralizing Titer (NT50) : 5 to <12 Years of Age: Before Dose 1 and 1 Month After Dose 2:Participants Without Evidence of Infection","description":"GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","timeFrame":"Phase 2/3: Before Dose 1 and 1 Month after Dose 2"},{"measure":"Phase 2/3: Geometric Mean Titer - NT50: 5 to <12 Years of Age: Pre-Dose 3 and 1 Month After Dose 3:Participants Without Evidence of Infection","description":"GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 \\*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population (EIP) included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","timeFrame":"Phase 2/3: From Dose 3 set: Pre-Dose 3 and 1 Month after Dose 3"},{"measure":"Phase 2/3: Geometric Mean Titer - NT50:2 to <5 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection","description":"GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 \\*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19.","timeFrame":"Phase 2/3: From Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3"},{"measure":"Phase 2/3: Geometric Mean Titer- NT50:6 Months to <2 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection","description":"GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19.","timeFrame":"Phase 2/3: From Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3"},{"measure":"Phase 2/3: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Dose 1 to 1 Month After Dose 2: >=5 to 12 Years of Age: Participants Without Evidence of Infection","description":"GMFR of SARS-CoV-2 neutralizing titers from dose 1 to 1 month after dose 2 were reported in this outcome measure. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Assay results below the LLOQ were set to 0.5\\* LLOQ in the analysis.","timeFrame":"Phase 2/3: From Dose 1 to 1 Month after Dose 2"},{"measure":"Phase 2/3:GMFR of SARS-CoV-2 Neutralizing Titers From Dose 3 to 1 Month After Dose 3: >=5 to 12 Years of Age: Participants Without Evidence of Infection","description":"GMFR of SARS-CoV-2 neutralizing titers from before Dose 3 to 1 month after Dose were reported in this outcome measure. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomized participants who received the study interventions to which they were randomized, had a valid and determined immunogenicity result within 28-42 days after Dose 3, and had no other important protocol deviations as determined by the clinicians.","timeFrame":"Phase 2/3: From Dose 3 to 1 Month after Dose 3"},{"measure":"Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Pre-Dose 3 and 1 Month After Dose 3: >=2 to 5 Years of Age: Participants Without Evidence of Infection","description":"GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs(based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 infection.Assay results below the LLOQ were set to 0.5\\*LLOQ in the analysis.","timeFrame":"Phase 2/3: From before dose 1 to Pre-Dose 3, 1 Month After Dose 3"},{"measure":"Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Pre-Dose 3 and 1 Month After Dose 3: >=6 Months to 2 Years of Age: Participants Without Evidence of Infection","description":"GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection prior to the 1-month post-Dose 2.","timeFrame":"Phase 2/3: From before dose 1 to Pre-Dose 3, 1 Month After Dose 3"},{"measure":"Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=5 to <12 Years of Age","description":"COVID-19 incidence from 7 days after dose 2 to prior to dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviations as determined by clinician on or before 7 days after Dose 2.","timeFrame":"Phase 2/3: From 7 days after Dose 2 to prior to Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.591; Placebo - 0.292)"},{"measure":"Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=5 to <12 Years of Age","description":"COVID-19 incidence from 7 days after dose 2 to prior to dose 3 with or without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviation as determined by clinician on or before 7 days after Dose 2.","timeFrame":"Phase 2/3: From 7 Days After Dose 2 to prior to Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.653; Placebo - 0.326)"},{"measure":"Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=6 Months to <5 Years of Age","description":"COVID-19 incidence from 7 days after dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by clinician on or before 7 days after Dose 3.","timeFrame":"Phase 2/3: From 7 Days After Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.124; Placebo - 0.054)"},{"measure":"Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=6 Months to <5 Years of Age","description":"COVID-19 incidence from 7 days after dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by the clinician on or before 7 days after Dose 3.","timeFrame":"Phase 2/3: From 7 Days After Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.149; Placebo - 0.067)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n1. Male or female participants ≥6 months to \\<12 years of age, at the time of randomization, at Visit 1 for the dose-finding/selected-dose evaluation. For the obtaining-serum-samples-for-potential-troponin I-testing portion of the study: Male or female participants between ≥5 and \\<16 years of age.\n2. Participants' parent(s)/legal guardian(s) and participants, as age appropriate, who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.\n3. Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.\n\n   Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in the therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.\n4. Participants are expected to be available for the duration of the study and whose parent(s)/legal guardian can be contacted by telephone during study participation.\n5. Negative urine pregnancy test for female participants who are biologically capable of having children.\n6. Female participant of childbearing potential or male participant able to father children who is willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the last dose of study intervention if at risk of pregnancy with her/his partner; or female participant not of childbearing potential or male participant not able to father children.\n7. The participant or participant's parent(s)/legal guardian is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. Depending on the age of the participant and according to local requirements, participants will also be asked to provide assent as appropriate (verbal or written).\n\nExclusion Criteria\n\n1. Phase 1 only: Past clinical (based on COVID-19 symptoms/signs alone, if a SARS CoV 2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19.\n2. Phase 1 only: Known infection with HIV, HCV, or HBV.\n3. Receipt of medications intended to prevent COVID-19.\n4. Previous or current diagnosis of MIS-C.\n5. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. Note: This includes both conditions that may increase the risk associated with study intervention administration or a condition that may interfere with the interpretation of study results\n6. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).\n7. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.\n8. Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic lupus erythematosus. Note: Stable type 1 diabetes and hypothyroidism are permitted.\n9. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\n10. Female who is pregnant or breastfeeding.\n11. Previous vaccination with any coronavirus vaccine.\n12. Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (\\<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.\n13. Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19 from 90 days before study intervention administration, or planned receipt throughout the study.\n14. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.\n15. Previous participation in other studies involving study intervention containing LNPs.\n16. Participants who are direct descendants (child or grandchild) of investigational site staff members or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"15 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of Alabama at Birmingham - School of Medicine","city":"Birmingham","state":"Alabama","zip":"35233","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Phoenix Children's Hospital","city":"Phoenix","state":"Arizona","zip":"85016","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"SCPMG/Kaiser Permanente Los Angeles Medical Center","city":"Los Angeles","state":"California","zip":"90027","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Matrix Clinical Research","city":"Los Angeles","state":"California","zip":"90057","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Madera Family Medical Group","city":"Madera","state":"California","zip":"93637","country":"United States","geoPoint":{"lat":36.96134,"lon":-120.06072}},{"facility":"Kaiser Permanente Oakland","city":"Oakland","state":"California","zip":"94611","country":"United States","geoPoint":{"lat":37.80437,"lon":-122.2708}},{"facility":"Clinical & Translational Research Unit (CTRU) & Spectrum BioBank, Stanford University","city":"Palo Alto","state":"California","zip":"94304","country":"United States","geoPoint":{"lat":37.44188,"lon":-122.14302}},{"facility":"Lucile Packard Children's Hospital Stanford","city":"Palo Alto","state":"California","zip":"94304","country":"United States","geoPoint":{"lat":37.44188,"lon":-122.14302}},{"facility":"Center for Clinical Trials, LLC","city":"Paramount","state":"California","zip":"90723","country":"United States","geoPoint":{"lat":33.88946,"lon":-118.15979}},{"facility":"Center for Clinical Trials","city":"Paramount","state":"California","zip":"90723","country":"United States","geoPoint":{"lat":33.88946,"lon":-118.15979}},{"facility":"Peninsula Research Associates","city":"Rolling Hills Estates","state":"California","zip":"90274","country":"United States","geoPoint":{"lat":33.78779,"lon":-118.35813}},{"facility":"Kaiser Permanente Sacramento","city":"Sacramento","state":"California","zip":"95815","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Kaiser Permanente Santa Clara","city":"Santa Clara","state":"California","zip":"95051","country":"United States","geoPoint":{"lat":37.35411,"lon":-121.95524}},{"facility":"Stanford Health Care Investigational Drug Service","city":"Stanford","state":"California","zip":"94305","country":"United States","geoPoint":{"lat":37.42411,"lon":-122.16608}},{"facility":"Stanford Health Care","city":"Stanford","state":"California","zip":"94305","country":"United States","geoPoint":{"lat":37.42411,"lon":-122.16608}},{"facility":"Bayview Research Group, LLC","city":"Valley Village","state":"California","zip":"91607","country":"United States","geoPoint":{"lat":34.16488,"lon":-118.3965}},{"facility":"Children's Hospital Colorado","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Yale Center for Clinical Investigation","city":"New Haven","state":"Connecticut","zip":"06519","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Emerson Clinical Research Institute","city":"Washington D.C.","state":"District of Columbia","zip":"20009","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Children's National Medical Center","city":"Washington D.C.","state":"District of Columbia","zip":"20010","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Velocity Clinical Research, Washington DC","city":"Washington D.C.","state":"District of Columbia","zip":"20016","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Clinical Neuroscience Solutions, Inc.","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Acevedo Clinical Research Associates","city":"Miami","state":"Florida","zip":"33142","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Clinical Neuroscience Solutions","city":"Orlando","state":"Florida","zip":"32801","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Emory Children's Center Illness POD","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Emory University School of Medicine","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Atlanta Center for Medical Research","city":"Atlanta","state":"Georgia","zip":"30331","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Meridian Clinical Research, LLC","city":"Macon","state":"Georgia","zip":"31210","country":"United States","geoPoint":{"lat":32.84069,"lon":-83.6324}},{"facility":"Rophe Adult and Pediatric Medicine/SKYCRNG","city":"Union City","state":"Georgia","zip":"30291","country":"United States","geoPoint":{"lat":33.58706,"lon":-84.54243}},{"facility":"Clinical Research Prime","city":"Idaho Falls","state":"Idaho","zip":"83404","country":"United States","geoPoint":{"lat":43.46658,"lon":-112.03414}},{"facility":"Solaris Clinical Research","city":"Meridian","state":"Idaho","zip":"83646","country":"United States","geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Newton","state":"Kansas","zip":"67114","country":"United States","geoPoint":{"lat":38.04668,"lon":-97.34504}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Kentucky Pediatric/ Adult Research","city":"Bardstown","state":"Kentucky","zip":"40004","country":"United States","geoPoint":{"lat":37.80923,"lon":-85.4669}},{"facility":"Novak Center for Children's Health","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Ochsner Clinic Foundation","city":"New Orleans","state":"Louisiana","zip":"70121","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Louisiana State University Health Sciences Shreveport","city":"Shreveport","state":"Louisiana","zip":"71101","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"Johns Hopkins Bayview Medical Center","city":"Baltimore","state":"Maryland","zip":"21224","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Boston Medical Center","city":"Boston","state":"Massachusetts","zip":"02118","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Michigan Center of Medical Research","city":"Bingham Farms","state":"Michigan","zip":"48025","country":"United States","geoPoint":{"lat":42.51587,"lon":-83.27326}},{"facility":"SKY Integrative Medical Center/SKYCRNG","city":"Ridgeland","state":"Mississippi","zip":"39157","country":"United States","geoPoint":{"lat":32.42848,"lon":-90.13231}},{"facility":"Clinical Research Professionals","city":"Chesterfield","state":"Missouri","zip":"63005","country":"United States","geoPoint":{"lat":38.66311,"lon":-90.57707}},{"facility":"Children's Mercy Hospital","city":"Kansas City","state":"Missouri","zip":"64108","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Meridian Clinical Research, LLC","city":"Hastings","state":"Nebraska","zip":"68901","country":"United States","geoPoint":{"lat":40.58612,"lon":-98.38839}},{"facility":"Velocity Clinical Research, Lincoln","city":"Lincoln","state":"Nebraska","zip":"68510","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"Children's Hospital & Medical Center","city":"Omaha","state":"Nebraska","zip":"68114","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Children's Physician's Clinic, Spring Valley","city":"Omaha","state":"Nebraska","zip":"68117","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Cancer Institute of New Jersey","city":"New Brunswick","state":"New Jersey","zip":"08901","country":"United States","geoPoint":{"lat":40.48622,"lon":-74.45182}},{"facility":"Rutgers University","city":"New Brunswick","state":"New Jersey","zip":"08901","country":"United States","geoPoint":{"lat":40.48622,"lon":-74.45182}},{"facility":"Meridian Clinical Research LLC","city":"Binghamton","state":"New York","zip":"13905","country":"United States","geoPoint":{"lat":42.09869,"lon":-75.91797}},{"facility":"Advanced Specialty Care","city":"Commack","state":"New York","zip":"11725","country":"United States","geoPoint":{"lat":40.84288,"lon":-73.29289}},{"facility":"Rochester Clinical Research, Inc.","city":"Rochester","state":"New York","zip":"14609","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"University of Rochester Medical Center","city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Stony Brook University","city":"Stony Brook","state":"New York","zip":"11794","country":"United States","geoPoint":{"lat":40.92565,"lon":-73.14094}},{"facility":"SUNY Upstate Medical University","city":"Syracuse","state":"New York","zip":"13210","country":"United States","geoPoint":{"lat":43.04812,"lon":-76.14742}},{"facility":"Atrium Health-STRIVE Vaccine Research Clinic","city":"Charlotte","state":"North Carolina","zip":"28207","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Teen Health Connection (study visits)","city":"Charlotte","state":"North Carolina","zip":"28211","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Duke University - Main Hospital and Clinics","city":"Durham","state":"North Carolina","zip":"27703","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Atrium Health-STRIVE Vaccine Research Clinic (study visits)","city":"Matthews","state":"North Carolina","zip":"28105","country":"United States","geoPoint":{"lat":35.11681,"lon":-80.72368}},{"facility":"Cincinnati Children's Hospital Medical Center Vaccine Research Center","city":"Cincinnati","state":"Ohio","zip":"45229","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Centricity Research Columbus Ohio Multispecialty","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"PriMed Clinical Research","city":"Dayton","state":"Ohio","zip":"45429","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"Senders Pediatrics","city":"South Euclid","state":"Ohio","zip":"44121","country":"United States","geoPoint":{"lat":41.52311,"lon":-81.51846}},{"facility":"Cyn3rgy Research","city":"Gresham","state":"Oregon","zip":"97030","country":"United States","geoPoint":{"lat":45.49818,"lon":-122.43148}},{"facility":"AHN Erie Health + Wellness Pavillion: West","city":"Erie","state":"Pennsylvania","zip":"16506","country":"United States","geoPoint":{"lat":42.12922,"lon":-80.08506}},{"facility":"Velocity Clinical Research-Providence","city":"East Greenwich","state":"Rhode Island","zip":"02818","country":"United States","geoPoint":{"lat":41.66038,"lon":-71.45589}},{"facility":"Coastal Pediatric Research","city":"Charleston","state":"South Carolina","zip":"29414","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"Tribe Clinical Research, LLC","city":"Greenville","state":"South Carolina","zip":"29607","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"Coastal Pediatric Research","city":"Summerville","state":"South Carolina","zip":"29486","country":"United States","geoPoint":{"lat":33.0185,"lon":-80.17565}},{"facility":"St. Jude Children's Research Hospital","city":"Memphis","state":"Tennessee","zip":"38105","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Clinical Research Associates Inc","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Innovo Research - Austin Regional Clinic","city":"Austin","state":"Texas","zip":"78726","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Driscoll Children's Hospital","city":"Corpus Christi","state":"Texas","zip":"78411","country":"United States","geoPoint":{"lat":27.80058,"lon":-97.39638}},{"facility":"Cedar Health Research","city":"Dallas","state":"Texas","zip":"75251","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Bay Colony Pediatrics","city":"Dickinson","state":"Texas","zip":"77539","country":"United States","geoPoint":{"lat":29.46079,"lon":-95.05132}},{"facility":"Proactive Clinical Research, LLC","city":"Edinburg","state":"Texas","zip":"78539","country":"United States","geoPoint":{"lat":26.30174,"lon":-98.16334}},{"facility":"Village Health Partners (Patient Seen Address)","city":"Frisco","state":"Texas","zip":"75033","country":"United States","geoPoint":{"lat":33.15067,"lon":-96.82361}},{"facility":"Helios Clinical Research - HOU","city":"Houston","state":"Texas","zip":"77008","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Helios Clinical Research","city":"Houston","state":"Texas","zip":"77008","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"HG Pediatrics","city":"Houston","state":"Texas","zip":"77008","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Van Tran Family Practice","city":"Houston","state":"Texas","zip":"77008","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Texas Children's Hospital - Clinical Research Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"West Houston Clinical Research Services","city":"Houston","state":"Texas","zip":"77055","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"DM Clinical Research - MDC","city":"Houston","state":"Texas","zip":"77065","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Pediatric Associates","city":"Houston","state":"Texas","zip":"77087","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"J. Lewis Research, Inc. / Foothill Family Clinic","city":"Salt Lake City","state":"Utah","zip":"84109","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"J. Lewis Research, Inc. / Foothill Family Clinic South","city":"Salt Lake City","state":"Utah","zip":"84121","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Pediatric Associates of Charlottesville, PLC (Private Pediatric Practice)","city":"Charlottesville","state":"Virginia","zip":"22902","country":"United States","geoPoint":{"lat":38.02931,"lon":-78.47668}},{"facility":"Virginia Research Center","city":"Midlothian","state":"Virginia","zip":"23114","country":"United States","geoPoint":{"lat":37.50598,"lon":-77.64916}},{"facility":"Seattle Children's Hospital","city":"Seattle","state":"Washington","zip":"98105","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Hospital Santo Antônio - Obras Sociais Irmã Dulce/ Centro de Pesquisa Clínica - CPEC","city":"Salvador","state":"Estado de Bahia","zip":"40415-006","country":"Brazil","geoPoint":{"lat":-12.97563,"lon":-38.49096}},{"facility":"Santa Casa De Misericórdia de Belo Horizonte","city":"Belo Horizonte","state":"Minas Gerais","zip":"30150-221","country":"Brazil","geoPoint":{"lat":-19.92083,"lon":-43.93778}},{"facility":"Serviço de Infectologia e Controle de Infecção Hospitalar de Curitiba/ Centro Médico São Francisco","city":"Curitiba","state":"Paraná","zip":"80810-050","country":"Brazil","geoPoint":{"lat":-25.42778,"lon":-49.27306}},{"facility":"CePCLIN - Centro de Estudos e Pesquisas em Moléstias Infecciosas Ltda","city":"Natal","state":"Rio Grande do Norte","zip":"59025-050","country":"Brazil","geoPoint":{"lat":-5.795,"lon":-35.20944}},{"facility":"CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos Ltda.","city":"São Paulo","zip":"04266-010","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"FVR, Oulu Clinic","city":"Oulu","state":"North Ostrobothnia","zip":"90220","country":"Finland","geoPoint":{"lat":65.01236,"lon":25.46816}},{"facility":"FVR, Järvenpää Clinic","city":"Jarvenpaa","state":"Uusimaa","zip":"04400","country":"Finland","geoPoint":{"lat":60.47369,"lon":25.08992}},{"facility":"FVR, Espoo Clinic","city":"Espoo","zip":"02230","country":"Finland","geoPoint":{"lat":60.2052,"lon":24.6522}},{"facility":"FVR, Helsinki South Clinic","city":"Helsinki","zip":"00100","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"MeVac - Meilahti Vaccine Research Center","city":"Helsinki","zip":"00290","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"FVR, Helsinki East Clinic","city":"Helsinki","zip":"00930","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"FVR, Kokkola Clinic","city":"Kokkola","zip":"67100","country":"Finland","geoPoint":{"lat":63.83847,"lon":23.13066}},{"facility":"FVR, Pori Clinic","city":"Pori","zip":"28100","country":"Finland","geoPoint":{"lat":61.48072,"lon":21.78518}},{"facility":"FVR, Seinäjoki Clinic","city":"Seinäjoki","zip":"60100","country":"Finland","geoPoint":{"lat":62.79446,"lon":22.82822}},{"facility":"FVR, Tampere Clinic","city":"Tampere","zip":"33100","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"FVR, Turku Clinic","city":"Turku","zip":"20520","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"facility":"CHRISTUS - LATAM HUB Center of excellence and innovation S.C.","city":"Monterrey","state":"Nuevo León","zip":"C.P. 64060","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"Kohler & Milstein Research S.A. de C.V.","city":"Mérida","state":"Yucatán","zip":"97070","country":"Mexico","geoPoint":{"lat":20.967,"lon":-89.62318}},{"facility":"Centro Multidisciplinario Para El Desarrollo Especializado De La Investigacion","city":"Mérida","state":"Yucatán","zip":"97130","country":"Mexico","geoPoint":{"lat":20.967,"lon":-89.62318}},{"facility":"Sociedad de Metabolismo y Corazón S.C.","city":"Veracruz","zip":"C.P. 91900","country":"Mexico","geoPoint":{"lat":19.18095,"lon":-96.1429}},{"facility":"MICS Centrum Medyczne Torun","city":"Torun","state":"Kuyavian-Pomeranian Voivodeship","zip":"87-100","country":"Poland","geoPoint":{"lat":53.01375,"lon":18.59814}},{"facility":"IN-VIVO Bydgoszcz","city":"Bydgoszcz","zip":"85-048","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Centrum Badan Klinicznych JCI","city":"Krakow","zip":"30-348","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Osrodek Badan Klinicznych Appletreeclinics","city":"Lodz","zip":"90-349","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"GRAVITA Diagnostyka i Leczenie nieplodnosci","city":"Lodz","zip":"91-347","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Rodzinne Centrum Medyczne LUBMED","city":"Luboń","zip":"62-030","country":"Poland","geoPoint":{"lat":52.34705,"lon":16.89267}},{"facility":"Niepubliczny Zaklad Lecznictwa Ambulatoryjnego Michalkowice Jarosz i Partnerzy Spolka Lekarska","city":"Siemianowice Śląskie","zip":"41-103","country":"Poland","geoPoint":{"lat":50.32738,"lon":19.02901}},{"facility":"Provita 001","city":"Warsaw","zip":"02-647","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Hospital Clinico Universitario Santiago de Compostela","city":"Santiago de Compostela","state":"A Coruña","zip":"15706","country":"Spain","geoPoint":{"lat":42.88052,"lon":-8.54569}},{"facility":"EBA Centelles","city":"Centelles","state":"Barcelona","zip":"08540","country":"Spain","geoPoint":{"lat":41.79746,"lon":2.21902}},{"facility":"Hospital Sant Joan de Deu","city":"Esplugues de Llobregat","state":"Barcelona","zip":"08950","country":"Spain","geoPoint":{"lat":41.37732,"lon":2.08809}},{"facility":"Hospital Universitari General de Catalunya","city":"Sant Cugat del Vallès","state":"Barcelona","zip":"08195","country":"Spain","geoPoint":{"lat":41.47063,"lon":2.08611}},{"facility":"Hospital Universitario HM Monteprincipe","city":"Boadilla del Monte","state":"Madrid","zip":"28660","country":"Spain","geoPoint":{"lat":40.405,"lon":-3.87835}},{"facility":"Hospital Universitario HM Puerta del Sur","city":"Madrid","state":"Madrid, Comunidad de","zip":"28938","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital de Antequera","city":"Antequera","state":"Málaga","zip":"29200","country":"Spain","geoPoint":{"lat":37.01938,"lon":-4.56123}},{"facility":"Grupo Pediatrico Uncibay","city":"Málaga","state":"Málaga","zip":"29015","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Hospital Universitario 12 de Octubre","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Instituto Hispalense de Pediatria","city":"Seville","zip":"41012","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}}]},"referencesModule":{"references":[{"pmid":"39197299","type":"DERIVED","citation":"Pather S, Charpentier N, van den Ouweland F, Rizzi R, Finlayson A, Salisch N, Muik A, Lindemann C, Khanim R, Abduljawad S, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO; ex-V3SWG). A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine. Vaccine. 2024 Sep 17;42(22):126165. doi: 10.1016/j.vaccine.2024.126165. Epub 2024 Aug 27."},{"pmid":"36929216","type":"DERIVED","citation":"Simoes EAF, Klein NP, Sabharwal C, Gurtman A, Kitchin N, Ukkonen B, Korbal P, Zou J, Xie X, Sarwar UN, Xu X, Lockhart S, Cunliffe L, Lu C, Ma H, Swanson KA, Koury K, Shi PY, Cooper D, Tureci Ӧ, Jansen KU, Sahin U, Gruber WC. Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds. J Pediatric Infect Dis Soc. 2023 Apr 28;12(4):234-238. doi: 10.1093/jpids/piad015."},{"pmid":"36791162","type":"DERIVED","citation":"Munoz FM, Sher LD, Sabharwal C, Gurtman A, Xu X, Kitchin N, Lockhart S, Riesenberg R, Sexter JM, Czajka H, Paulsen GC, Maldonado Y, Walter EB, Talaat KR, Englund JA, Sarwar UN, Hansen C, Iwamoto M, Webber C, Cunliffe L, Ukkonen B, Martinez SN, Pahud BA, Munjal I, Domachowske JB, Swanson KA, Ma H, Koury K, Mather S, Lu C, Zou J, Xie X, Shi PY, Cooper D, Tureci O, Sahin U, Jansen KU, Gruber WC; C4591007 Clinical Trial Group. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. N Engl J Med. 2023 Feb 16;388(7):621-634. doi: 10.1056/NEJMoa2211031."},{"pmid":"34752019","type":"DERIVED","citation":"Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, Barnett ED, Munoz FM, Maldonado Y, Pahud BA, Domachowske JB, Simoes EAF, Sarwar UN, Kitchin N, Cunliffe L, Rojo P, Kuchar E, Ramet M, Munjal I, Perez JL, Frenck RW Jr, Lagkadinou E, Swanson KA, Ma H, Xu X, Koury K, Mather S, Belanger TJ, Cooper D, Tureci O, Dormitzer PR, Sahin U, Jansen KU, Gruber WC; C4591007 Clinical Trial Group. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2022 Jan 6;386(1):35-46. doi: 10.1056/NEJMoa2116298. Epub 2021 Nov 9."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://pmiform.com/clinical-trial-info-request?StudyID=C4591007"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Out of 11837 participants enrolled, 11760 were vaccinated.","recruitmentDetails":"The study consisted of 2 parts, Phase 1 and Phase 2/3.","groups":[{"id":"FG000","title":"Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age","description":"Participants aged 6 months to less than (\\<) 2 years of age received 2 doses of 3 microgram (mcg) BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"FG001","title":"Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"FG002","title":"Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"FG003","title":"Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"FG004","title":"Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"FG005","title":"Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"FG006","title":"Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"FG007","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"FG008","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study. Participants received third dose of placebo approximately 60 days after vaccination 2. Following unblinding participants received BNT162b2 3 mcg in the open-label phase."},{"id":"FG009","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg or 10 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"FG010","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study. Participants received third dose of placebo approximately 60 days after vaccination 2. Following unblinding participants received BNT162b2 3 mcg or 10 mcg depending on the age at vaccination in the open-label phase."},{"id":"FG011","title":"Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg or 30 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"FG012","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study. Following unblinding participants received BNT162b2 10 mcg or 30 mcg depending on the age at vaccination in the open-label phase."},{"id":"FG013","title":"Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"FG014","title":"Phase 2/3:Troponin Group:Placebo:5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study. Following unblinding participants received BNT162b2 10 mcg or 30 mcg depending on the age at vaccination in the open-label phase."},{"id":"FG015","title":"Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age","description":"Participants aged 12 to \\<16 years received 2 doses of 30 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2."}],"periods":[{"title":"Phase 1","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"32"},{"groupId":"FG003","numSubjects":"16"},{"groupId":"FG004","numSubjects":"16"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","comment":"Participants did not enter Phase 1 of the study.","numSubjects":"0"},{"groupId":"FG008","comment":"Participants did not enter Phase 1 of the study.","numSubjects":"0"},{"groupId":"FG009","comment":"Participants did not enter Phase 1 of the study.","numSubjects":"0"},{"groupId":"FG010","comment":"Participants did not enter Phase 1 of the study.","numSubjects":"0"},{"groupId":"FG011","comment":"Participants did not enter Phase 1 of the study.","numSubjects":"0"},{"groupId":"FG012","comment":"Participants did not enter Phase 1 of the study.","numSubjects":"0"},{"groupId":"FG013","comment":"Participants did not enter Phase 1 of the study.","numSubjects":"0"},{"groupId":"FG014","comment":"Participants did not enter Phase 1 of the study.","numSubjects":"0"},{"groupId":"FG015","comment":"Participants did not enter Phase 1 of the study.","numSubjects":"0"}]},{"type":"Vaccination 1","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"32"},{"groupId":"FG003","numSubjects":"16"},{"groupId":"FG004","numSubjects":"16"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"Vaccination 2","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"32"},{"groupId":"FG003","numSubjects":"16"},{"groupId":"FG004","numSubjects":"16"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"Vaccination 3","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","comment":"Of the 16 participants that received 3mcg at Dose 1 and Dose 2, 10 received 3 mcg \\& 3 received 10 mcg at Dose 3","numSubjects":"13"},{"groupId":"FG002","comment":"Of the 32 participants that received 10mcg at Dose 1 and Dose 2, 17 received 3 mcg \\& 10 received 10 mcg at Dose 3.","numSubjects":"27"},{"groupId":"FG003","comment":"Of 16 participants that received dose 1 \\& 2 at 10 mcg, 1 participant received 30 mcg and 15 participants received 10 mcg.","numSubjects":"16"},{"groupId":"FG004","comment":"7 participants received 10mcg and 1 participant received 30mcg at Dose 3.","numSubjects":"8"},{"groupId":"FG005","comment":"Participants received 10 mcg at Dose 3","numSubjects":"4"},{"groupId":"FG006","comment":"Participants received 10 mcg at Dose 3","numSubjects":"12"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"Safety Population","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"32"},{"groupId":"FG003","numSubjects":"16"},{"groupId":"FG004","numSubjects":"16"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"14"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"18"},{"groupId":"FG003","numSubjects":"14"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"11"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"Withdrawal by parent/guardian/participants","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"}]}]},{"title":"Phase 2/3","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Participants did not enter Phase 2/3 of the study.","numSubjects":"0"},{"groupId":"FG001","comment":"Participants did not enter Phase 2/3 of the study.","numSubjects":"0"},{"groupId":"FG002","comment":"Participants did not enter Phase 2/3 of the study.","numSubjects":"0"},{"groupId":"FG003","comment":"Participants did not enter Phase 2/3 of the study.","numSubjects":"0"},{"groupId":"FG004","comment":"Participants did not enter Phase 2/3 of the study.","numSubjects":"0"},{"groupId":"FG005","comment":"Participants did not enter Phase 2/3 of the study.","numSubjects":"0"},{"groupId":"FG006","comment":"Participants did not enter Phase 2/3 of the study.","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1458"},{"groupId":"FG008","numSubjects":"718"},{"groupId":"FG009","numSubjects":"2368"},{"groupId":"FG010","numSubjects":"1173"},{"groupId":"FG011","numSubjects":"3109"},{"groupId":"FG012","numSubjects":"1538"},{"groupId":"FG013","numSubjects":"518"},{"groupId":"FG014","numSubjects":"260"},{"groupId":"FG015","numSubjects":"506"}]},{"type":"Vaccination 1","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1458"},{"groupId":"FG008","numSubjects":"718"},{"groupId":"FG009","numSubjects":"2368"},{"groupId":"FG010","numSubjects":"1173"},{"groupId":"FG011","numSubjects":"3109"},{"groupId":"FG012","numSubjects":"1538"},{"groupId":"FG013","numSubjects":"518"},{"groupId":"FG014","numSubjects":"260"},{"groupId":"FG015","comment":"1 participant received BNT162b2 10 mcg as dose 1.","numSubjects":"506"}]},{"type":"Vaccination 2","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1445"},{"groupId":"FG008","numSubjects":"672"},{"groupId":"FG009","comment":"11 participants received BNT162b2 10 mcg as dose 2.","numSubjects":"2343"},{"groupId":"FG010","numSubjects":"1073"},{"groupId":"FG011","numSubjects":"3101"},{"groupId":"FG012","numSubjects":"1532"},{"groupId":"FG013","numSubjects":"514"},{"groupId":"FG014","numSubjects":"110"},{"groupId":"FG015","numSubjects":"496"}]},{"type":"Vaccination 3","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1324"},{"groupId":"FG008","numSubjects":"237"},{"groupId":"FG009","comment":"204 participants received BNT162b2 10 mcg as dose 3.","numSubjects":"2093"},{"groupId":"FG010","numSubjects":"405"},{"groupId":"FG011","comment":"145 participants received BNT162b2 30 mcg as dose 3.","numSubjects":"2555"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","comment":"11 participants received BNT162b2 30 mcg as dose 3.","numSubjects":"429"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","comment":"A total of 19 participants were excluded from the safety population because parent/guardian did not provide acceptable dual parental informed consent required per local regulation.","numSubjects":"452"}]},{"type":"Safety Population","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1458"},{"groupId":"FG008","numSubjects":"718"},{"groupId":"FG009","numSubjects":"2368"},{"groupId":"FG010","numSubjects":"1173"},{"groupId":"FG011","numSubjects":"3109"},{"groupId":"FG012","numSubjects":"1538"},{"groupId":"FG013","numSubjects":"518"},{"groupId":"FG014","numSubjects":"260"},{"groupId":"FG015","numSubjects":"487"}]},{"type":"First Dose of BNT162b2 in Open Label Period After Unblinding","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","comment":"Participants received BNT162b2 3 mcg as first dose after unblinding.","numSubjects":"581"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","comment":"706 participants received BNT162b2 3 mcg and 81 participants received 10 mcg as first dose after unblinding.","numSubjects":"787"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","comment":"Participants received BNT162b2 10 mcg as first dose after unblinding.","numSubjects":"1262"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","comment":"Participants received BNT162b2 10 mcg as first dose after unblinding.","numSubjects":"243"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"Second Dose of BNT162b2 in Open Label Period After Unblinding","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","comment":"Participants received BNT162b2 3 mcg as second dose after unblinding.","numSubjects":"569"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","comment":"680 participants received BNT162b2 3 mcg and 92 participants (13 participants who received BNT162b2 3 mcg as first dose post-unblinding and 79 participants who received BNT162b2 10 mcg as first dose post-unblinding) received BNT162b2 10 mcg as second dose after unblinding","numSubjects":"772"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","comment":"Participants received BNT162b2 10 mcg as second dose after unblinding.","numSubjects":"1254"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","comment":"Participants received BNT162b2 10 mcg as second dose after unblinding.","numSubjects":"239"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"Third Dose of BNT162b2 in Open Label Period After Unblinding","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","comment":"Participants received BNT162b2 3 mcg as third dose after unblinding.","numSubjects":"534"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","comment":"581 participants received BNT162b2 3 mcg and 113 participants received 10 mcg as third dose after unblinding.","numSubjects":"694"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","comment":"957 participants received BNT162b2 10 mcg and 91 participants received 30 mcg as third dose after unblinding.","numSubjects":"1048"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","comment":"202 participants received BNT162b2 10 mcg and 9 participants received 30 mcg as third dose after unblinding.","numSubjects":"211"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"712"},{"groupId":"FG008","numSubjects":"261"},{"groupId":"FG009","numSubjects":"1214"},{"groupId":"FG010","numSubjects":"406"},{"groupId":"FG011","numSubjects":"1605"},{"groupId":"FG012","numSubjects":"635"},{"groupId":"FG013","numSubjects":"395"},{"groupId":"FG014","numSubjects":"188"},{"groupId":"FG015","numSubjects":"443"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"746"},{"groupId":"FG008","numSubjects":"457"},{"groupId":"FG009","numSubjects":"1154"},{"groupId":"FG010","numSubjects":"767"},{"groupId":"FG011","numSubjects":"1504"},{"groupId":"FG012","numSubjects":"903"},{"groupId":"FG013","numSubjects":"123"},{"groupId":"FG014","numSubjects":"72"},{"groupId":"FG015","numSubjects":"63"}]}],"dropWithdraws":[{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"25"},{"groupId":"FG008","numSubjects":"16"},{"groupId":"FG009","numSubjects":"148"},{"groupId":"FG010","numSubjects":"82"},{"groupId":"FG011","numSubjects":"474"},{"groupId":"FG012","numSubjects":"272"},{"groupId":"FG013","numSubjects":"31"},{"groupId":"FG014","numSubjects":"20"},{"groupId":"FG015","numSubjects":"6"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"465"},{"groupId":"FG008","numSubjects":"221"},{"groupId":"FG009","numSubjects":"464"},{"groupId":"FG010","numSubjects":"171"},{"groupId":"FG011","numSubjects":"86"},{"groupId":"FG012","numSubjects":"47"},{"groupId":"FG013","numSubjects":"11"},{"groupId":"FG014","numSubjects":"4"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"Withdrawal by parent/guardian/participants","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"199"},{"groupId":"FG008","numSubjects":"196"},{"groupId":"FG009","numSubjects":"428"},{"groupId":"FG010","numSubjects":"458"},{"groupId":"FG011","numSubjects":"816"},{"groupId":"FG012","numSubjects":"543"},{"groupId":"FG013","numSubjects":"66"},{"groupId":"FG014","numSubjects":"37"},{"groupId":"FG015","numSubjects":"40"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"53"},{"groupId":"FG008","numSubjects":"23"},{"groupId":"FG009","numSubjects":"109"},{"groupId":"FG010","numSubjects":"55"},{"groupId":"FG011","numSubjects":"126"},{"groupId":"FG012","numSubjects":"41"},{"groupId":"FG013","numSubjects":"14"},{"groupId":"FG014","numSubjects":"10"},{"groupId":"FG015","numSubjects":"15"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"1"},{"groupId":"FG014","numSubjects":"1"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"3"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"Refused further study procedures","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"2"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety set included all participants who received at least 1 dose of the study intervention. Participants were analyzed according to the treatment which they received.","groups":[{"id":"BG000","title":"Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age","description":"Participants aged 6 months to less than (\\<) 2 years of age received 2 doses of 3 microgram (mcg) BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"BG001","title":"Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"BG002","title":"Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"BG003","title":"Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"BG004","title":"Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"BG005","title":"Phase 1: 5 to <12 Years 30/30 mcg","description":"Participants aged 5 to \\<12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"BG006","title":"Phase 1: 5 to <12 Years 30/10 mcg","description":"Participants aged 5 to \\<12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"BG007","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"BG008","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study. Participants received third dose of placebo approximately 60 days after vaccination 2. Following unblinding participants received BNT162b2 3 mcg in the open-label phase."},{"id":"BG009","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"BG010","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study. Participants received third dose of placebo approximately 60 days after vaccination 2. Following unblinding participants received BNT162b2 3 mcg or 10 mcg depending on the age at vaccination in the open-label phase."},{"id":"BG011","title":"Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"BG012","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study. Following unblinding participants received BNT162b2 10 mcg or 30 mcg depending on the age at vaccination in the open-label phase."},{"id":"BG013","title":"Phase 2/3:Troponin Group:BNT162b2(10 mcg):5 to<12 Years of Age","description":"Participants aged 5 to \\<12 years were randomised to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"BG014","title":"Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study. Following unblinding participants received BNT162b2 10 mcg or 30 mcg depending on the age at vaccination in the open-label phase."},{"id":"BG015","title":"Phase 2/3:Troponin Group:BNT162b2(30 mcg):12 to<16years of Age","description":"Participants aged 12 to \\<16 years were received 2 doses of 30 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"BG016","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"32"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"16"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"1458"},{"groupId":"BG008","value":"718"},{"groupId":"BG009","value":"2368"},{"groupId":"BG010","value":"1173"},{"groupId":"BG011","value":"3109"},{"groupId":"BG012","value":"1538"},{"groupId":"BG013","value":"518"},{"groupId":"BG014","value":"260"},{"groupId":"BG015","value":"487"},{"groupId":"BG016","value":"11741"}]}],"measures":[{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Infants and toddlers (28 days-23 months)","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1458"},{"groupId":"BG008","value":"718"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"2192"}]},{"title":"Children (2-11 years)","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"32"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"16"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2368"},{"groupId":"BG010","value":"1173"},{"groupId":"BG011","value":"3109"},{"groupId":"BG012","value":"1538"},{"groupId":"BG013","value":"518"},{"groupId":"BG014","value":"260"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"9062"}]},{"title":"Adolescents (12-17 years)","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"487"},{"groupId":"BG016","value":"487"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"728"},{"groupId":"BG008","value":"372"},{"groupId":"BG009","value":"1197"},{"groupId":"BG010","value":"570"},{"groupId":"BG011","value":"1500"},{"groupId":"BG012","value":"759"},{"groupId":"BG013","value":"252"},{"groupId":"BG014","value":"120"},{"groupId":"BG015","value":"216"},{"groupId":"BG016","value":"5764"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"730"},{"groupId":"BG008","value":"346"},{"groupId":"BG009","value":"1171"},{"groupId":"BG010","value":"603"},{"groupId":"BG011","value":"1609"},{"groupId":"BG012","value":"779"},{"groupId":"BG013","value":"266"},{"groupId":"BG014","value":"140"},{"groupId":"BG015","value":"271"},{"groupId":"BG016","value":"5977"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"248"},{"groupId":"BG008","value":"93"},{"groupId":"BG009","value":"426"},{"groupId":"BG010","value":"193"},{"groupId":"BG011","value":"526"},{"groupId":"BG012","value":"265"},{"groupId":"BG013","value":"52"},{"groupId":"BG014","value":"34"},{"groupId":"BG015","value":"422"},{"groupId":"BG016","value":"2267"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"16"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"1205"},{"groupId":"BG008","value":"620"},{"groupId":"BG009","value":"1934"},{"groupId":"BG010","value":"979"},{"groupId":"BG011","value":"2579"},{"groupId":"BG012","value":"1273"},{"groupId":"BG013","value":"466"},{"groupId":"BG014","value":"226"},{"groupId":"BG015","value":"65"},{"groupId":"BG016","value":"9451"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"5"},{"groupId":"BG009","value":"8"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"4"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"23"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"4"},{"groupId":"BG011","value":"13"},{"groupId":"BG012","value":"4"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"209"},{"groupId":"BG016","value":"242"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"101"},{"groupId":"BG008","value":"51"},{"groupId":"BG009","value":"147"},{"groupId":"BG010","value":"92"},{"groupId":"BG011","value":"256"},{"groupId":"BG012","value":"118"},{"groupId":"BG013","value":"49"},{"groupId":"BG014","value":"16"},{"groupId":"BG015","value":"4"},{"groupId":"BG016","value":"843"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"10"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"13"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"73"},{"groupId":"BG008","value":"34"},{"groupId":"BG009","value":"138"},{"groupId":"BG010","value":"71"},{"groupId":"BG011","value":"179"},{"groupId":"BG012","value":"101"},{"groupId":"BG013","value":"19"},{"groupId":"BG014","value":"11"},{"groupId":"BG015","value":"40"},{"groupId":"BG016","value":"671"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"1126"},{"groupId":"BG008","value":"562"},{"groupId":"BG009","value":"1870"},{"groupId":"BG010","value":"913"},{"groupId":"BG011","value":"2404"},{"groupId":"BG012","value":"1199"},{"groupId":"BG013","value":"425"},{"groupId":"BG014","value":"219"},{"groupId":"BG015","value":"228"},{"groupId":"BG016","value":"9034"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"149"},{"groupId":"BG008","value":"65"},{"groupId":"BG009","value":"189"},{"groupId":"BG010","value":"86"},{"groupId":"BG011","value":"235"},{"groupId":"BG012","value":"106"},{"groupId":"BG013","value":"23"},{"groupId":"BG014","value":"13"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"876"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"5"},{"groupId":"BG009","value":"18"},{"groupId":"BG010","value":"6"},{"groupId":"BG011","value":"12"},{"groupId":"BG012","value":"10"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"5"},{"groupId":"BG016","value":"62"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age","description":"Local reactions were collected in electronic diary (e-diary) or during unscheduled clinical assessments from Day 1 to 7 after Dose 1. Redness and swelling were measured and recorded in measuring device unit (mdu) where, 1 mdu = 0.5 centimeter (cm) and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 Emergency room (ER) visit or hospitalization). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% confidence interval was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: From Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG002","title":"Phase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG003","title":"Phase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"100.0","lowerLimit":"39.8","upperLimit":"100.0"},{"groupId":"OG003","value":"16.7","lowerLimit":"2.1","upperLimit":"48.4"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"75.0","lowerLimit":"19.4","upperLimit":"99.4"},{"groupId":"OG003","value":"16.7","lowerLimit":"2.1","upperLimit":"48.4"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"87.5","lowerLimit":"61.7","upperLimit":"98.4"},{"groupId":"OG001","value":"93.8","lowerLimit":"69.8","upperLimit":"99.8"},{"groupId":"OG002","value":"100.0","lowerLimit":"39.8","upperLimit":"100.0"},{"groupId":"OG003","value":"83.3","lowerLimit":"51.6","upperLimit":"97.9"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"68.8","lowerLimit":"41.3","upperLimit":"89.0"},{"groupId":"OG001","value":"56.3","lowerLimit":"29.9","upperLimit":"80.2"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"50.0","lowerLimit":"21.1","upperLimit":"78.9"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"},{"groupId":"OG001","value":"37.5","lowerLimit":"15.2","upperLimit":"64.6"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"33.3","lowerLimit":"9.9","upperLimit":"65.1"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG002","title":"Phase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG003","title":"Phase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"37.5","lowerLimit":"15.2","upperLimit":"64.6"},{"groupId":"OG001","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"},{"groupId":"OG002","value":"75.0","lowerLimit":"19.4","upperLimit":"99.4"},{"groupId":"OG003","value":"16.7","lowerLimit":"2.1","upperLimit":"48.4"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG001","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"31.3","lowerLimit":"11.0","upperLimit":"58.7"},{"groupId":"OG001","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"},{"groupId":"OG001","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"87.5","lowerLimit":"61.7","upperLimit":"98.4"},{"groupId":"OG001","value":"75.0","lowerLimit":"47.6","upperLimit":"92.7"},{"groupId":"OG002","value":"100.0","lowerLimit":"39.8","upperLimit":"100.0"},{"groupId":"OG003","value":"91.7","lowerLimit":"61.5","upperLimit":"99.8"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"47.6","upperLimit":"92.7"},{"groupId":"OG001","value":"50.0","lowerLimit":"24.7","upperLimit":"75.3"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"83.3","lowerLimit":"51.6","upperLimit":"97.9"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG001","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4(necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants aged 5 to \\<12 years were administered BNT162b2 10 mcg at Dose 3; hence, combined data is reported in this outcome measure. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 1: 5 to <12 Years BNT162b2 10 mcg","description":"All participants aged 5 to \\<12 years who received the third dose of 10 mcg BNT162b2 as part of this study were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"28.9","lowerLimit":"15.4","upperLimit":"45.9"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"21.1","lowerLimit":"9.6","upperLimit":"37.3"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"7.9","lowerLimit":"1.7","upperLimit":"21.4"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"13.2","lowerLimit":"4.4","upperLimit":"28.1"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"10.5","lowerLimit":"2.9","upperLimit":"24.8"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.1","upperLimit":"13.8"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"86.8","lowerLimit":"71.9","upperLimit":"95.6"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"68.4","lowerLimit":"51.3","upperLimit":"82.5"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"18.4","lowerLimit":"7.7","upperLimit":"34.3"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 degree Celsius (deg C); categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG002","title":"Phase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG003","title":"Phase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}]}],"classes":[{"title":"Fever: >=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"33.3","lowerLimit":"9.9","upperLimit":"65.1"}]}]},{"title":"Fever:38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"16.7","lowerLimit":"2.1","upperLimit":"48.4"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"16.7","lowerLimit":"2.1","upperLimit":"48.4"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"24.7","upperLimit":"75.3"},{"groupId":"OG001","value":"68.8","lowerLimit":"41.3","upperLimit":"89.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"39.8","upperLimit":"100.0"},{"groupId":"OG003","value":"50.0","lowerLimit":"21.1","upperLimit":"78.9"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"37.5","lowerLimit":"15.2","upperLimit":"64.6"},{"groupId":"OG001","value":"31.3","lowerLimit":"11.0","upperLimit":"58.7"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"16.7","lowerLimit":"2.1","upperLimit":"48.4"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG001","value":"37.5","lowerLimit":"15.2","upperLimit":"64.6"},{"groupId":"OG002","value":"75.0","lowerLimit":"19.4","upperLimit":"99.4"},{"groupId":"OG003","value":"33.3","lowerLimit":"9.9","upperLimit":"65.1"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG001","value":"31.3","lowerLimit":"11.0","upperLimit":"58.7"},{"groupId":"OG002","value":"75.0","lowerLimit":"19.4","upperLimit":"99.4"},{"groupId":"OG003","value":"33.3","lowerLimit":"9.9","upperLimit":"65.1"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"},{"groupId":"OG001","value":"31.3","lowerLimit":"11.0","upperLimit":"58.7"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"25.0","lowerLimit":"5.5","upperLimit":"57.2"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"16.7","lowerLimit":"2.1","upperLimit":"48.4"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG001","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG002","value":"100.0","lowerLimit":"39.8","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"75.0","lowerLimit":"19.4","upperLimit":"99.4"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG002","title":"Phase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG003","title":"Phase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}]}],"classes":[{"title":"Fever: >=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG001","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"},{"groupId":"OG002","value":"100.0","lowerLimit":"39.8","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"75.0","lowerLimit":"19.4","upperLimit":"99.4"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"68.8","lowerLimit":"41.3","upperLimit":"89.0"},{"groupId":"OG001","value":"62.5","lowerLimit":"35.4","upperLimit":"84.8"},{"groupId":"OG002","value":"100.0","lowerLimit":"39.8","upperLimit":"100.0"},{"groupId":"OG003","value":"75.0","lowerLimit":"42.8","upperLimit":"94.5"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"43.8","lowerLimit":"19.8","upperLimit":"70.1"},{"groupId":"OG001","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"58.3","lowerLimit":"27.7","upperLimit":"84.8"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG001","value":"37.5","lowerLimit":"15.2","upperLimit":"64.6"},{"groupId":"OG002","value":"75.0","lowerLimit":"19.4","upperLimit":"99.4"},{"groupId":"OG003","value":"16.7","lowerLimit":"2.1","upperLimit":"48.4"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"24.7","upperLimit":"75.3"},{"groupId":"OG001","value":"56.3","lowerLimit":"29.9","upperLimit":"80.2"},{"groupId":"OG002","value":"75.0","lowerLimit":"19.4","upperLimit":"99.4"},{"groupId":"OG003","value":"33.3","lowerLimit":"9.9","upperLimit":"65.1"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG001","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"25.0","lowerLimit":"5.5","upperLimit":"57.2"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG001","value":"31.3","lowerLimit":"11.0","upperLimit":"58.7"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"31.3","lowerLimit":"11.0","upperLimit":"58.7"},{"groupId":"OG001","value":"43.8","lowerLimit":"19.8","upperLimit":"70.1"},{"groupId":"OG002","value":"75.0","lowerLimit":"19.4","upperLimit":"99.4"},{"groupId":"OG003","value":"33.3","lowerLimit":"9.9","upperLimit":"65.1"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG001","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG002","value":"75.0","lowerLimit":"19.4","upperLimit":"99.4"},{"groupId":"OG003","value":"33.3","lowerLimit":"9.9","upperLimit":"65.1"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"8.3","lowerLimit":"0.2","upperLimit":"38.5"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"25.0","lowerLimit":"0.6","upperLimit":"80.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"60.2"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"26.5"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3:>=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants aged 5 to \\<12 years were administered BNT162b2 10 mcg at Dose 3; hence, combined data is reported in this outcome measure. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 1: 5 to <12 Years BNT162b2 10 mcg","description":"Participants aged 5 to \\<12 years who received the third dose of 10 mcg BNT162b2 as part of this study were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"classes":[{"title":"Fever:>=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.1","upperLimit":"13.8"}]}]},{"title":"Fever:38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.1","upperLimit":"13.8"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"39.5","lowerLimit":"24.0","upperLimit":"56.6"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"21.1","lowerLimit":"9.6","upperLimit":"37.3"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"6.0","upperLimit":"31.3"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.1","upperLimit":"13.8"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"34.2","lowerLimit":"19.6","upperLimit":"51.4"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"21.1","lowerLimit":"9.6","upperLimit":"37.3"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"10.5","lowerLimit":"2.9","upperLimit":"24.8"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.1","upperLimit":"13.8"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"6.0","upperLimit":"31.3"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"13.2","lowerLimit":"4.4","upperLimit":"28.1"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.1","upperLimit":"13.8"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.1","upperLimit":"13.8"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.1","upperLimit":"13.8"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"7.9","lowerLimit":"1.7","upperLimit":"21.4"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.1","upperLimit":"13.8"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"5.3","lowerLimit":"0.6","upperLimit":"17.7"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.1","upperLimit":"13.8"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"0.1","upperLimit":"13.8"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"9.3"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"32"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"28.1","lowerLimit":"13.7","upperLimit":"46.7"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"25.0","lowerLimit":"11.5","upperLimit":"43.4"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"9.4","lowerLimit":"2.0","upperLimit":"25.0"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"31.3","lowerLimit":"11.0","upperLimit":"58.7"},{"groupId":"OG001","value":"62.5","lowerLimit":"43.7","upperLimit":"78.9"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG001","value":"56.3","lowerLimit":"37.7","upperLimit":"73.6"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"32"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"15.6","lowerLimit":"5.3","upperLimit":"32.8"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"15.6","lowerLimit":"5.3","upperLimit":"32.8"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"37.5","lowerLimit":"15.2","upperLimit":"64.6"},{"groupId":"OG001","value":"53.1","lowerLimit":"34.7","upperLimit":"70.9"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"37.5","lowerLimit":"15.2","upperLimit":"64.6"},{"groupId":"OG001","value":"43.8","lowerLimit":"26.4","upperLimit":"62.3"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"9.4","lowerLimit":"2.0","upperLimit":"25.0"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Data reported in \"Phase 1: BNT162b2: 2 to \\<5 Years of Age (Dose 3- 3 mcg)\" arm is for only participants whose e-diary data was transmitted after dose 3. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg)","description":"Participants aged 2 to \\<5 years at the time of receiving third dose received age appropriate dose of 3 mcg BNT162b2 intramuscularly as part of this study."},{"id":"OG001","title":"Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg)","description":"Participants in the 2 to \\< 5 years of age group who aged up to 5 years at the time of the 3rd dose received the age-appropriate dose of 10 mcg BNT162b2 intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"13"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"0.1","upperLimit":"19.6"},{"groupId":"OG001","value":"15.4","lowerLimit":"1.9","upperLimit":"45.4"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"0.1","upperLimit":"19.6"},{"groupId":"OG001","value":"15.4","lowerLimit":"1.9","upperLimit":"45.4"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"34.6","lowerLimit":"17.2","upperLimit":"55.7"},{"groupId":"OG001","value":"84.6","lowerLimit":"54.6","upperLimit":"98.1"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"34.6","lowerLimit":"17.2","upperLimit":"55.7"},{"groupId":"OG001","value":"38.5","lowerLimit":"13.9","upperLimit":"68.4"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"38.5","lowerLimit":"13.9","upperLimit":"68.4"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"32"}]}],"classes":[{"title":"Fever: >=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"18.8","lowerLimit":"7.2","upperLimit":"36.4"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG001","value":"46.9","lowerLimit":"29.1","upperLimit":"65.3"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"},{"groupId":"OG001","value":"34.4","lowerLimit":"18.6","upperLimit":"53.2"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"12.5","lowerLimit":"3.5","upperLimit":"29.0"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG001","value":"9.4","lowerLimit":"2.0","upperLimit":"25.0"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"32"}]}],"classes":[{"title":"Fever: >=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"18.8","lowerLimit":"7.2","upperLimit":"36.4"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"9.4","lowerLimit":"2.0","upperLimit":"25.0"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG001","value":"59.4","lowerLimit":"40.6","upperLimit":"76.3"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG001","value":"31.3","lowerLimit":"16.1","upperLimit":"50.0"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG001","value":"28.1","lowerLimit":"13.7","upperLimit":"46.7"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"},{"groupId":"OG001","value":"15.6","lowerLimit":"5.3","upperLimit":"32.8"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"9.4","lowerLimit":"2.0","upperLimit":"25.0"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"12.5","lowerLimit":"3.5","upperLimit":"29.0"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"},{"groupId":"OG001","value":"12.5","lowerLimit":"3.5","upperLimit":"29.0"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"9.4","lowerLimit":"2.0","upperLimit":"25.0"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"0.8","upperLimit":"20.8"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"0.1","upperLimit":"16.2"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Data reported in \"Phase 1: BNT162b2: 2 to \\<5 Years of Age (Dose 3- 3 mcg)\" arm is for only participants whose e-diary data was transmitted after dose 3. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg)","description":"Participants aged 2 to \\<5 years at the time of receiving third dose received age appropriate dose of 3 mcg BNT162b2 intramuscularly as part of this study."},{"id":"OG001","title":"Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg)","description":"Participants in the 2 to \\< 5 years of age group who aged up to 5 years at the time of the 3rd dose received the age-appropriate dose of 10 mcg BNT162b2 intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"13"}]}],"classes":[{"title":"Fever: >=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"15.4","lowerLimit":"1.9","upperLimit":"45.4"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"30.8","lowerLimit":"14.3","upperLimit":"51.8"},{"groupId":"OG001","value":"53.8","lowerLimit":"25.1","upperLimit":"80.8"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"19.2","lowerLimit":"6.6","upperLimit":"39.4"},{"groupId":"OG001","value":"23.1","lowerLimit":"5.0","upperLimit":"53.8"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"2.4","upperLimit":"30.2"},{"groupId":"OG001","value":"30.8","lowerLimit":"9.1","upperLimit":"61.4"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"0.1","upperLimit":"19.6"},{"groupId":"OG001","value":"23.1","lowerLimit":"5.0","upperLimit":"53.8"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"0.1","upperLimit":"19.6"},{"groupId":"OG001","value":"15.4","lowerLimit":"1.9","upperLimit":"45.4"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"15.4","lowerLimit":"1.9","upperLimit":"45.4"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"23.1","lowerLimit":"5.0","upperLimit":"53.8"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"23.1","lowerLimit":"5.0","upperLimit":"53.8"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"0.1","upperLimit":"19.6"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"0.1","upperLimit":"19.6"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"15.4","lowerLimit":"1.9","upperLimit":"45.4"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"7.7","lowerLimit":"0.2","upperLimit":"36.0"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"13.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age","description":"Participants aged 6 months to \\<2 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Tenderness at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Tenderness at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Tenderness at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Tenderness at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Tenderness at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age","description":"Participants aged 6 months to \\< 2 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Tenderness at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Tenderness at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Tenderness at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Tenderness at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Tenderness at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 ER visit or hospitalization for severe tenderness at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age","description":"Participants aged 6 months to \\<2 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"1.7","upperLimit":"40.5"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"1.7","upperLimit":"40.5"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"0.2","upperLimit":"31.9"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"0.2","upperLimit":"31.9"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Tenderness at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"26.7","lowerLimit":"7.8","upperLimit":"55.1"}]}]},{"title":"Tenderness at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"26.7","lowerLimit":"7.8","upperLimit":"55.1"}]}]},{"title":"Tenderness at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Tenderness at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Tenderness at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of Age","description":"Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 1. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age","description":"Participants aged 6 months to \\< 2 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"classes":[{"title":"Fever: >=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Decreased appetite: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Decreased appetite: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Decreased appetite: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Decreased appetite: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Decreased appetite: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Drowsiness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"}]}]},{"title":"Drowsiness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"}]}]},{"title":"Drowsiness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Drowsiness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Drowsiness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Irritability: Any","categories":[{"measurements":[{"groupId":"OG000","value":"43.8","lowerLimit":"19.8","upperLimit":"70.1"}]}]},{"title":"Irritability: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"}]}]},{"title":"Irritability: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"}]}]},{"title":"Irritability: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Irritability: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of Age","description":"Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 2.Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake),severe (refusal to feed).Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted).Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age","description":"Participants aged 6 months to \\<2 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"classes":[{"title":"Fever: >=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Decreased appetite: Any","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"}]}]},{"title":"Decreased appetite: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"}]}]},{"title":"Decreased appetite: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Decreased appetite: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Decreased appetite: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Drowsiness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Drowsiness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Drowsiness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Drowsiness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Drowsiness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Irritability: Any","categories":[{"measurements":[{"groupId":"OG000","value":"31.3","lowerLimit":"11.0","upperLimit":"58.7"}]}]},{"title":"Irritability: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"31.3","lowerLimit":"11.0","upperLimit":"58.7"}]}]},{"title":"Irritability: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Irritability: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]},{"title":"Irritability: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of Age","description":"Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 3. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity).Irritability: mild (easily consolable), moderate (requiring increased attention), severe(Inconsolable; crying cannot be comforted).Grade 4 for all events except fever: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age","description":"Participants aged 6 months to \\< 2 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Fever: >=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"0.2","upperLimit":"31.9"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"0.2","upperLimit":"31.9"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Decreased appetite: Any","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"1.7","upperLimit":"40.5"}]}]},{"title":"Decreased appetite: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"0.2","upperLimit":"31.9"}]}]},{"title":"Decreased appetite: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"0.2","upperLimit":"31.9"}]}]},{"title":"Decreased appetite: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Decreased appetite: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Drowsiness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"0.2","upperLimit":"31.9"}]}]},{"title":"Drowsiness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Drowsiness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"0.2","upperLimit":"31.9"}]}]},{"title":"Drowsiness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Drowsiness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Irritability: Any","categories":[{"measurements":[{"groupId":"OG000","value":"26.7","lowerLimit":"7.8","upperLimit":"55.1"}]}]},{"title":"Irritability: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"1.7","upperLimit":"40.5"}]}]},{"title":"Irritability: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"1.7","upperLimit":"40.5"}]}]},{"title":"Irritability: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]},{"title":"Irritability: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"21.8"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants Reporting Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: From Dose 1 to 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG002","title":"Phase 1: BNT162b2 (30/30 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG003","title":"Phase 1: BNT162b2 (30/10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","lowerLimit":"19.8","upperLimit":"70.1"},{"groupId":"OG001","value":"31.3","lowerLimit":"11.0","upperLimit":"58.7"},{"groupId":"OG002","value":"50.0","lowerLimit":"6.8","upperLimit":"93.2"},{"groupId":"OG003","value":"25.0","lowerLimit":"5.5","upperLimit":"57.2"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants aged 5 to \\<12 years were administered BNT162b2 10 mcg at Dose 3; hence, combined data is reported in this outcome measure. Here, 'Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: From Dose 3 to 1 Month after Dose 3","groups":[{"id":"OG000","title":"Phase 1: 5 to <12 Years BNT162b2 10 mcg","description":"Participants aged 5 to \\<12 years who received the third dose of 10 mcg BNT162b2 as part of this study were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"6.0","upperLimit":"31.3"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants Reporting Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 2: >=5 to <12 Years of Age","description":"A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: From Dose 1 to 6 Months after Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG002","title":"Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG003","title":"Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG003","value":"0","lowerLimit":"0","upperLimit":"0"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic Exact 2-sided 95% CI based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants aged 5 to \\<12 years were administered BNT162b2 10 mcg at Dose 3; hence, combined data is reported in this outcome measure. Here, 'Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: From Dose 3 to 6 Months after Dose 3","groups":[{"id":"OG000","title":"Phase 1: 5 to <12 Years BNT162b2 10 mcg","description":"Participants aged 5 to \\<12 years who received the third dose of 10 mcg BNT162b2 as part of this study were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: From Dose 1 to 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG001","value":"37.5","lowerLimit":"21.1","upperLimit":"56.3"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=2 to <5 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Exact 2-sided 95% CI based on the Clopper and Pearson method. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: From Dose 3 to 1 Month after Dose 3","groups":[{"id":"OG000","title":"Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg)","description":"Participants aged 2 to \\<5 years at the time of receiving third dose received age appropriate dose of 3 mcg BNT162b2 intramuscularly as part of this study."},{"id":"OG001","title":"Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg)","description":"Participants in the 2 to \\< 5years of age group who aged up to 5 years at the time of the 3rd dose received the age-appropriate dose of 10 mcg BNT162b2 intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","lowerLimit":"2.4","upperLimit":"29.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"24.7"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: From Dose 1 to 6 Months after Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"20.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"10.9"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=2 to <5 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: From Dose 3 to 6 Months after Dose 3","groups":[{"id":"OG000","title":"Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 3 mcg)","description":"Participants aged 2 to \\<5 years at the time of receiving third dose received age appropriate dose of 3 mcg BNT162b2 intramuscularly as part of this study."},{"id":"OG001","title":"Phase 1: BNT162b2: 2 to <5 Years of Age (Dose 3- 10 mcg)","description":"Participants in the 2 to \\< 5years of age group who aged up to 5 years at the time of the 3rd dose received the age-appropriate dose of 10 mcg BNT162b2 intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"12.8"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"24.7"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=6 Months to <2 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: From Dose 1 to 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age","description":"Participants aged 6 months to \\<2 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"1.6","upperLimit":"38.3"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=6 Months to <2 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided 95% CI based on the Clopper and Pearson method.Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: From Dose 3 to 1 Month after Dose 3","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age","description":"Participants aged 6 months to \\<2 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"0.2","upperLimit":"31.9"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=6 Months to <2 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.Exact 2-sided 95% CI based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: From Dose 1 to 6 Months after Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age","description":"Participants aged 6 months to \\< 2 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"20.6"}]}]}]},{"type":"PRIMARY","title":"Phase 1: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 1: From Dose 3 to 6 Months after Dose 3","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age","description":"Participants aged 6 months to \\<2 years of age received 2 doses of 3 microgram (mcg) BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"21.8"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \\>2.0 to 5.0 cm), moderate (\\>5.0 to 10.0), severe \\>10.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"515"},{"groupId":"OG001","value":"260"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"15.5","lowerLimit":"12.5","upperLimit":"19.0"},{"groupId":"OG001","value":"6.2","lowerLimit":"3.6","upperLimit":"9.8"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"11.8","lowerLimit":"9.2","upperLimit":"15.0"},{"groupId":"OG001","value":"5.4","lowerLimit":"3.0","upperLimit":"8.9"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.7","lowerLimit":"2.2","upperLimit":"5.7"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.0","upperLimit":"2.1"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.0","upperLimit":"2.1"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"8.3","upperLimit":"13.9"},{"groupId":"OG001","value":"4.6","lowerLimit":"2.4","upperLimit":"7.9"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"7.6","lowerLimit":"5.4","upperLimit":"10.2"},{"groupId":"OG001","value":"2.7","lowerLimit":"1.1","upperLimit":"5.5"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.3","lowerLimit":"1.9","upperLimit":"5.2"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.6","upperLimit":"4.4"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"72.4","lowerLimit":"68.3","upperLimit":"76.2"},{"groupId":"OG001","value":"28.1","lowerLimit":"22.7","upperLimit":"34.0"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"57.7","lowerLimit":"53.3","upperLimit":"62.0"},{"groupId":"OG001","value":"23.5","lowerLimit":"18.4","upperLimit":"29.1"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"14.8","lowerLimit":"11.8","upperLimit":"18.1"},{"groupId":"OG001","value":"4.6","lowerLimit":"2.4","upperLimit":"7.9"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \\>2.0 to 5.0 cm), moderate (\\>5.0 to 10.0), severe \\>10.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age","description":"Participants aged 12 to \\<16 years received 2 doses of 30 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"475"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"1.0","upperLimit":"3.8"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"0.6","upperLimit":"3.0"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.1","upperLimit":"1.8"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"4.4","lowerLimit":"2.8","upperLimit":"6.7"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"1.5","upperLimit":"4.6"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"0.7","upperLimit":"3.3"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"72.4","lowerLimit":"68.2","upperLimit":"76.4"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"43.8","lowerLimit":"39.3","upperLimit":"48.4"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"28.2","lowerLimit":"24.2","upperLimit":"32.5"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.5"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"497"},{"groupId":"OG001","value":"107"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"16.7","lowerLimit":"13.5","upperLimit":"20.3"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.2","upperLimit":"6.6"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.9","lowerLimit":"7.4","upperLimit":"12.8"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.2","upperLimit":"6.6"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.8","lowerLimit":"4.8","upperLimit":"9.4"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"8.8","upperLimit":"14.6"},{"groupId":"OG001","value":"4.7","lowerLimit":"1.5","upperLimit":"10.6"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.8","lowerLimit":"4.8","upperLimit":"9.4"},{"groupId":"OG001","value":"2.8","lowerLimit":"0.6","upperLimit":"8.0"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"4.6","lowerLimit":"3.0","upperLimit":"6.9"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.2","upperLimit":"6.6"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"66.8","lowerLimit":"62.5","upperLimit":"70.9"},{"groupId":"OG001","value":"23.4","lowerLimit":"15.7","upperLimit":"32.5"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"48.3","lowerLimit":"43.8","upperLimit":"52.8"},{"groupId":"OG001","value":"19.6","lowerLimit":"12.6","upperLimit":"28.4"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"18.5","lowerLimit":"15.2","upperLimit":"22.2"},{"groupId":"OG001","value":"3.7","lowerLimit":"1.0","upperLimit":"9.3"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \\>2.0 to 5.0 cm),moderate (\\>5.0 to 10.0), severe \\>10.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age","description":"Participants aged 12 to \\<16 years received 2 doses of 30 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.2","upperLimit":"2.3"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.6"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.8","upperLimit":"3.5"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.2","upperLimit":"2.3"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.2","upperLimit":"2.3"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"57.8","lowerLimit":"53.1","upperLimit":"62.4"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"36.6","lowerLimit":"32.1","upperLimit":"41.3"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"20.8","lowerLimit":"17.1","upperLimit":"24.8"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.6"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants of Phase 2/3 Troponin Group: Placebo: 5 to \\<12 Years of age: group did not receive dose 3 and therefore were not analyzed for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"394"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"17.0","lowerLimit":"13.4","upperLimit":"21.1"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"11.2","lowerLimit":"8.2","upperLimit":"14.7"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"3.7","upperLimit":"8.6"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"12.7","lowerLimit":"9.6","upperLimit":"16.4"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.4","lowerLimit":"6.7","upperLimit":"12.7"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.3","lowerLimit":"1.8","upperLimit":"5.6"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"69.3","lowerLimit":"64.5","upperLimit":"73.8"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"48.0","lowerLimit":"42.9","upperLimit":"53.0"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"20.8","lowerLimit":"16.9","upperLimit":"25.2"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.1","upperLimit":"1.8"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \\>2.0 to 5.0 cm), moderate (\\>5.0 to 10.0), severe \\>10.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age","description":"Participants aged 12 to \\<16 years received 2 doses of 30 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"405"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"1.9","upperLimit":"5.7"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"1.5","upperLimit":"5.1"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.1","upperLimit":"1.8"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"1.5","upperLimit":"5.1"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"0.9","upperLimit":"3.9"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.3","upperLimit":"2.5"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"63.5","lowerLimit":"58.6","upperLimit":"68.2"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"35.8","lowerLimit":"31.1","upperLimit":"40.7"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"27.4","lowerLimit":"23.1","upperLimit":"32.0"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1:Troponin Group: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"515"},{"groupId":"OG001","value":"260"}]}],"classes":[{"title":"Fever: >= 38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"0.5","upperLimit":"2.8"},{"groupId":"OG001","value":"3.1","lowerLimit":"1.3","upperLimit":"6.0"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.2","upperLimit":"2.0"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.6","upperLimit":"4.4"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.1","upperLimit":"1.7"},{"groupId":"OG001","value":"1.2","lowerLimit":"0.2","upperLimit":"3.3"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"37.1","lowerLimit":"32.9","upperLimit":"41.4"},{"groupId":"OG001","value":"37.7","lowerLimit":"31.8","upperLimit":"43.9"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"24.1","lowerLimit":"20.4","upperLimit":"28.0"},{"groupId":"OG001","value":"23.8","lowerLimit":"18.8","upperLimit":"29.5"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"13.0","lowerLimit":"10.2","upperLimit":"16.2"},{"groupId":"OG001","value":"13.1","lowerLimit":"9.2","upperLimit":"17.8"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.1","upperLimit":"2.8"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"25.4","lowerLimit":"21.7","upperLimit":"29.4"},{"groupId":"OG001","value":"25.8","lowerLimit":"20.6","upperLimit":"31.5"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"18.3","lowerLimit":"15.0","upperLimit":"21.9"},{"groupId":"OG001","value":"19.2","lowerLimit":"14.6","upperLimit":"24.6"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.8","lowerLimit":"4.8","upperLimit":"9.3"},{"groupId":"OG001","value":"6.5","lowerLimit":"3.9","upperLimit":"10.3"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.0","upperLimit":"1.4"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"7.2","lowerLimit":"5.1","upperLimit":"9.8"},{"groupId":"OG001","value":"9.6","lowerLimit":"6.3","upperLimit":"13.9"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"3.8","upperLimit":"8.0"},{"groupId":"OG001","value":"6.5","lowerLimit":"3.9","upperLimit":"10.3"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"0.5","upperLimit":"2.8"},{"groupId":"OG001","value":"3.1","lowerLimit":"1.3","upperLimit":"6.0"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"0.8","upperLimit":"3.3"},{"groupId":"OG001","value":"2.3","lowerLimit":"0.9","upperLimit":"5.0"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"0.7","upperLimit":"3.0"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.6","upperLimit":"4.4"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.0","upperLimit":"2.1"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.2","lowerLimit":"4.3","upperLimit":"8.7"},{"groupId":"OG001","value":"8.5","lowerLimit":"5.4","upperLimit":"12.5"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.0","lowerLimit":"4.1","upperLimit":"8.4"},{"groupId":"OG001","value":"8.1","lowerLimit":"5.1","upperLimit":"12.1"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.0","upperLimit":"2.1"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"11.7","lowerLimit":"9.0","upperLimit":"14.7"},{"groupId":"OG001","value":"10.0","lowerLimit":"6.6","upperLimit":"14.3"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"8.2","lowerLimit":"5.9","upperLimit":"10.9"},{"groupId":"OG001","value":"7.7","lowerLimit":"4.8","upperLimit":"11.6"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"2.1","upperLimit":"5.5"},{"groupId":"OG001","value":"2.3","lowerLimit":"0.9","upperLimit":"5.0"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"3.5","upperLimit":"7.5"},{"groupId":"OG001","value":"6.9","lowerLimit":"4.2","upperLimit":"10.7"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"2.9","upperLimit":"6.6"},{"groupId":"OG001","value":"5.4","lowerLimit":"3.0","upperLimit":"8.9"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.2","upperLimit":"2.0"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.4","upperLimit":"3.9"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Troponin Group: >=12 to <16 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age","description":"Participants aged 12 to \\<16 years received 2 doses of 30 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"475"}]}],"classes":[{"title":"Fever:>=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"4.2","lowerLimit":"2.6","upperLimit":"6.4"}]}]},{"title":"Fever: 8.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"1.2","upperLimit":"4.1"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.5","upperLimit":"2.7"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.1","upperLimit":"1.8"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"42.3","lowerLimit":"37.8","upperLimit":"46.9"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"26.3","lowerLimit":"22.4","upperLimit":"30.5"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"15.6","lowerLimit":"12.4","upperLimit":"19.2"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.5"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"29.0","upperLimit":"37.7"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"22.9","lowerLimit":"19.2","upperLimit":"27.0"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"7.7","upperLimit":"13.4"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"11.4","lowerLimit":"8.7","upperLimit":"14.6"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"6.3","upperLimit":"11.5"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","lowerLimit":"1.3","upperLimit":"4.4"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"2.9","lowerLimit":"1.6","upperLimit":"4.9"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"1.5","upperLimit":"4.6"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"9.1","lowerLimit":"6.6","upperLimit":"12.0"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.9","lowerLimit":"4.8","upperLimit":"9.6"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"1.0","upperLimit":"3.8"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"26.3","lowerLimit":"22.4","upperLimit":"30.5"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"14.7","lowerLimit":"11.7","upperLimit":"18.2"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"8.3","upperLimit":"14.1"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.1","upperLimit":"1.8"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"10.5","lowerLimit":"7.9","upperLimit":"13.6"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.1","lowerLimit":"3.3","upperLimit":"7.4"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"3.6","upperLimit":"7.9"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin Group: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"497"},{"groupId":"OG001","value":"107"}]}],"classes":[{"title":"Fever: >=38.0","categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"3.3","upperLimit":"7.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Fever:38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.1","upperLimit":"3.9"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.8","upperLimit":"3.4"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.3","upperLimit":"2.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"38.2","lowerLimit":"33.9","upperLimit":"42.7"},{"groupId":"OG001","value":"29.0","lowerLimit":"20.6","upperLimit":"38.5"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"22.5","lowerLimit":"18.9","upperLimit":"26.5"},{"groupId":"OG001","value":"15.9","lowerLimit":"9.5","upperLimit":"24.2"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"15.5","lowerLimit":"12.4","upperLimit":"19.0"},{"groupId":"OG001","value":"13.1","lowerLimit":"7.3","upperLimit":"21.0"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"30.2","lowerLimit":"26.2","upperLimit":"34.4"},{"groupId":"OG001","value":"20.6","lowerLimit":"13.4","upperLimit":"29.5"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"20.1","lowerLimit":"16.7","upperLimit":"23.9"},{"groupId":"OG001","value":"14.0","lowerLimit":"8.1","upperLimit":"22.1"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"9.9","lowerLimit":"7.4","upperLimit":"12.8"},{"groupId":"OG001","value":"6.5","lowerLimit":"2.7","upperLimit":"13.0"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"9.1","lowerLimit":"6.7","upperLimit":"11.9"},{"groupId":"OG001","value":"7.5","lowerLimit":"3.3","upperLimit":"14.2"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"3.9","upperLimit":"8.3"},{"groupId":"OG001","value":"6.5","lowerLimit":"2.7","upperLimit":"13.0"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"1.9","upperLimit":"5.2"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.0","upperLimit":"5.1"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"1.0","upperLimit":"3.7"},{"groupId":"OG001","value":"3.7","lowerLimit":"1.0","upperLimit":"9.3"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.8","upperLimit":"3.4"},{"groupId":"OG001","value":"2.8","lowerLimit":"0.6","upperLimit":"8.0"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.0","upperLimit":"5.1"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"7.4","lowerLimit":"5.3","upperLimit":"10.1"},{"groupId":"OG001","value":"5.6","lowerLimit":"2.1","upperLimit":"11.8"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"7.0","lowerLimit":"5.0","upperLimit":"9.7"},{"groupId":"OG001","value":"5.6","lowerLimit":"2.1","upperLimit":"11.8"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"14.7","lowerLimit":"11.7","upperLimit":"18.1"},{"groupId":"OG001","value":"11.2","lowerLimit":"5.9","upperLimit":"18.8"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.3","lowerLimit":"6.9","upperLimit":"12.2"},{"groupId":"OG001","value":"9.3","lowerLimit":"4.6","upperLimit":"16.5"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"5.4","lowerLimit":"3.6","upperLimit":"7.8"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.2","upperLimit":"6.6"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.4","lowerLimit":"4.4","upperLimit":"9.0"},{"groupId":"OG001","value":"6.5","lowerLimit":"2.7","upperLimit":"13.0"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.2","lowerLimit":"2.6","upperLimit":"6.4"},{"groupId":"OG001","value":"6.5","lowerLimit":"2.7","upperLimit":"13.0"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.1","upperLimit":"3.9"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.4"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Troponin Group: >=12 to <16 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age","description":"Participants aged 12 to \\<16 years received 2 doses of 30 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"448"}]}],"classes":[{"title":"Fever: >=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"3.3","lowerLimit":"1.9","upperLimit":"5.5"}]}]},{"title":"Fever:38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"0.6","upperLimit":"3.2"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.5","upperLimit":"2.9"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.6"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"36.4","lowerLimit":"31.9","upperLimit":"41.0"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"21.0","lowerLimit":"17.3","upperLimit":"25.1"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"15.0","lowerLimit":"11.8","upperLimit":"18.6"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.6"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"28.9","upperLimit":"37.8"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"19.4","lowerLimit":"15.9","upperLimit":"23.4"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"13.2","lowerLimit":"10.2","upperLimit":"16.7"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.1","upperLimit":"1.9"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"11.2","lowerLimit":"8.4","upperLimit":"14.4"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"7.4","lowerLimit":"5.1","upperLimit":"10.2"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"2.2","upperLimit":"6.0"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.1","upperLimit":"4.1"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"0.9","upperLimit":"3.8"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"4.9","upperLimit":"9.9"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.1","lowerLimit":"3.3","upperLimit":"7.6"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.8","upperLimit":"3.5"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"19.6","lowerLimit":"16.1","upperLimit":"23.6"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"9.6","upperLimit":"15.9"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.9","lowerLimit":"4.7","upperLimit":"9.7"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"4.6","upperLimit":"9.4"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"2.2","upperLimit":"6.0"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"1.4","upperLimit":"4.6"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants of Phase 2/3: Troponin group: Placebo: 5 to \\<12 years of age: group did not receive Dose 3 and therefore were not analyzed for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"394"},{"groupId":"OG001","value":"0"}]}],"classes":[{"title":"Fever: >=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"4.6","lowerLimit":"2.7","upperLimit":"7.1"}]}]},{"title":"Fever:38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","lowerLimit":"1.2","upperLimit":"4.6"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.3","upperLimit":"2.6"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.3","upperLimit":"2.6"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"38.8","lowerLimit":"34.0","upperLimit":"43.8"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"26.4","lowerLimit":"22.1","upperLimit":"31.0"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"11.9","lowerLimit":"8.9","upperLimit":"15.5"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.1","upperLimit":"1.8"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"23.6","lowerLimit":"19.5","upperLimit":"28.1"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"16.2","lowerLimit":"12.7","upperLimit":"20.3"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.9","lowerLimit":"4.6","upperLimit":"9.8"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.1","upperLimit":"1.8"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"8.9","lowerLimit":"6.3","upperLimit":"12.1"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"3.7","upperLimit":"8.6"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"1.4","upperLimit":"4.9"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.7","upperLimit":"3.6"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"0.6","upperLimit":"3.3"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"2.9","upperLimit":"7.4"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.6","lowerLimit":"2.7","upperLimit":"7.1"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"18.5","lowerLimit":"14.8","upperLimit":"22.7"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"10.2","lowerLimit":"7.4","upperLimit":"13.6"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"8.4","lowerLimit":"5.8","upperLimit":"11.6"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"3.7","upperLimit":"8.6"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.1","lowerLimit":"2.3","upperLimit":"6.5"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.7","upperLimit":"3.6"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Troponin Group: >=12 to <16 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from up to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age","description":"Participants aged 12 to \\<16 years received 2 doses of 30 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"405"}]}],"classes":[{"title":"Fever: >=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"1.9","upperLimit":"5.7"}]}]},{"title":"Fever: 8.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"0.7","upperLimit":"3.5"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.4","upperLimit":"2.9"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.1","upperLimit":"1.8"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"36.8","lowerLimit":"32.1","upperLimit":"41.7"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"21.7","lowerLimit":"17.8","upperLimit":"26.1"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"14.8","lowerLimit":"11.5","upperLimit":"18.7"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.4"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"35.3","lowerLimit":"30.7","upperLimit":"40.2"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"23.0","lowerLimit":"19.0","upperLimit":"27.4"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"11.6","lowerLimit":"8.7","upperLimit":"15.1"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.2","upperLimit":"2.1"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"12.8","lowerLimit":"9.7","upperLimit":"16.5"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"8.4","lowerLimit":"5.9","upperLimit":"11.5"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"4.4","lowerLimit":"2.7","upperLimit":"6.9"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"1.4","upperLimit":"4.8"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.0","upperLimit":"4.2"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.1","upperLimit":"1.8"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"4.4","lowerLimit":"2.7","upperLimit":"6.9"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.0","lowerLimit":"2.3","upperLimit":"6.3"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.1","upperLimit":"1.8"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"15.1","upperLimit":"22.9"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"10.6","lowerLimit":"7.8","upperLimit":"14.0"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"8.1","lowerLimit":"5.7","upperLimit":"11.3"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"6.4","lowerLimit":"4.2","upperLimit":"9.3"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.0","lowerLimit":"2.3","upperLimit":"6.3"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","lowerLimit":"1.2","upperLimit":"4.5"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=5 to <12 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 1 to 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Troponin Group: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"518"},{"groupId":"OG001","value":"260"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"5.1","upperLimit":"9.7"},{"groupId":"OG001","value":"8.1","lowerLimit":"5.1","upperLimit":"12.1"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Troponin Group: >=12 to <16 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 1 to 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age","description":"Participants aged 12 to \\<16 years received 2 doses of 30 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"487"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","lowerLimit":"3.5","upperLimit":"7.7"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group: >=5 to <12 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants of Phase 2/3: Troponin group: Placebo: 5 to \\<12 years of age: data was not collected and were analyzed as participant in this group did not receive Dose 3 and therefore were not analyzed for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 3 to 1 Month after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"418"},{"groupId":"OG001","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"8.6","upperLimit":"14.9"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: Troponin Group:>=12 to <16 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 3 to 1 month from dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 3 to 1 Month after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age","description":"Participants aged 12 to \\<16 years received 2 doses of 30 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"433"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"0.5","upperLimit":"3.0"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : Troponin Group: >=5 to <12 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 1 to 6 Months after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3:Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"518"},{"groupId":"OG001","value":"260"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.4"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Troponin Group: >=12 to <16 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 1 to 6 Months after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age","description":"Participants aged 12 to \\<16 years received 2 doses of 30 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"487"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.0","upperLimit":"1.5"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: Troponin Group: >=5 to <12 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants of Phase 2/3: Troponin group: Placebo: 5 to \\<12 years of age: data was not collected and were analyzed as participant in this group did not receive Dose 3 and therefore were not analyzed for this outcome measure. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 3 to 6 Months after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: Troponin Group: BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Troponin Group: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"418"},{"groupId":"OG001","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.1","upperLimit":"1.7"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3 : Troponin Group:>=12 to <16 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 3 to 6 Months after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age","description":"Participants aged 12 to \\<16 years received 2 doses of 30 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"433"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0.8"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"classes":[{"title":"Redness: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","lowerLimit":"12.8","upperLimit":"15.3"},{"groupId":"OG001","value":"5.9","lowerLimit":"4.8","upperLimit":"7.2"}]}]},{"title":"Redness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","lowerLimit":"8.3","upperLimit":"10.3"},{"groupId":"OG001","value":"5.1","lowerLimit":"4.0","upperLimit":"6.3"}]}]},{"title":"Redness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","lowerLimit":"4.0","upperLimit":"5.5"},{"groupId":"OG001","value":"0.7","lowerLimit":"0.4","upperLimit":"1.3"}]}]},{"title":"Redness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Redness: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Swelling: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"9.3","upperLimit":"11.5"},{"groupId":"OG001","value":"3.0","lowerLimit":"2.2","upperLimit":"4.0"}]}]},{"title":"Swelling: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"4.9","upperLimit":"6.6"},{"groupId":"OG001","value":"1.8","lowerLimit":"1.2","upperLimit":"2.6"}]}]},{"title":"Swelling: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","lowerLimit":"3.9","upperLimit":"5.4"},{"groupId":"OG001","value":"1.2","lowerLimit":"0.7","upperLimit":"1.9"}]}]},{"title":"Swelling: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Swelling: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Pain at the injection site: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","lowerLimit":"71.3","upperLimit":"74.5"},{"groupId":"OG001","value":"31.5","lowerLimit":"29.2","upperLimit":"33.9"}]}]},{"title":"Pain at the injection site: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.5","lowerLimit":"56.7","upperLimit":"60.2"},{"groupId":"OG001","value":"28.3","lowerLimit":"26.1","upperLimit":"30.7"}]}]},{"title":"Pain at the injection site: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"13.1","upperLimit":"15.6"},{"groupId":"OG001","value":"3.1","lowerLimit":"2.3","upperLimit":"4.1"}]}]},{"title":"Pain at the injection site: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.1","upperLimit":"0.4"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Pain at the injection site: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity),severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"classes":[{"title":"Redness: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"17.4","upperLimit":"20.2"},{"groupId":"OG001","value":"5.2","lowerLimit":"4.1","upperLimit":"6.4"}]}]},{"title":"Redness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"9.2","upperLimit":"11.4"},{"groupId":"OG001","value":"3.7","lowerLimit":"2.8","upperLimit":"4.8"}]}]},{"title":"Redness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","lowerLimit":"7.4","upperLimit":"9.4"},{"groupId":"OG001","value":"1.3","lowerLimit":"0.8","upperLimit":"2.0"}]}]},{"title":"Redness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Redness: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Swelling: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","lowerLimit":"13.5","upperLimit":"16.0"},{"groupId":"OG001","value":"2.7","lowerLimit":"1.9","upperLimit":"3.6"}]}]},{"title":"Swelling: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","lowerLimit":"7.1","upperLimit":"9.1"},{"groupId":"OG001","value":"2.0","lowerLimit":"1.3","upperLimit":"2.8"}]}]},{"title":"Swelling: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","lowerLimit":"5.8","upperLimit":"7.6"},{"groupId":"OG001","value":"0.7","lowerLimit":"0.4","upperLimit":"1.3"}]}]},{"title":"Swelling: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Swelling: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Pain at the injection site: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.2","lowerLimit":"69.5","upperLimit":"72.8"},{"groupId":"OG001","value":"28.5","lowerLimit":"26.3","upperLimit":"30.9"}]}]},{"title":"Pain at the injection site: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.6","lowerLimit":"51.8","upperLimit":"55.4"},{"groupId":"OG001","value":"25.6","lowerLimit":"23.4","upperLimit":"27.8"}]}]},{"title":"Pain at the injection site: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","lowerLimit":"16.1","upperLimit":"18.8"},{"groupId":"OG001","value":"2.9","lowerLimit":"2.1","upperLimit":"3.9"}]}]},{"title":"Pain at the injection site: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.1","upperLimit":"0.4"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Pain at the injection site: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=5 to <12 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild(\\>=0.5 to 2.0 cm),moderate (\\>2.0 to 7.0 cm),severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants of Phase 2/3: Placebo: 5 to \\<12 years of age: group did not receive Dose 3 and therefore were not analyzed for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2265"},{"groupId":"OG001","value":"0"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"15.6","lowerLimit":"14.2","upperLimit":"17.2"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.4","lowerLimit":"8.3","upperLimit":"10.7"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.1","lowerLimit":"5.1","upperLimit":"7.2"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"12.6","lowerLimit":"11.3","upperLimit":"14.1"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.5","lowerLimit":"5.6","upperLimit":"7.6"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.1","lowerLimit":"5.1","upperLimit":"7.2"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Pain at the injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"69.2","lowerLimit":"67.3","upperLimit":"71.1"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"48.0","lowerLimit":"46.0","upperLimit":"50.1"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"20.9","lowerLimit":"19.3","upperLimit":"22.7"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.1","upperLimit":"0.6"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe(prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"classes":[{"title":"Fever:>=38.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"1.6","upperLimit":"2.6"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.9","upperLimit":"2.1"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.8","upperLimit":"1.6"},{"groupId":"OG001","value":"0.7","lowerLimit":"0.3","upperLimit":"1.2"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.4","upperLimit":"1.1"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.3","upperLimit":"1.1"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Fever: >40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1532"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Fatigue: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","lowerLimit":"32.8","upperLimit":"36.2"},{"groupId":"OG001","value":"32.4","lowerLimit":"30.1","upperLimit":"34.8"}]}]},{"title":"Fatigue: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","lowerLimit":"21.2","upperLimit":"24.2"},{"groupId":"OG001","value":"21.1","lowerLimit":"19.1","upperLimit":"23.2"}]}]},{"title":"Fatigue: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","lowerLimit":"10.5","upperLimit":"12.8"},{"groupId":"OG001","value":"11.2","lowerLimit":"9.6","upperLimit":"12.9"}]}]},{"title":"Fatigue: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.1","upperLimit":"0.4"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Fatigue: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Headache: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","lowerLimit":"21.2","upperLimit":"24.2"},{"groupId":"OG001","value":"24.3","lowerLimit":"22.2","upperLimit":"26.5"}]}]},{"title":"Headache: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","lowerLimit":"15.8","upperLimit":"18.5"},{"groupId":"OG001","value":"18.0","lowerLimit":"16.1","upperLimit":"20.0"}]}]},{"title":"Headache: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"4.7","upperLimit":"6.4"},{"groupId":"OG001","value":"5.9","lowerLimit":"4.8","upperLimit":"7.2"}]}]},{"title":"Headache: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.1","upperLimit":"0.9"}]}]},{"title":"Headache: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Chills: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"4.8","upperLimit":"6.5"},{"groupId":"OG001","value":"5.5","lowerLimit":"4.4","upperLimit":"6.7"}]}]},{"title":"Chills: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"3.8","upperLimit":"5.2"},{"groupId":"OG001","value":"4.5","lowerLimit":"3.5","upperLimit":"5.7"}]}]},{"title":"Chills: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.8","upperLimit":"1.6"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.5","upperLimit":"1.6"}]}]},{"title":"Chills: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Chills: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Vomiting: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"1.6","upperLimit":"2.6"},{"groupId":"OG001","value":"2.0","lowerLimit":"1.3","upperLimit":"2.8"}]}]},{"title":"Vomiting: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"1.3","upperLimit":"2.2"},{"groupId":"OG001","value":"1.8","lowerLimit":"1.2","upperLimit":"2.6"}]}]},{"title":"Vomiting: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.2","upperLimit":"0.6"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Vomiting: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Vomiting: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Diarrhea: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","lowerLimit":"5.6","upperLimit":"7.3"},{"groupId":"OG001","value":"4.9","lowerLimit":"3.9","upperLimit":"6.1"}]}]},{"title":"Diarrhea: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","lowerLimit":"5.1","upperLimit":"6.8"},{"groupId":"OG001","value":"4.7","lowerLimit":"3.7","upperLimit":"5.9"}]}]},{"title":"Diarrhea: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.2","upperLimit":"0.8"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Diarrhea: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Diarrhea: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"New or worsened muscle pain: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","lowerLimit":"8.3","upperLimit":"10.4"},{"groupId":"OG001","value":"8.2","lowerLimit":"6.9","upperLimit":"9.7"}]}]},{"title":"New or worsened muscle pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"5.8","upperLimit":"7.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"5.1","upperLimit":"7.6"}]}]},{"title":"New or worsened muscle pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"2.1","upperLimit":"3.3"},{"groupId":"OG001","value":"2.0","lowerLimit":"1.3","upperLimit":"2.8"}]}]},{"title":"New or worsened muscle pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"New or worsened muscle pain:G4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"New or worsened joint pain:Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"2.8","upperLimit":"4.1"},{"groupId":"OG001","value":"4.6","lowerLimit":"3.6","upperLimit":"5.7"}]}]},{"title":"New or worsened joint pain:Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"1.8","upperLimit":"2.9"},{"groupId":"OG001","value":"3.7","lowerLimit":"2.8","upperLimit":"4.7"}]}]},{"title":"New or worsened joint pain:Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.8","upperLimit":"1.6"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.5","upperLimit":"1.5"}]}]},{"title":"New or worsened joint pain:Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"New or worsened joint pain: G4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3096"},{"groupId":"OG001","value":"1531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 deg C; categorized as \\>=38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C,\\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"classes":[{"title":"Fever: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"5.5","upperLimit":"7.2"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.9","upperLimit":"2.1"}]}]},{"title":"Fever: >=38.0 to 38.4 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","lowerLimit":"2.7","upperLimit":"4.0"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.5","upperLimit":"1.5"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"1.8","upperLimit":"2.9"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.1","upperLimit":"0.8"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.4","upperLimit":"1.0"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Fever: >40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1522"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Fatigue: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.2","lowerLimit":"37.4","upperLimit":"40.9"},{"groupId":"OG001","value":"25.2","lowerLimit":"23.0","upperLimit":"27.4"}]}]},{"title":"Fatigue: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","lowerLimit":"20.3","upperLimit":"23.2"},{"groupId":"OG001","value":"15.1","lowerLimit":"13.4","upperLimit":"17.0"}]}]},{"title":"Fatigue: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","lowerLimit":"15.3","upperLimit":"17.9"},{"groupId":"OG001","value":"9.8","lowerLimit":"8.3","upperLimit":"11.4"}]}]},{"title":"Fatigue: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.6","upperLimit":"1.3"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.1","upperLimit":"0.7"}]}]},{"title":"Fatigue: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Headache: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.4","lowerLimit":"26.8","upperLimit":"30.0"},{"groupId":"OG001","value":"18.7","lowerLimit":"16.7","upperLimit":"20.7"}]}]},{"title":"Headache: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"17.4","upperLimit":"20.2"},{"groupId":"OG001","value":"13.2","lowerLimit":"11.6","upperLimit":"15.0"}]}]},{"title":"Headache: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","lowerLimit":"8.3","upperLimit":"10.4"},{"groupId":"OG001","value":"5.4","lowerLimit":"4.3","upperLimit":"6.6"}]}]},{"title":"Headache: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.1","upperLimit":"0.5"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Headache: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Chills: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","lowerLimit":"8.8","upperLimit":"10.9"},{"groupId":"OG001","value":"4.3","lowerLimit":"3.4","upperLimit":"5.5"}]}]},{"title":"Chills: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"5.8","upperLimit":"7.6"},{"groupId":"OG001","value":"3.4","lowerLimit":"2.6","upperLimit":"4.5"}]}]},{"title":"Chills: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","lowerLimit":"2.5","upperLimit":"3.7"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.5","upperLimit":"1.5"}]}]},{"title":"Chills: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Chills: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Vomiting: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"1.6","upperLimit":"2.6"},{"groupId":"OG001","value":"1.8","lowerLimit":"1.2","upperLimit":"2.6"}]}]},{"title":"Vomiting: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"1.4","upperLimit":"2.4"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.9","upperLimit":"2.2"}]}]},{"title":"Vomiting: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.1","upperLimit":"0.4"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.1","upperLimit":"0.8"}]}]},{"title":"Vomiting: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Vomiting: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Diarrhea: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","lowerLimit":"4.6","upperLimit":"6.3"},{"groupId":"OG001","value":"5.0","lowerLimit":"4.0","upperLimit":"6.2"}]}]},{"title":"Diarrhea: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","lowerLimit":"4.1","upperLimit":"5.7"},{"groupId":"OG001","value":"4.6","lowerLimit":"3.6","upperLimit":"5.8"}]}]},{"title":"Diarrhea: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.3","upperLimit":"0.8"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.1","upperLimit":"0.9"}]}]},{"title":"Diarrhea: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Diarrhea: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"New or worsened muscle pain:Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","lowerLimit":"10.9","upperLimit":"13.2"},{"groupId":"OG001","value":"6.8","lowerLimit":"5.6","upperLimit":"8.2"}]}]},{"title":"New or worsened muscle pain:Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"7.1","upperLimit":"9.0"},{"groupId":"OG001","value":"4.5","lowerLimit":"3.5","upperLimit":"5.6"}]}]},{"title":"New or worsened muscle pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","lowerLimit":"3.3","upperLimit":"4.7"},{"groupId":"OG001","value":"2.4","lowerLimit":"1.7","upperLimit":"3.3"}]}]},{"title":"New or worsened muscle pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"New or worsened muscle pain: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"New or worsened joint pain:Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"4.4","upperLimit":"6.0"},{"groupId":"OG001","value":"3.7","lowerLimit":"2.9","upperLimit":"4.8"}]}]},{"title":"New or worsened joint pain:Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"2.8","upperLimit":"4.1"},{"groupId":"OG001","value":"2.8","lowerLimit":"2.0","upperLimit":"3.7"}]}]},{"title":"New or worsened joint pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"1.4","upperLimit":"2.4"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.6","upperLimit":"1.6"}]}]},{"title":"New or worsened joint pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"New or worsened joint pain: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3064"},{"groupId":"OG001","value":"1521"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=5 to <12 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 deg C; categorized as \\>=38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C,\\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants of Phase 2/3: Placebo: 5 to \\<12 years of age: group did not receive Dose 3 and therefore were not analyzed for this outcome measure.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2265"},{"groupId":"OG001","value":"0"}]}],"classes":[{"title":"Fever: >=38.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"6.8","lowerLimit":"5.8","upperLimit":"7.9"}]}]},{"title":"Fever:38.0 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"4.1","lowerLimit":"3.3","upperLimit":"5.0"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"1.3","upperLimit":"2.4"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.5","upperLimit":"1.4"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"39.6","lowerLimit":"37.6","upperLimit":"41.7"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"21.0","lowerLimit":"19.4","upperLimit":"22.8"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"17.3","lowerLimit":"15.8","upperLimit":"18.9"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.9","upperLimit":"1.8"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"26.9","lowerLimit":"25.1","upperLimit":"28.8"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"16.2","lowerLimit":"14.7","upperLimit":"17.8"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"9.1","upperLimit":"11.7"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.2","upperLimit":"0.8"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"10.2","lowerLimit":"9.0","upperLimit":"11.5"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.2","lowerLimit":"5.2","upperLimit":"7.3"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.9","lowerLimit":"3.1","upperLimit":"4.8"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"2.1","upperLimit":"3.4"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.6","upperLimit":"2.9"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.2","upperLimit":"0.8"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"4.6","lowerLimit":"3.8","upperLimit":"5.5"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"3.5","upperLimit":"5.2"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.1","upperLimit":"0.6"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"New or worsened muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"15.5","lowerLimit":"14.0","upperLimit":"17.0"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"8.8","lowerLimit":"7.7","upperLimit":"10.0"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.5","lowerLimit":"5.6","upperLimit":"7.6"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"New or worsened joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"4.8","upperLimit":"6.7"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"2.8","upperLimit":"4.3"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.6","upperLimit":"2.9"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=2 to <5 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis\\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity),severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2327"},{"groupId":"OG001","value":"1164"}]}],"classes":[{"title":"Redness: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2327"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","lowerLimit":"7.9","upperLimit":"10.3"},{"groupId":"OG001","value":"8.4","lowerLimit":"6.9","upperLimit":"10.2"}]}]},{"title":"Redness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2327"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","lowerLimit":"6.7","upperLimit":"8.9"},{"groupId":"OG001","value":"7.5","lowerLimit":"6.0","upperLimit":"9.1"}]}]},{"title":"Redness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2327"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.8","upperLimit":"1.8"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.4","upperLimit":"1.6"}]}]},{"title":"Redness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2327"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Redness: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2327"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"Swelling: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2327"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","lowerLimit":"3.2","upperLimit":"4.8"},{"groupId":"OG001","value":"3.1","lowerLimit":"2.2","upperLimit":"4.3"}]}]},{"title":"Swelling: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2327"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"2.7","upperLimit":"4.3"},{"groupId":"OG001","value":"2.5","lowerLimit":"1.7","upperLimit":"3.6"}]}]},{"title":"Swelling: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2327"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.2","upperLimit":"0.8"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.2","upperLimit":"1.2"}]}]},{"title":"Swelling: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2327"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"Swelling: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2327"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"Pain at the injection site: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2305"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","lowerLimit":"28.4","upperLimit":"32.2"},{"groupId":"OG001","value":"20.6","lowerLimit":"18.3","upperLimit":"23.1"}]}]},{"title":"Pain at the injection site: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2305"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","lowerLimit":"26.3","upperLimit":"30.0"},{"groupId":"OG001","value":"19.4","lowerLimit":"17.2","upperLimit":"21.8"}]}]},{"title":"Pain at the injection site: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2305"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.6","upperLimit":"2.8"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.6","upperLimit":"1.9"}]}]},{"title":"Pain at the injection site: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2305"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Pain at the injection site: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2305"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=2 to <5 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"classes":[{"title":"Redness: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","lowerLimit":"9.9","upperLimit":"12.7"},{"groupId":"OG001","value":"5.4","lowerLimit":"4.1","upperLimit":"6.9"}]}]},{"title":"Redness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","lowerLimit":"8.3","upperLimit":"10.9"},{"groupId":"OG001","value":"4.6","lowerLimit":"3.4","upperLimit":"6.1"}]}]},{"title":"Redness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"1.1","upperLimit":"2.3"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.3","upperLimit":"1.5"}]}]},{"title":"Redness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Redness: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Swelling: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"4.7","upperLimit":"6.7"},{"groupId":"OG001","value":"2.0","lowerLimit":"1.3","upperLimit":"3.1"}]}]},{"title":"Swelling: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","lowerLimit":"3.6","upperLimit":"5.4"},{"groupId":"OG001","value":"1.8","lowerLimit":"1.1","upperLimit":"2.8"}]}]},{"title":"Swelling: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.8","upperLimit":"1.8"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.0","upperLimit":"0.7"}]}]},{"title":"Swelling: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Swelling: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Pain at the injection site: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.5","lowerLimit":"28.5","upperLimit":"32.5"},{"groupId":"OG001","value":"20.3","lowerLimit":"17.9","upperLimit":"22.9"}]}]},{"title":"Pain at the injection site: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.2","lowerLimit":"26.3","upperLimit":"30.2"},{"groupId":"OG001","value":"19.4","lowerLimit":"17.0","upperLimit":"21.9"}]}]},{"title":"Pain at the injection site: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.6","upperLimit":"2.9"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.4","upperLimit":"1.6"}]}]},{"title":"Pain at the injection site: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Pain at the injection site: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=2 to <5 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization. Grade 4 reactions were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"classes":[{"title":"Redness: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","lowerLimit":"8.4","upperLimit":"12.7"},{"groupId":"OG001","value":"4.8","lowerLimit":"2.9","upperLimit":"7.5"}]}]},{"title":"Redness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","lowerLimit":"7.1","upperLimit":"11.2"},{"groupId":"OG001","value":"4.0","lowerLimit":"2.2","upperLimit":"6.5"}]}]},{"title":"Redness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"0.7","upperLimit":"2.4"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.2","upperLimit":"2.3"}]}]},{"title":"Redness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Redness: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Swelling: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","lowerLimit":"2.0","upperLimit":"4.6"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.6","upperLimit":"3.4"}]}]},{"title":"Swelling: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","lowerLimit":"1.8","upperLimit":"4.3"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.6","upperLimit":"3.4"}]}]},{"title":"Swelling: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"0.9"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Swelling: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Swelling: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Pain at the injection site: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","lowerLimit":"24.9","upperLimit":"31.3"},{"groupId":"OG001","value":"12.8","lowerLimit":"9.6","upperLimit":"16.6"}]}]},{"title":"Pain at the injection site: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","lowerLimit":"23.0","upperLimit":"29.2"},{"groupId":"OG001","value":"12.0","lowerLimit":"8.9","upperLimit":"15.7"}]}]},{"title":"Pain at the injection site: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"1.2","upperLimit":"3.3"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.2","upperLimit":"2.3"}]}]},{"title":"Pain at the injection site: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Pain at the injection site: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=2 to <5 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 deg C; categorized as \\>=38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C,\\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2325"},{"groupId":"OG001","value":"1164"}]}],"classes":[{"title":"Fever:>=38.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2325"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"4.6","upperLimit":"6.5"},{"groupId":"OG001","value":"5.7","lowerLimit":"4.4","upperLimit":"7.2"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2325"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","lowerLimit":"2.4","upperLimit":"3.8"},{"groupId":"OG001","value":"2.6","lowerLimit":"1.7","upperLimit":"3.7"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2325"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"1.0","upperLimit":"2.0"},{"groupId":"OG001","value":"2.1","lowerLimit":"1.3","upperLimit":"3.1"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2325"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.6","upperLimit":"1.4"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.5","upperLimit":"1.8"}]}]},{"title":"Fever: >40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2325"},{"groupId":"OG001","value":"1164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"Fatigue: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","lowerLimit":"28.7","upperLimit":"32.5"},{"groupId":"OG001","value":"31.9","lowerLimit":"29.2","upperLimit":"34.7"}]}]},{"title":"Fatigue: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"17.2","upperLimit":"20.4"},{"groupId":"OG001","value":"19.5","lowerLimit":"17.3","upperLimit":"21.9"}]}]},{"title":"Fatigue: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"10.2","upperLimit":"12.8"},{"groupId":"OG001","value":"11.6","lowerLimit":"9.9","upperLimit":"13.6"}]}]},{"title":"Fatigue: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.2","upperLimit":"0.7"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.4","upperLimit":"1.5"}]}]},{"title":"Fatigue: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"Headache: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","lowerLimit":"4.2","upperLimit":"6.1"},{"groupId":"OG001","value":"4.8","lowerLimit":"3.7","upperLimit":"6.2"}]}]},{"title":"Headache: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","lowerLimit":"3.2","upperLimit":"4.8"},{"groupId":"OG001","value":"3.7","lowerLimit":"2.7","upperLimit":"5.0"}]}]},{"title":"Headache: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.7","upperLimit":"1.6"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.5","upperLimit":"1.8"}]}]},{"title":"Headache: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Headache: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"Chills: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"2.1","upperLimit":"3.5"},{"groupId":"OG001","value":"2.9","lowerLimit":"2.0","upperLimit":"4.1"}]}]},{"title":"Chills: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"1.3","upperLimit":"2.4"},{"groupId":"OG001","value":"2.0","lowerLimit":"1.3","upperLimit":"3.0"}]}]},{"title":"Chills: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.5","upperLimit":"1.3"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.4","upperLimit":"1.6"}]}]},{"title":"Chills: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.4"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Chills: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"Vomiting: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"2.8","upperLimit":"4.4"},{"groupId":"OG001","value":"2.9","lowerLimit":"2.0","upperLimit":"4.1"}]}]},{"title":"Vomiting: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","lowerLimit":"2.2","upperLimit":"3.6"},{"groupId":"OG001","value":"2.1","lowerLimit":"1.3","upperLimit":"3.1"}]}]},{"title":"Vomiting: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.4","upperLimit":"1.1"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.4","upperLimit":"1.6"}]}]},{"title":"Vomiting: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"Vomiting: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"Diarrhea: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"7.4","upperLimit":"9.8"},{"groupId":"OG001","value":"8.3","lowerLimit":"6.8","upperLimit":"10.0"}]}]},{"title":"Diarrhea: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","lowerLimit":"6.8","upperLimit":"9.0"},{"groupId":"OG001","value":"7.4","lowerLimit":"6.0","upperLimit":"9.1"}]}]},{"title":"Diarrhea: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.4","upperLimit":"1.1"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.4","upperLimit":"1.6"}]}]},{"title":"Diarrhea: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"Diarrhea: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"New or worsened muscle pain:Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"2.0","upperLimit":"3.3"},{"groupId":"OG001","value":"2.3","lowerLimit":"1.5","upperLimit":"3.4"}]}]},{"title":"New or worsened muscle pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"1.4","upperLimit":"2.6"},{"groupId":"OG001","value":"1.7","lowerLimit":"1.1","upperLimit":"2.7"}]}]},{"title":"New or worsened muscle pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.4","upperLimit":"1.1"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.2","upperLimit":"1.1"}]}]},{"title":"New or worsened muscle pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"New or worsened muscle pain: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"New or worsened joint pain: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.8","upperLimit":"1.7"},{"groupId":"OG001","value":"1.8","lowerLimit":"1.1","upperLimit":"2.8"}]}]},{"title":"New or worsened joint pain:Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.6","upperLimit":"1.4"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.8","upperLimit":"2.2"}]}]},{"title":"New or worsened joint pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.1","upperLimit":"0.5"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.1","upperLimit":"1.0"}]}]},{"title":"New or worsened joint pain:Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]},{"title":"New or worsened joint pain: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2304"},{"groupId":"OG001","value":"1159"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.3"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=2 to <5 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"classes":[{"title":"Fever: >=38.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"4.3","upperLimit":"6.2"},{"groupId":"OG001","value":"5.8","lowerLimit":"4.4","upperLimit":"7.4"}]}]},{"title":"Fever:38.0 to 38.4 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","lowerLimit":"1.8","upperLimit":"3.2"},{"groupId":"OG001","value":"2.2","lowerLimit":"1.4","upperLimit":"3.3"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"1.0","upperLimit":"2.2"},{"groupId":"OG001","value":"2.6","lowerLimit":"1.7","upperLimit":"3.8"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.7","upperLimit":"1.6"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.4","upperLimit":"1.6"}]}]},{"title":"Fever: >40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2094"},{"groupId":"OG001","value":"1038"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.4"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Fatigue: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","lowerLimit":"24.2","upperLimit":"28.0"},{"groupId":"OG001","value":"24.3","lowerLimit":"21.7","upperLimit":"27.0"}]}]},{"title":"Fatigue: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","lowerLimit":"13.9","upperLimit":"17.1"},{"groupId":"OG001","value":"14.7","lowerLimit":"12.6","upperLimit":"17.0"}]}]},{"title":"Fatigue: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","lowerLimit":"9.0","upperLimit":"11.6"},{"groupId":"OG001","value":"9.3","lowerLimit":"7.6","upperLimit":"11.2"}]}]},{"title":"Fatigue: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.2","upperLimit":"0.8"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.1","upperLimit":"1.0"}]}]},{"title":"Fatigue: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Headache: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","lowerLimit":"3.8","upperLimit":"5.6"},{"groupId":"OG001","value":"4.1","lowerLimit":"3.0","upperLimit":"5.5"}]}]},{"title":"Headache: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"2.7","upperLimit":"4.3"},{"groupId":"OG001","value":"2.6","lowerLimit":"1.7","upperLimit":"3.8"}]}]},{"title":"Headache: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.7","upperLimit":"1.7"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.8","upperLimit":"2.4"}]}]},{"title":"Headache: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Headache: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Chills: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"2.5","upperLimit":"4.0"},{"groupId":"OG001","value":"2.8","lowerLimit":"1.9","upperLimit":"4.0"}]}]},{"title":"Chills: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.6","upperLimit":"2.9"},{"groupId":"OG001","value":"2.2","lowerLimit":"1.4","upperLimit":"3.3"}]}]},{"title":"Chills: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.6","upperLimit":"1.5"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.2","upperLimit":"1.3"}]}]},{"title":"Chills: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Chills: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Vomiting: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"2.6","upperLimit":"4.2"},{"groupId":"OG001","value":"3.4","lowerLimit":"2.4","upperLimit":"4.7"}]}]},{"title":"Vomiting: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"2.3","upperLimit":"3.8"},{"groupId":"OG001","value":"2.9","lowerLimit":"2.0","upperLimit":"4.1"}]}]},{"title":"Vomiting: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.2","upperLimit":"0.8"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.2","upperLimit":"1.1"}]}]},{"title":"Vomiting: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Vomiting: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"Diarrhea: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","lowerLimit":"5.7","upperLimit":"7.9"},{"groupId":"OG001","value":"8.0","lowerLimit":"6.4","upperLimit":"9.8"}]}]},{"title":"Diarrhea: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","lowerLimit":"4.9","upperLimit":"7.0"},{"groupId":"OG001","value":"7.1","lowerLimit":"5.6","upperLimit":"8.9"}]}]},{"title":"Diarrhea: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.5","upperLimit":"1.3"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.3","upperLimit":"1.5"}]}]},{"title":"Diarrhea: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Diarrhea: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"New or worsened muscle pain: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"2.0","upperLimit":"3.4"},{"groupId":"OG001","value":"2.6","lowerLimit":"1.7","upperLimit":"3.8"}]}]},{"title":"New or worsened muscle pain:Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"1.3","upperLimit":"2.6"},{"groupId":"OG001","value":"2.0","lowerLimit":"1.3","upperLimit":"3.1"}]}]},{"title":"New or worsened muscle pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.4","upperLimit":"1.2"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.2","upperLimit":"1.3"}]}]},{"title":"New or worsened muscle pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"New or worsened muscle pain: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"New or worsened joint pain:Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.8","upperLimit":"1.8"},{"groupId":"OG001","value":"1.2","lowerLimit":"0.6","upperLimit":"2.0"}]}]},{"title":"New or worsened joint pain:Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.6","upperLimit":"1.4"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.4","upperLimit":"1.6"}]}]},{"title":"New or worsened joint pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.1","upperLimit":"0.7"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.1","upperLimit":"0.8"}]}]},{"title":"New or worsened joint pain:Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]},{"title":"New or worsened joint pain: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2082"},{"groupId":"OG001","value":"1037"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.4"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=2 to <5 Years of Age","description":"Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 C; categorized as \\>=38.0 deg C, 38.0 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain \\& new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild:1-2 times in 24 hours, moderate: \\>2 times in 24 hours; severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: except fever; ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"classes":[{"title":"Fever: >=38.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","lowerLimit":"3.7","upperLimit":"6.9"},{"groupId":"OG001","value":"5.6","lowerLimit":"3.5","upperLimit":"8.4"}]}]},{"title":"Fever:38.0 to 38.4 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","lowerLimit":"1.5","upperLimit":"3.8"},{"groupId":"OG001","value":"2.1","lowerLimit":"0.9","upperLimit":"4.1"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"1.0","upperLimit":"2.9"},{"groupId":"OG001","value":"1.9","lowerLimit":"0.8","upperLimit":"3.8"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.4","upperLimit":"1.8"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.6","upperLimit":"3.4"}]}]},{"title":"Fever: >40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"799"},{"groupId":"OG001","value":"376"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Fatigue: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","lowerLimit":"22.5","upperLimit":"28.7"},{"groupId":"OG001","value":"24.3","lowerLimit":"20.0","upperLimit":"28.9"}]}]},{"title":"Fatigue: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"13.5","upperLimit":"18.8"},{"groupId":"OG001","value":"14.7","lowerLimit":"11.2","upperLimit":"18.7"}]}]},{"title":"Fatigue: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","lowerLimit":"7.3","upperLimit":"11.4"},{"groupId":"OG001","value":"9.3","lowerLimit":"6.6","upperLimit":"12.7"}]}]},{"title":"Fatigue: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.0","upperLimit":"0.9"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.5"}]}]},{"title":"Fatigue: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Headache: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"3.2","upperLimit":"6.2"},{"groupId":"OG001","value":"4.0","lowerLimit":"2.3","upperLimit":"6.5"}]}]},{"title":"Headache: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","lowerLimit":"1.8","upperLimit":"4.3"},{"groupId":"OG001","value":"2.9","lowerLimit":"1.5","upperLimit":"5.2"}]}]},{"title":"Headache: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"0.9","upperLimit":"2.8"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.3","upperLimit":"2.7"}]}]},{"title":"Headache: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Headache: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Chills: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"1.7","upperLimit":"4.2"},{"groupId":"OG001","value":"2.7","lowerLimit":"1.3","upperLimit":"4.8"}]}]},{"title":"Chills: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"1.3","upperLimit":"3.4"},{"groupId":"OG001","value":"2.4","lowerLimit":"1.1","upperLimit":"4.5"}]}]},{"title":"Chills: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.1","upperLimit":"1.3"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.5"}]}]},{"title":"Chills: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Chills: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Vomiting: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"1.2","upperLimit":"3.3"},{"groupId":"OG001","value":"4.3","lowerLimit":"2.5","upperLimit":"6.8"}]}]},{"title":"Vomiting: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"0.8","upperLimit":"2.6"},{"groupId":"OG001","value":"2.9","lowerLimit":"1.5","upperLimit":"5.2"}]}]},{"title":"Vomiting: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.1","upperLimit":"1.3"},{"groupId":"OG001","value":"1.3","lowerLimit":"0.4","upperLimit":"3.1"}]}]},{"title":"Vomiting: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Vomiting: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Diarrhea: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","lowerLimit":"3.5","upperLimit":"6.7"},{"groupId":"OG001","value":"5.6","lowerLimit":"3.5","upperLimit":"8.4"}]}]},{"title":"Diarrhea: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"2.6","upperLimit":"5.4"},{"groupId":"OG001","value":"4.5","lowerLimit":"2.7","upperLimit":"7.2"}]}]},{"title":"Diarrhea: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.5","upperLimit":"2.1"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.3","upperLimit":"2.7"}]}]},{"title":"Diarrhea: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Diarrhea: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"New or worsened muscle pain: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"1.1","upperLimit":"3.1"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.6","upperLimit":"3.4"}]}]},{"title":"New or worsened muscle pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"0.8","upperLimit":"2.6"},{"groupId":"OG001","value":"1.3","lowerLimit":"0.4","upperLimit":"3.1"}]}]},{"title":"New or worsened muscle pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.1"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.5"}]}]},{"title":"New or worsened muscle pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"New or worsened muscle pain: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"New or worsened joint pain: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.5","upperLimit":"2.1"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.3","upperLimit":"2.7"}]}]},{"title":"New or worsened joint pain: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.4","upperLimit":"1.8"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.3","upperLimit":"2.7"}]}]},{"title":"New or worsened joint pain: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"New or worsened joint pain: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.7"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"New or worsened joint pain: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"793"},{"groupId":"OG001","value":"375"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.0"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: >=6 Months to <2 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 1. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"classes":[{"title":"Redness: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","lowerLimit":"9.2","upperLimit":"12.4"},{"groupId":"OG001","value":"7.6","lowerLimit":"5.7","upperLimit":"9.8"}]}]},{"title":"Redness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","lowerLimit":"8.3","upperLimit":"11.5"},{"groupId":"OG001","value":"7.2","lowerLimit":"5.4","upperLimit":"9.3"}]}]},{"title":"Redness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.5","upperLimit":"1.5"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.1","upperLimit":"1.2"}]}]},{"title":"Redness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Redness: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Swelling: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"2.8","upperLimit":"4.9"},{"groupId":"OG001","value":"2.5","lowerLimit":"1.5","upperLimit":"4.0"}]}]},{"title":"Swelling: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","lowerLimit":"2.5","upperLimit":"4.4"},{"groupId":"OG001","value":"2.2","lowerLimit":"1.3","upperLimit":"3.6"}]}]},{"title":"Swelling: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.2","upperLimit":"0.9"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Swelling: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Swelling: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Tenderness at injection site: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","lowerLimit":"15.3","upperLimit":"19.3"},{"groupId":"OG001","value":"12.6","lowerLimit":"10.2","upperLimit":"15.3"}]}]},{"title":"Tenderness at injection site: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","lowerLimit":"14.4","upperLimit":"18.3"},{"groupId":"OG001","value":"11.5","lowerLimit":"9.2","upperLimit":"14.1"}]}]},{"title":"Tenderness at injection site:Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.4","upperLimit":"1.5"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.5","upperLimit":"2.2"}]}]},{"title":"Tenderness at injection site:Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.4"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Tenderness at injection site: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 2: >=6 Months to <2 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 2. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate(hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1323"},{"groupId":"OG001","value":"666"}]}],"classes":[{"title":"Redness: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1323"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","lowerLimit":"8.3","upperLimit":"11.6"},{"groupId":"OG001","value":"6.3","lowerLimit":"4.6","upperLimit":"8.4"}]}]},{"title":"Redness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1323"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","lowerLimit":"7.6","upperLimit":"10.7"},{"groupId":"OG001","value":"5.9","lowerLimit":"4.2","upperLimit":"7.9"}]}]},{"title":"Redness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1323"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.4","upperLimit":"1.5"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.1","upperLimit":"1.3"}]}]},{"title":"Redness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1323"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Redness: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1323"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Swelling: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1323"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","lowerLimit":"3.1","upperLimit":"5.3"},{"groupId":"OG001","value":"1.5","lowerLimit":"0.7","upperLimit":"2.7"}]}]},{"title":"Swelling: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1323"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"2.6","upperLimit":"4.6"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.6","upperLimit":"2.5"}]}]},{"title":"Swelling: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1323"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.3","upperLimit":"1.2"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Swelling: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1323"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Swelling: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1323"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Tenderness at injection site: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","lowerLimit":"13.5","upperLimit":"17.5"},{"groupId":"OG001","value":"9.3","lowerLimit":"7.2","upperLimit":"11.8"}]}]},{"title":"Tenderness at injection site:Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","lowerLimit":"12.0","upperLimit":"15.8"},{"groupId":"OG001","value":"7.7","lowerLimit":"5.8","upperLimit":"10.0"}]}]},{"title":"Tenderness at injection site:Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"1.0","upperLimit":"2.4"},{"groupId":"OG001","value":"1.7","lowerLimit":"0.8","upperLimit":"2.9"}]}]},{"title":"Tenderness at injection site:Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.4"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Tenderness at injection site: G4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.6"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Local Reactions Within 7 Days After Dose 3: >=6 Months to <2 Years of Age","description":"Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after Dose 3. Redness and swelling were measured and recorded in mdu where,1 mdu =0.5 cm and were graded as mild (\\>=0.5 to 2.0 cm), moderate (\\>2.0 to 7.0 cm), severe (\\>7.0 cm) and Grade 4 (necrosis \\[redness and swelling\\] or exfoliative dermatitis \\[redness\\]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) and Grade 4 (ER visit or hospitalization).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"classes":[{"title":"Redness: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","lowerLimit":"5.0","upperLimit":"9.9"},{"groupId":"OG001","value":"5.0","lowerLimit":"2.5","upperLimit":"8.7"}]}]},{"title":"Redness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"3.2","upperLimit":"7.4"},{"groupId":"OG001","value":"4.5","lowerLimit":"2.2","upperLimit":"8.1"}]}]},{"title":"Redness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"0.9","upperLimit":"3.7"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"2.5"}]}]},{"title":"Redness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Redness: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Swelling: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","lowerLimit":"1.8","upperLimit":"5.3"},{"groupId":"OG001","value":"2.3","lowerLimit":"0.7","upperLimit":"5.2"}]}]},{"title":"Swelling: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"0.9","upperLimit":"3.7"},{"groupId":"OG001","value":"2.3","lowerLimit":"0.7","upperLimit":"5.2"}]}]},{"title":"Swelling: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.5","upperLimit":"2.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Swelling: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Swelling: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Tenderness at injection site:Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","lowerLimit":"11.6","upperLimit":"18.3"},{"groupId":"OG001","value":"9.9","lowerLimit":"6.3","upperLimit":"14.6"}]}]},{"title":"Tenderness at injection site:Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","lowerLimit":"10.0","upperLimit":"16.4"},{"groupId":"OG001","value":"8.6","lowerLimit":"5.2","upperLimit":"13.0"}]}]},{"title":"Tenderness at injection site: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.8","upperLimit":"3.4"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.3","upperLimit":"3.9"}]}]},{"title":"Tenderness at injection site:Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Tenderness at injection site: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 1: >=6 Months to <2 Years of Age","description":"Systemic events recorded in an e-diary \\& at unscheduled clinical assessments up to Day 7 after Dose 1. Fever: oral temperature \\>= 38.0 deg C; categorised as \\>=38.0 to 38.4 deg C,\\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Decreased appetite: mild (decreased interest in eating),moderate (decreased oral intake),severe(refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 1","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"classes":[{"title":"Fever: >=38.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","lowerLimit":"5.9","upperLimit":"8.7"},{"groupId":"OG001","value":"7.4","lowerLimit":"5.6","upperLimit":"9.6"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"2.5","upperLimit":"4.5"},{"groupId":"OG001","value":"3.5","lowerLimit":"2.3","upperLimit":"5.1"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.5","upperLimit":"3.1"},{"groupId":"OG001","value":"2.5","lowerLimit":"1.5","upperLimit":"4.0"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"1.0","upperLimit":"2.3"},{"groupId":"OG001","value":"1.3","lowerLimit":"0.6","upperLimit":"2.4"}]}]},{"title":"Fever: >40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1439"},{"groupId":"OG001","value":"712"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.4"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Decreased appetite: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","lowerLimit":"20.5","upperLimit":"24.9"},{"groupId":"OG001","value":"21.2","lowerLimit":"18.3","upperLimit":"24.5"}]}]},{"title":"Decreased appetite: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","lowerLimit":"10.7","upperLimit":"14.2"},{"groupId":"OG001","value":"12.0","lowerLimit":"9.7","upperLimit":"14.7"}]}]},{"title":"Decreased appetite: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"8.6","upperLimit":"11.8"},{"groupId":"OG001","value":"8.9","lowerLimit":"6.9","upperLimit":"11.3"}]}]},{"title":"Decreased appetite: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"0.6"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Decreased appetite: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Drowsiness: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","lowerLimit":"25.5","upperLimit":"30.2"},{"groupId":"OG001","value":"30.0","lowerLimit":"26.7","upperLimit":"33.6"}]}]},{"title":"Drowsiness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","lowerLimit":"19.8","upperLimit":"24.2"},{"groupId":"OG001","value":"22.7","lowerLimit":"19.6","upperLimit":"25.9"}]}]},{"title":"Drowsiness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"4.5","upperLimit":"6.9"},{"groupId":"OG001","value":"6.9","lowerLimit":"5.2","upperLimit":"9.1"}]}]},{"title":"Drowsiness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"0.6"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.1","upperLimit":"1.2"}]}]},{"title":"Drowsiness: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Irritability: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","lowerLimit":"48.4","upperLimit":"53.6"},{"groupId":"OG001","value":"48.2","lowerLimit":"44.4","upperLimit":"51.9"}]}]},{"title":"Irritability: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","lowerLimit":"18.6","upperLimit":"22.8"},{"groupId":"OG001","value":"18.3","lowerLimit":"15.5","upperLimit":"21.3"}]}]},{"title":"Irritability: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.7","lowerLimit":"27.3","upperLimit":"32.1"},{"groupId":"OG001","value":"29.6","lowerLimit":"26.3","upperLimit":"33.1"}]}]},{"title":"Irritability: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.3","upperLimit":"1.3"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Irritability: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1425"},{"groupId":"OG001","value":"706"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.5"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 2: >=6 Months to <2 Years of Age","description":"Systemic events recorded in an e-diary \\& at unscheduled clinical assessments up to Day 7 after Dose 2. Fever: oral temperature \\>= 38.0 deg C; categorised as \\>=38.0 to 38.4 deg C,\\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1322"},{"groupId":"OG001","value":"666"}]}],"classes":[{"title":"Fever: >=38.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1322"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","lowerLimit":"6.3","upperLimit":"9.2"},{"groupId":"OG001","value":"6.5","lowerLimit":"4.7","upperLimit":"8.6"}]}]},{"title":"Fever: 38.0 to 38.4 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1322"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","lowerLimit":"2.7","upperLimit":"4.8"},{"groupId":"OG001","value":"3.6","lowerLimit":"2.3","upperLimit":"5.3"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1322"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"1.4","upperLimit":"3.0"},{"groupId":"OG001","value":"1.7","lowerLimit":"0.8","upperLimit":"2.9"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1322"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"1.2","upperLimit":"2.8"},{"groupId":"OG001","value":"1.2","lowerLimit":"0.5","upperLimit":"2.4"}]}]},{"title":"Fever: >40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1322"},{"groupId":"OG001","value":"666"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.4"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Decreased appetite: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","lowerLimit":"20.3","upperLimit":"24.9"},{"groupId":"OG001","value":"19.4","lowerLimit":"16.5","upperLimit":"22.6"}]}]},{"title":"Decreased appetite: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.9","lowerLimit":"12.1","upperLimit":"15.9"},{"groupId":"OG001","value":"11.3","lowerLimit":"9.0","upperLimit":"14.0"}]}]},{"title":"Decreased appetite: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","lowerLimit":"6.7","upperLimit":"9.8"},{"groupId":"OG001","value":"8.0","lowerLimit":"6.0","upperLimit":"10.3"}]}]},{"title":"Decreased appetite: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.2","upperLimit":"1.0"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Decreased appetite: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Drowsiness: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","lowerLimit":"21.8","upperLimit":"26.5"},{"groupId":"OG001","value":"21.4","lowerLimit":"18.3","upperLimit":"24.7"}]}]},{"title":"Drowsiness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","lowerLimit":"15.8","upperLimit":"20.0"},{"groupId":"OG001","value":"16.9","lowerLimit":"14.1","upperLimit":"19.9"}]}]},{"title":"Drowsiness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","lowerLimit":"4.8","upperLimit":"7.4"},{"groupId":"OG001","value":"4.4","lowerLimit":"2.9","upperLimit":"6.2"}]}]},{"title":"Drowsiness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.1","upperLimit":"0.8"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Drowsiness: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Irritability: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","lowerLimit":"44.2","upperLimit":"49.6"},{"groupId":"OG001","value":"41.4","lowerLimit":"37.6","upperLimit":"45.3"}]}]},{"title":"Irritability: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","lowerLimit":"16.4","upperLimit":"20.7"},{"groupId":"OG001","value":"15.8","lowerLimit":"13.1","upperLimit":"18.8"}]}]},{"title":"Irritability: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","lowerLimit":"25.4","upperLimit":"30.3"},{"groupId":"OG001","value":"24.7","lowerLimit":"21.5","upperLimit":"28.2"}]}]},{"title":"Irritability: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.3","upperLimit":"1.2"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.3","upperLimit":"2.0"}]}]},{"title":"Irritability: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1314"},{"groupId":"OG001","value":"664"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.6"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants With Systemic Events Within 7 Days After Dose 3: >=6 Months to <2 Years of Age","description":"Systemic events recorded in an e-diary and at unscheduled clinical assessments up to Day 7 after Dose 3. Fever: oral temperature \\>= 38.0 deg C; categorised as \\>=38.0 to 38.4 deg C,\\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe(disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). Grade 4 for all events: ER visit or hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.","populationDescription":"Safety population consisted of all participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Day 1 to Day 7 after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"classes":[{"title":"Fever:>=38.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","lowerLimit":"4.1","upperLimit":"8.7"},{"groupId":"OG001","value":"5.9","lowerLimit":"3.2","upperLimit":"9.8"}]}]},{"title":"Fever:38.0 to 38.4 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","lowerLimit":"1.8","upperLimit":"5.3"},{"groupId":"OG001","value":"3.2","lowerLimit":"1.3","upperLimit":"6.4"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"0.5","upperLimit":"2.8"},{"groupId":"OG001","value":"1.8","lowerLimit":"0.5","upperLimit":"4.5"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.4","upperLimit":"2.5"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.1","upperLimit":"3.2"}]}]},{"title":"Fever: >40.0 deg C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Decreased appetite: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","lowerLimit":"16.0","upperLimit":"23.5"},{"groupId":"OG001","value":"13.1","lowerLimit":"8.9","upperLimit":"18.2"}]}]},{"title":"Decreased appetite: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","lowerLimit":"8.5","upperLimit":"14.5"},{"groupId":"OG001","value":"7.2","lowerLimit":"4.2","upperLimit":"11.4"}]}]},{"title":"Decreased appetite: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","lowerLimit":"5.2","upperLimit":"10.3"},{"groupId":"OG001","value":"5.9","lowerLimit":"3.2","upperLimit":"9.8"}]}]},{"title":"Decreased appetite: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.2","upperLimit":"2.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Decreased appetite: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Drowsiness: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","lowerLimit":"17.8","upperLimit":"25.6"},{"groupId":"OG001","value":"12.2","lowerLimit":"8.2","upperLimit":"17.2"}]}]},{"title":"Drowsiness: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"12.6","upperLimit":"19.5"},{"groupId":"OG001","value":"9.0","lowerLimit":"5.6","upperLimit":"13.6"}]}]},{"title":"Drowsiness: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","lowerLimit":"3.4","upperLimit":"7.7"},{"groupId":"OG001","value":"2.7","lowerLimit":"1.0","upperLimit":"5.8"}]}]},{"title":"Drowsiness: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.6"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"2.5"}]}]},{"title":"Drowsiness: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Irritability: Any","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","lowerLimit":"37.4","upperLimit":"46.7"},{"groupId":"OG001","value":"36.9","lowerLimit":"30.6","upperLimit":"43.7"}]}]},{"title":"Irritability: Mild","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"12.6","upperLimit":"19.5"},{"groupId":"OG001","value":"15.3","lowerLimit":"10.8","upperLimit":"20.7"}]}]},{"title":"Irritability: Moderate","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","lowerLimit":"21.8","upperLimit":"30.0"},{"groupId":"OG001","value":"21.6","lowerLimit":"16.4","upperLimit":"27.6"}]}]},{"title":"Irritability: Severe","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.1","upperLimit":"1.6"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]},{"title":"Irritability: Grade 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"0.8"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.6"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=5 to <12 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 1 to 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3109"},{"groupId":"OG001","value":"1538"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","lowerLimit":"9.6","upperLimit":"11.9"},{"groupId":"OG001","value":"9.8","lowerLimit":"8.3","upperLimit":"11.3"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3: >=5 to <12 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants of Phase 2/3: Placebo: 5 to \\<12 years of age: group did not receive Dose 3 and therefore were not analyzed for this outcome measure.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 3 to 1 Month after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2408"},{"groupId":"OG001","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"7.0","upperLimit":"9.2"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=5 to <12 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 1 to 6 Months after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3109"},{"groupId":"OG001","value":"1538"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.1","upperLimit":"0.5"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.5"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=5 to <12 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants of Phase 2/3: Placebo: 5 to \\<12 years of age: group did not receive Dose 3 and therefore were not analyzed for this outcome measure.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 3 to 6 Months after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2408"},{"groupId":"OG001","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.2","upperLimit":"0.8"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: >=2 to <5 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after dose 1 to 1 month from dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 1 to 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2350"},{"groupId":"OG001","value":"1173"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","lowerLimit":"11.8","upperLimit":"14.6"},{"groupId":"OG001","value":"13.0","lowerLimit":"11.1","upperLimit":"15.0"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3:>=2 to <5 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 3 to 1 Month after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"863"},{"groupId":"OG001","value":"405"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"3.2","upperLimit":"6.1"},{"groupId":"OG001","value":"6.4","lowerLimit":"4.2","upperLimit":"9.3"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: >=2 to <5 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 1 to 6 Months after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2350"},{"groupId":"OG001","value":"1173"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.2","upperLimit":"0.8"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.4","upperLimit":"1.6"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3:>=2 to <5 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was an important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 3 to 6 Months after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"863"},{"groupId":"OG001","value":"405"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.1","upperLimit":"1.0"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"0.9"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2 : >=6 Months to <2 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 1 to 1 month after dose 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 1 to 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1447"},{"groupId":"OG001","value":"718"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","lowerLimit":"19.4","upperLimit":"23.7"},{"groupId":"OG001","value":"19.9","lowerLimit":"17.1","upperLimit":"23.0"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Adverse Events From Dose 3 to 1 Month After Dose 3 : >=6 Months to <2 Years of Age","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from dose 3 to 1 month after dose 3 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 3 to 1 Month after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"483"},{"groupId":"OG001","value":"237"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","lowerLimit":"7.8","upperLimit":"13.4"},{"groupId":"OG001","value":"7.6","lowerLimit":"4.6","upperLimit":"11.7"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2 : >=6 Months to <2 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 1 to 6 Months after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1447"},{"groupId":"OG001","value":"718"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"1.1","upperLimit":"2.5"},{"groupId":"OG001","value":"2.4","lowerLimit":"1.4","upperLimit":"3.8"}]}]}]},{"type":"PRIMARY","title":"Phase 2/3: Percentage of Participants Reporting Serious Adverse Events From Dose 3 to 6 Months After Dose 3: >=6 Months to <2 Years of Age","description":"An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.Participants were analyzed according to the treatment which they received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Phase 2/3: From Dose 3 to 6 Months after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"483"},{"groupId":"OG001","value":"237"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"1.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"1.5"}]}]}]},{"type":"PRIMARY","title":"Phase2/3:Geometric Mean Ratio(GMR)Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants>=5 to<12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort:1 Month After Dose 2:Participants Without Evidence of Infection","description":"GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of the titers and the corresponding CIs (based on student t distribution). GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\\*LLOQ. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants of the age 16 to 25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section and GMR is reported under statistical analysis.","populationDescription":"Evaluable immunogenicity population (EIP) included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after study vaccination, \\& had no other important protocol deviations as determined by clinician.'Number of Participants Analyzed'=participants evaluable for this outcome measure. Phase 2/3: Placebo: 5 to 12 years of age: was not applicable for this outcome measure analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"C4591007 (>=5 to <12 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years","description":"Participants aged 16 to 25 years from study C4591001 (NCT04816643) who received 2 doses of original BNT162b2 30 mcg were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"264"},{"groupId":"OG001","value":"253"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1197.6","lowerLimit":"1106.1","upperLimit":"1296.6"},{"groupId":"OG001","value":"1146.5","lowerLimit":"1045.5","upperLimit":"1257.2"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Phase 2/3: Geometric Mean Ratio for SARS-CoV-2 Neutralizing Titers in Participants \\>=5 to \\<12 Years of age to Participants 16 to 25 Years of age from Phase 2/3 of the C4591001 Study: 1 Month after Dose 2","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio","paramValue":"1.04","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.93","ciUpperLimit":"1.18"}]},{"type":"PRIMARY","title":"Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=5 to <12 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection","description":"Seroresponse is defined as achieving a \\>=4 fold rise from baseline (before Dose 1). Assay result below a postvaccination \\>=4\\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","populationDescription":"Analysis was performed in Evaluable Immunogenicity population. Participants of Phase 2/3: Placebo: 5 to \\<12 years of age: analysis was not performed as it was not the part of pre-specified analysis in the protocol. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"C4591007 (>=5 to <12 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Historical Cohort:C4591001 BNT162b2(30 mcg)16 to 25 Years","description":"Participants aged 16 to 25 years from study C4591001 (NCT04816643) who received 2 doses of original BNT162b2 30 mcg were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"264"},{"groupId":"OG001","value":"253"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","lowerLimit":"97.3","upperLimit":"99.9"},{"groupId":"OG001","value":"99.2","lowerLimit":"97.2","upperLimit":"99.9"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Difference in Percentages of Participants With Seroresponse - Participants Without Evidence of Infection up to 1 Month After Dose 2 - Immunobridging Subset - Phase 2/3 - Comparison of 5 to \\<12 Years of Age to Study C4591001 Phase 2/3 - 16 Through 25 Years of Age","nonInferiorityType":"OTHER","paramType":"Difference in percentage","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.0","ciUpperLimit":"2.2"}]},{"type":"PRIMARY","title":"Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection","description":"GMRs \\& corresponding 2-sided CIs were calculated by exponentiating mean difference of logarithm of titers \\& corresponding CIs(based on student t distribution).GMTs \\& 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs(based on the Student t distribution).Assay results below LLOQ were set to 0.5\\*LLOQ.Results include those from comparator group of C4591001(NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\\& had no medical history of COVID-19 were also included.GMT is reported in descriptive analysis section \\& GMR is reported under statistical analysis.EIP included all eligible randomized participants who received study intervention to which they were randomized,had a valid\\&determinate immunogenicity result within 28-42 days after study vaccination,had no other important protocol deviations as determined by clinician.","populationDescription":"Analysis was performed in Evaluable Immunogenicity population. Participants of Phase 2/3: Placebo: 2 to \\<5 years of age: analysis was not performed as it was not the part of pre-specified analysis in the protocol. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"C4591007 (>=2 to <5 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years","description":"Participants aged 16 to 25 years from study C4591001 (NCT04816643) who received 2 doses of original BNT162b2 30 mcg were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"243"},{"groupId":"OG001","value":"252"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"763.9","lowerLimit":"688.5","upperLimit":"847.5"},{"groupId":"OG001","value":"1255.4","lowerLimit":"1131.2","upperLimit":"1393.3"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Geometric Mean Ratio for SARS-CoV-2 Neutralizing Titers in Participants \\>=2 to \\<5 Years of age to Participants 16 to 25 Years of age from Phase 2/3 of the C4591001 study: at 1 Month after Dose- 2 Phase 2/3","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio","paramValue":"0.61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.53","ciUpperLimit":"0.70"}]},{"type":"PRIMARY","title":"Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection","description":"Seroresponse is defined as achieving a \\>=4-fold rise from baseline (before Dose 1). Assay result below a postvaccination \\>=4\\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","populationDescription":"Analysis was performed in Evaluable Immunogenicity population. Participants of Phase 2/3: Placebo: 2 to \\<5 years of age: analysis was not performed as it was not the part of pre-specified analysis in the protocol. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"C4591007 (>=2 to <5 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years","description":"Participants aged 16 to 25 years from study C4591001 (NCT04816643) who received 2 doses of original BNT162b2 30 mcg were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"243"},{"groupId":"OG001","value":"251"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.7","lowerLimit":"93.6","upperLimit":"98.6"},{"groupId":"OG001","value":"97.6","lowerLimit":"94.9","upperLimit":"99.1"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Phase 2/3: Difference in Percentage of Participants who Achieved Seroresponse in \\>=2 to \\<5 Years of age and 16 to 25 Years of age from Phase 2/3 of the C4591001 study: 1 Month after Dose 2","nonInferiorityType":"OTHER","paramType":"Difference in Percentage","paramValue":"-0.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.3","ciUpperLimit":"2.3"}]},{"type":"PRIMARY","title":"Phase 2/3: GMR Based on GMT for SARS-CoV-2 Neutralizing Titers in Participants >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort: 1 Month After Dose 2: Participants Without Evidence of Infection","description":"GMRs \\& corresponding 2-sided CIs were calculated by exponentiating mean difference of logarithm of titers \\& corresponding CIs(based on student t distribution).GMTs \\& 2-sided 95% CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs(based on the Student t distribution).Assay results below LLOQ were set to 0.5\\*LLOQ.Results include those from comparator group of C4591001(NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\\& had no medical history of COVID-19 were also included.GMT is reported in descriptive analysis section \\& GMR is reported under statistical analysis.EIP included all eligible randomized participants who received study intervention to which they were randomized,had a valid\\&determinate immunogenicity result within 28-42 days after study vaccination,had no other important protocol deviations as determined by clinician.","populationDescription":"Analysis was performed in Evaluable Immunogenicity population. Participants of Phase 2/3: Placebo: 6 months to \\<2 years of age: analysis was not performed as it was not the part of pre-specified analysis in the protocol. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"C4591007 (>=6 Months to <2 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years","description":"Participants aged 16 to 25 years from study C4591001 (NCT04816643) who received 2 doses of original BNT162b2 30 mcg were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"238"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"979.7","lowerLimit":"893.2","upperLimit":"1074.6"},{"groupId":"OG001","value":"946.8","lowerLimit":"850.8","upperLimit":"1053.7"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Phase 2/3: Geometric Mean Ratio for SARS-CoV-2 Neutralizing Titers in Participants \\>=6 Months to \\<2 Years of age to Participants 16 to 25 Years of age from Phase 2/3 of the C4591001 study: at 1 Month after Dose 2","nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio","paramValue":"1.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.90","ciUpperLimit":"1.19"}]},{"type":"PRIMARY","title":"Phase 2/3: Difference in Percentage of Participants Who Achieved Seroresponse in >=6 Months to <2 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort : 1 Month After Dose 2: Participants Without Evidence of Infection","description":"Seroresponse is defined as achieving a \\>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \\>=4\\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","populationDescription":"Analysis was performed in Evaluable Immunogenicity population. Participants of Phase 2/3: Placebo: analysis was not performed as it was not the part of pre-specified analysis in the protocol. Here, 'Number of Participants Analyzed (N)' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"C4591007 (>=6 Months to <2 years): 1 Month after Dose 2 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years","description":"Participants aged 16 to 25 years from study C4591001 (NCT04816643) who received 2 doses of original BNT162b2 30 mcg were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"238"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","lowerLimit":"95.3","upperLimit":"99.3"},{"groupId":"OG001","value":"96.2","lowerLimit":"92.9","upperLimit":"98.3"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Phase 2/3: Difference in Percentage of Participants who Achieved Seroresponse in \\>=6 Months to \\<2 Years of age and 16 to 25 Years of age from Phase 2/3 of the C4591001 study : 1 Month after Dose 2","nonInferiorityType":"OTHER","paramType":"Difference in Percentage","paramValue":"1.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.4","ciUpperLimit":"5.2"}]},{"type":"PRIMARY","title":"Phase 2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 3 in Participants Aged>=2 to<5Years Compared With Study C4591001 Phase2/3 16 to 25 Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection","description":"GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of logarithm of the titers and the corresponding CIs(based on student t distribution).GMTs \\& 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5\\*LLOQ. Results include those from comparator group of C4591001 (NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30 mcg who had no serological or virological evidence of past SARS-CoV-2 infection \\& had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section \\& GMR is reported under statistical analysis.","populationDescription":"EIP included all eligible randomized participants who received study intervention to which they were randomized,had valid\\&determinate immunogenicity result within 28-42days after study vaccination,had no other important protocol deviation as determined by clinician.Phase 2/3:Placebo:2-5 years of age:group was not applicable for this outcome measure analysis.However,data for this group reported in outcome measure 96.'Number of Participant Analyzed'=participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"C4591007 (>=2 to <5 years):1 Month after Dose 2 and C4591001 Historical cohort (16-25 years):1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years","description":"Participants aged 16 to 25 years from study C4591001 (NCT04816643) who received 2 doses of original BNT162b2 30 mcg were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1535.2","lowerLimit":"1388.2","upperLimit":"1697.8"},{"groupId":"OG001","value":"1180.0","lowerLimit":"1066.6","upperLimit":"1305.4"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Phase 2/3: Geometric Mean Ratio for SARS-CoV-2 Neutralizing Titers at 1 Month after dose 3 in Participants \\>=2 to \\<5 Years of age to those at 1 month after Dose 2 in participants 16 to 25 years of age from Phase 2/3 of the C4591001 study","nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio","paramValue":"1.30","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.13","ciUpperLimit":"1.50"}]},{"type":"PRIMARY","title":"Phase 2/3:Difference in Percentage of Participants With Seroresponse in 2 to <5 Years of Age Compared With Study C4591001 Phase 2/3 16 to 25 Years of Age Historical Cohort: Participants Without Evidence of Infection","description":"Seroresponse is defined as achieving a \\>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \\>=4\\*LLOQ is considered a seroresponse.Results include those from a comparator group of C4591001 (NCT04368728) Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","populationDescription":"Analysis was performed in Evaluable Immunogenicity population. Participants of Phase 2/3: Placebo: 2 to \\<5 years of age: analysis was not performed as it was not the part of pre-specified analysis in the protocol. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"C4591007 (>=2 to <5 years): 1 Month after Dose 3 and C4591001 Historical cohort (16-25 years): 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years","description":"Participants aged 16 to 25 years from study C4591001 (NCT04816643) who received 2 doses of original BNT162b2 30 mcg were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"97.4","upperLimit":"100.0"},{"groupId":"OG001","value":"98.8","lowerLimit":"95.8","upperLimit":"99.9"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Phase 2/3: Difference in Percentages of Participants With Seroresponse - Participants Without Evidence of Infection - Immunobridging Subset - Comparison of Study C4591007 Phase 2/3 2 to \\<5 Years of Age (1 Month After Dose 3) and Study C4591001 Phase 2/3 16 Through 25 Years of Age (1 Month After Dose 2)","nonInferiorityType":"OTHER","paramType":"Difference in Percentages","paramValue":"1.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.5","ciUpperLimit":"4.2"}]},{"type":"PRIMARY","title":"Phase2/3:GMR Based on GMT for SARS-CoV-2 Neutralizing Titers at 1 Month After Dose3 in Participants Aged 6Month to 2Year Compared With Study C4591001 Phase2/3 16 to 25Years Historical Cohort(1 Month After Dose 2):Participants Without Evidence of Infection","description":"GMRs and the corresponding 2-sided CIs were calculated by exponentiating the mean difference of the logarithm of titers and the corresponding CIs (based on student t distribution). GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5\\*LLOQ. Results include those from comparator group of C4591001 (NCT04368728) Phase2/3 participants of age 16-25 years who received 2 doses of original BNT162b2 30mcg who had no serological or virological evidence of past SARS-CoV-2 infection\\& had no medical history of COVID-19 were also included. GMT is reported in descriptive analysis section \\& GMR is reported under statistical analysis.","populationDescription":"EIP included all eligible randomized participants who received study intervention to which they were randomized, had valid \\& determinate immunogenicity result within 28-42 days after study vaccination, had no other important protocol deviation as determined by clinician. Phase 2/3:Placebo:6 months to 2 years of age: group was not applicable for this outcome measure analysis. However, data for this group were reported in outcome measure 97.Here,'N'=participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"C4591007 (>=6 months to <2 years):1 Month after Dose 3 and C4591001 Historical cohort (16-25 years):1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years","description":"Participants aged 16 to 25 years from study C4591001 (NCT04816643) who received 2 doses of original BNT162b2 30 mcg were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1406.5","lowerLimit":"1211.3","upperLimit":"1633.1"},{"groupId":"OG001","value":"1180.0","lowerLimit":"1066.6","upperLimit":"1305.4"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Phase 2/3: Geometric Mean Ratio for SARS-CoV-2 Neutralizing Titers at 1 Month after dose 3 in Participants 6 Months to \\<2 Years of age to those at 1 month after Dose 3 in participants 16 to 25 years of age from Phase 2/3 of the C4591001 study","nonInferiorityType":"OTHER","paramType":"Geometric mean ratio","paramValue":"1.19","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.00","ciUpperLimit":"1.42"}]},{"type":"PRIMARY","title":"Phase 2/3:Difference in Percentage of Participants With Seroresponse in 6 Months to <2 Years (1 Month After Dose 3) Compared With Study C4591001 Phase 2/3 16 to 25 Years Historical Cohort (1 Month After Dose 2): Participants Without Evidence of Infection","description":"Seroresponse is defined as achieving a \\>=4-fold rise from baseline(before Dose 1). Assay result below a postvaccination \\>=4\\*LLOQ is considered a seroresponse. Results include those from a comparator group of C4591001(NCT04368728)Phase 2/3 participants who had no serological or virological evidence (prior to the 1-month post-Dose 2 blood sample collection) of past SARS-CoV-2 infection were included for this analysis. Percentage of participants with seroresponse is reported in descriptive analysis section and the difference in percentage of participants is reported under statistical analysis. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","populationDescription":"Analysis was performed in Evaluable Immunogenicity population. Participants of Phase 2/3: Placebo: 6 months to \\<2 years of age: analysis was not performed as it was not the part of pre-specified analysis in the protocol. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"C4591007 (>=6 Months to <2 years):1 Month after Dose 3 and C4591001 Historical cohort (16-25 years):1 month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Historical Cohort: C4591001 BNT162b2 (30 mcg) 16 to 25 Years","description":"Participants aged 16 to 25 years from study C4591001 (NCT04816643) who received 2 doses of original BNT162b2 30 mcg were included."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"95.5","upperLimit":"100.0"},{"groupId":"OG001","value":"98.8","lowerLimit":"95.8","upperLimit":"99.9"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Phase 2/3: Difference in Percentages of Participants With Seroresponse - Participants Without Evidence of Infection - Immunobridging Subset - Comparison of Study C4591007 Phase 2/3 6 Months to \\<2 Years of Age (1 Month After Dose 3) and Study C4591001 Phase 2/3 16 Through 25 Years of Age (1 Month After Dose 2) - Evaluable Immunogenicity Population","nonInferiorityType":"OTHER","paramType":"Difference in percentage","paramValue":"1.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.4","ciUpperLimit":"4.2"}]},{"type":"SECONDARY","title":"Phase 1: Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=6 Months to <2 Years of Age: Participants Without Evidence of Infection","description":"GMT of SARS-CoV-2 neutralizing titer after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.","populationDescription":"Analysis was performed in Evaluable Immunogenicity population. Participants without evidence of prior infection were included in the analysis. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Phase 1: 7 days post Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 6 Months to < 2 Years of Age","description":"Participants aged 6 months to \\<2 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1643.8","lowerLimit":"1151.3","upperLimit":"2347.1"}]}]}]},{"type":"SECONDARY","title":"Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=2 to <5 Years of Age: Participants Without Evidence of Infection","description":"GMT of SARS-CoV-2 neutralizing titers after the study vaccination was reported in this outcome measure. GMT and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution).Assay results below the LLOQ were set to 0.5\\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.","populationDescription":"Analysis was performed in Evaluable Immunogenicity population. Participants without evidence of prior infection were included in the analysis. Here, 'Number of Participants Analyzed (N)' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Phase 1: 7 days post Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"29"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1350.4","lowerLimit":"973.1","upperLimit":"1873.9"},{"groupId":"OG001","value":"2059.5","lowerLimit":"1679.1","upperLimit":"2526.0"}]}]}]},{"type":"SECONDARY","title":"Phase 1: GMT of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer at 7 Days After Dose 2: >=5 to <12 Years of Age: Participants Without Evidence of Infection","description":"GMT of SARS-CoV-2 neutralizing titer after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs(based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ. Evaluable Immunogenicity Population consisted of all eligible randomized participants who received 2 doses with the same dose level to which they were randomized, with Dose 2 received within the predefined window, had at least 1 valid and determinate immunogenicity result after Dose 2 from the blood sample collected within an appropriate window after Dose 2(within 6-8 days after Dose 2 for Phase 1), and had no other important protocol deviations as determined by the clinician.","populationDescription":"EIP. Participants without evidence of prior infection were included in analysis.'N'=participants evaluable. Due to observed high frequency of local reactions in 5-\\<12years of age, after dose 2 in 30/10 \\& 30/30 mcg group, a Sponsor decision was made to discontinue 30/10 \\& 30/30 mcg dose level. Samples from BNT 30/10 participants were not tested due to discontinuation of this group.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Phase 1: 7 days post Dose 2","groups":[{"id":"OG000","title":"Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG002","title":"Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG003","title":"Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4162.6","lowerLimit":"2584.7","upperLimit":"6704.0"},{"groupId":"OG001","value":"4583.4","lowerLimit":"2802.9","upperLimit":"7494.8"},{"groupId":"OG002","value":"242.1","lowerLimit":"199.6","upperLimit":"293.7"}]}]}]},{"type":"SECONDARY","title":"Phase 2/3: Geometric Mean Titer - Neutralizing Titer (NT50) : 5 to <12 Years of Age: Before Dose 1 and 1 Month After Dose 2:Participants Without Evidence of Infection","description":"GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","populationDescription":"Analysis was performed in Evaluable Immunogenicity population. Participants without evidence of prior infection were included in the analysis. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Phase 2/3: Before Dose 1 and 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3:BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"264"},{"groupId":"OG001","value":"130"}]}],"classes":[{"title":"Pre-dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"9.9","upperLimit":"10.3"},{"groupId":"OG001","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"1 Month after Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"1197.6","lowerLimit":"1106.1","upperLimit":"1296.6"},{"groupId":"OG001","value":"10.7","lowerLimit":"9.7","upperLimit":"11.8"}]}]}]},{"type":"SECONDARY","title":"Phase 2/3: Geometric Mean Titer - NT50: 5 to <12 Years of Age: Pre-Dose 3 and 1 Month After Dose 3:Participants Without Evidence of Infection","description":"GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 \\*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population (EIP) included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician.","populationDescription":"Analysis was performed in EIP. Participants who received Dose 3 \\& completed 1month post-Dose 3 visit in Dose 3 EIP without evidence of prior infection up 1 month post-Dose 3 were included. Participants of Phase 2/3: Placebo: 5 to \\<12 years of age: data was not collected and were analyzed as participant in this group did not receive Dose 3 and therefore were not analyzed for this outcome measure. Here, 'Number of Participants Analyzed'=participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Phase 2/3: From Dose 3 set: Pre-Dose 3 and 1 Month after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"0"}]}],"classes":[{"title":"Pre-Dose 3","categories":[{"measurements":[{"groupId":"OG000","value":"271.0","lowerLimit":"229.1","upperLimit":"320.6"}]}]},{"title":"1 Month after Dose 3","categories":[{"measurements":[{"groupId":"OG000","value":"2720.9","lowerLimit":"2280.1","upperLimit":"3247.0"}]}]}]},{"type":"SECONDARY","title":"Phase 2/3: Geometric Mean Titer - NT50:2 to <5 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection","description":"GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 \\*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19.","populationDescription":"Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Phase 2/3: From Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"59"}]}],"classes":[{"title":"Pre-Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","lowerLimit":"20.3","upperLimit":"21.2"},{"groupId":"OG001","value":"20.5","lowerLimit":"20.5","upperLimit":"20.5"}]}]},{"title":"Pre-Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"59"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"401.1","lowerLimit":"361.7","upperLimit":"444.7"},{"groupId":"OG001","value":"20.9","lowerLimit":"20.1","upperLimit":"21.8"}]}]},{"title":"1 Month after Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"59"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1535.2","lowerLimit":"1388.2","upperLimit":"1697.8"},{"groupId":"OG001","value":"22.9","lowerLimit":"19.5","upperLimit":"26.8"}]}]}]},{"type":"SECONDARY","title":"Phase 2/3: Geometric Mean Titer- NT50:6 Months to <2 Years of Age: Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3: Participants Without Evidence of Infection","description":"GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titer and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19.","populationDescription":"Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Phase 2/3: From Pre-Dose 1, Pre-Dose 3 and 1 Month After Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"49"}]}],"classes":[{"title":"Pre- Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","lowerLimit":"20.2","upperLimit":"21.5"},{"groupId":"OG001","value":"20.5","lowerLimit":"20.5","upperLimit":"20.5"}]}]},{"title":"Pre-Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"317.0","lowerLimit":"268.8","upperLimit":"373.9"},{"groupId":"OG001","value":"24.2","lowerLimit":"19.7","upperLimit":"29.8"}]}]},{"title":"1 Month After Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1406.5","lowerLimit":"1211.3","upperLimit":"1633.1"},{"groupId":"OG001","value":"22.3","lowerLimit":"18.8","upperLimit":"26.4"}]}]}]},{"type":"SECONDARY","title":"Phase 2/3: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers From Dose 1 to 1 Month After Dose 2: >=5 to 12 Years of Age: Participants Without Evidence of Infection","description":"GMFR of SARS-CoV-2 neutralizing titers from dose 1 to 1 month after dose 2 were reported in this outcome measure. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Assay results below the LLOQ were set to 0.5\\* LLOQ in the analysis.","populationDescription":"Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"Phase 2/3: From Dose 1 to 1 Month after Dose 2","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"264"},{"groupId":"OG001","value":"130"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118.2","lowerLimit":"109.2","upperLimit":"127.9"},{"groupId":"OG001","value":"1.1","lowerLimit":"1.0","upperLimit":"1.2"}]}]}]},{"type":"SECONDARY","title":"Phase 2/3:GMFR of SARS-CoV-2 Neutralizing Titers From Dose 3 to 1 Month After Dose 3: >=5 to 12 Years of Age: Participants Without Evidence of Infection","description":"GMFR of SARS-CoV-2 neutralizing titers from before Dose 3 to 1 month after Dose were reported in this outcome measure. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection or had no medical history of COVID-19. Evaluable immunogenicity population included all eligible randomized participants who received the study interventions to which they were randomized, had a valid and determined immunogenicity result within 28-42 days after Dose 3, and had no other important protocol deviations as determined by the clinicians.","populationDescription":"Analysis was performed in Evaluable Immunogenicity population.Participants aged 5- \\<12 years who received Dose 3\\& completed 1 month post-Dose 3 visit in Dose3 evaluable immunogenicity population without evidence of prior infection up 1 month post-Dose3 included in this analysis.Participants of Phase 2/3:Troponin group: Placebo:5-\\<12 years of age:No participants received dose 3 from this arm to this outcome measure.'Number of Participants Analyzed'=participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"Phase 2/3: From Dose 3 to 1 Month after Dose 3","groups":[{"id":"OG000","title":"Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","lowerLimit":"8.1","upperLimit":"12.4"}]}]}]},{"type":"SECONDARY","title":"Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Pre-Dose 3 and 1 Month After Dose 3: >=2 to 5 Years of Age: Participants Without Evidence of Infection","description":"GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs(based on the Student t distribution). Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection and had no medical history of COVID-19 infection.Assay results below the LLOQ were set to 0.5\\*LLOQ in the analysis.","populationDescription":"Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"Phase 2/3: From before dose 1 to Pre-Dose 3, 1 Month After Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 2 to <5 Years of Age","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"57"}]}],"classes":[{"title":"Pre-Dose 3","categories":[{"measurements":[{"groupId":"OG000","value":"19.2","lowerLimit":"17.4","upperLimit":"21.3"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.1"}]}]},{"title":"1 Month after Dose 3","categories":[{"measurements":[{"groupId":"OG000","value":"73.3","lowerLimit":"66.3","upperLimit":"81.1"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.9","upperLimit":"1.3"}]}]}]},{"type":"SECONDARY","title":"Phase 2/3: GMFR of SARS-CoV-2 Neutralizing Titers From Before Dose 1 to Pre-Dose 3 and 1 Month After Dose 3: >=6 Months to 2 Years of Age: Participants Without Evidence of Infection","description":"GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ in the analysis. Participants included in this analysis had no serological or virological evidence of past SARS-CoV-2 infection prior to the 1-month post-Dose 2.","populationDescription":"Evaluable immunogenicity population included all eligible randomized participants who received the study intervention to which they were randomized, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for specified rows.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"Phase 2/3: From before dose 1 to Pre-Dose 3, 1 Month After Dose 3","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <2 Years of Age","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"48"}]}],"classes":[{"title":"Pre-Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","lowerLimit":"12.9","upperLimit":"18.3"},{"groupId":"OG001","value":"1.2","lowerLimit":"1.0","upperLimit":"1.5"}]}]},{"title":"1 Month after Dose 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","lowerLimit":"58.2","upperLimit":"80.4"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.9","upperLimit":"1.3"}]}]}]},{"type":"SECONDARY","title":"Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=5 to <12 Years of Age","description":"COVID-19 incidence from 7 days after dose 2 to prior to dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviations as determined by clinician on or before 7 days after Dose 2.","populationDescription":"Analysis was performed in Evaluable efficacy population. Participants who received 2 doses of original BNT162b2 10 mcg or placebo during the blinded follow up period without evidence of infection prior to 7 days after Dose 2 were included in this analysis. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events per 1000 person-years","timeFrame":"Phase 2/3: From 7 days after Dose 2 to prior to Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.591; Placebo - 0.292)","groups":[{"id":"OG000","title":"Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2703"},{"groupId":"OG001","value":"1348"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.920"},{"groupId":"OG001","value":"143.836"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Vaccine efficacy was estimated by 100\\*(1 - illness rate ratio \\[IRR\\]) in each of two age groups, where IRR=calculated ratio of confirmed COVID-19 illness per 1000 person-years of blinded follow-up in the active vaccine group to the corresponding illness rate in the placebo group.","nonInferiorityType":"OTHER","paramType":"Vaccine Efficacy","paramValue":"88.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"76.2","ciUpperLimit":"94.7"}]},{"type":"SECONDARY","title":"Phase 2/3: COVID-19 Incidence From 7 Days After Dose 2 to Prior to Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=5 to <12 Years of Age","description":"COVID-19 incidence from 7 days after dose 2 to prior to dose 3 with or without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviation as determined by clinician on or before 7 days after Dose 2.","populationDescription":"Analysis was performed in Evaluable efficacy population. Participants who received 2 doses of original BNT162b2 10 mcg/placebo during blinded follow up period with and without evidence of infection prior to 7 days after Dose 2 were included in this analysis. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events per 1000 person-years","timeFrame":"Phase 2/3: From 7 Days After Dose 2 to prior to Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.653; Placebo - 0.326)","groups":[{"id":"OG000","title":"Phase 2/3:BNT162b2 (10 mcg):5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study. Participants received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2."},{"id":"OG001","title":"Phase 2/3: Placebo: 5 to <12 Years of Age","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly separated by 21 days interval as part of this study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3018"},{"groupId":"OG001","value":"1511"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.377"},{"groupId":"OG001","value":"128.834"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Vaccine efficacy was estimated by 100\\*(1 - illness rate ratio \\[IRR\\]) in each of two age groups, where IRR=calculated ratio of confirmed COVID-19 illness per 1000 person-years of blinded follow-up in the active vaccine group to the corresponding illness rate in the placebo group.","nonInferiorityType":"OTHER","paramType":"Vaccine Efficacy","paramValue":"85.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"72.4","ciUpperLimit":"93.2"}]},{"type":"SECONDARY","title":"Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants Without Serological or Virological Evidence: >=6 Months to <5 Years of Age","description":"COVID-19 incidence from 7 days after dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by clinician on or before 7 days after Dose 3.","populationDescription":"Analysis was performed in Evaluable efficacy population. Participants who received 3 doses of original BNT162b2 3 mcg/placebo during the blinded follow up period without evidence of infection prior to 7 days after Dose 3 were included in this analysis. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events per 1000 person-years","timeFrame":"Phase 2/3: From 7 Days After Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.124; Placebo - 0.054)","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <5 Years of Age","description":"Participants aged 6 months to \\<5 years of age who received 3 doses of original BNT162b2 3 mcg during the blinded follow up period without evidence of infection prior to 7 days after Dose 3."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <5 Years of Age","description":"Participants aged 6 months to \\<5 years of age who received placebo during the blinded follow up period without evidence of infection prior to 7 days after Dose 3."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"873"},{"groupId":"OG001","value":"381"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104.839"},{"groupId":"OG001","value":"388.889"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Vaccine efficacy was estimated by 100\\*(1 - illness rate ratio \\[IRR\\]) in each of two age groups, where IRR=calculated ratio of confirmed COVID-19 illness per 1000 person-years of blinded follow-up in the active vaccine group to the corresponding illness rate in the placebo group.","nonInferiorityType":"OTHER","paramType":"Vaccine Efficacy","paramValue":"73.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"43.8","ciUpperLimit":"87.6"}]},{"type":"SECONDARY","title":"Phase 2/3: COVID-19 Incidence From 7 Days After Dose 3 Per 1000 Person-Years of Blinded Follow-up in Participants With or Without Serological or Virological Evidence: >=6 Months to <5 Years of Age","description":"COVID-19 incidence from 7 days after dose 3 without the evidence of infection were reported in this outcome measure. Evaluable efficacy population included all eligible randomized participants who received all vaccination as randomized, with Dose 3 received within the predefined window (within 19-42 days after Dose 2) and have no other important protocol deviations as determined by the clinician on or before 7 days after Dose 3.","populationDescription":"Analysis was performed in Evaluable efficacy population. Participants who received 3 doses of original BNT162b2 3 mcg/placebo during the blinded follow up period with and without evidence of infection prior to 7 days after Dose 3 were included in this analysis. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events per 1000 person-years","timeFrame":"Phase 2/3: From 7 Days After Dose 3 (Surveillance time [1000 person-years]: BNT162b2 - 0.149; Placebo - 0.067)","groups":[{"id":"OG000","title":"Phase 2/3: BNT162b2 (3 mcg): 6 Months to <5 Years of Age","description":"Participants aged 6 months to \\<5 years of age who received 3 doses of original BNT162b2 3 mcg during the blinded follow up period with or without evidence of infection prior to 7 days after Dose 3."},{"id":"OG001","title":"Phase 2/3: Placebo: 6 Months to <5 Years of Age","description":"Participants aged 6 months to \\<5 years of age who received placebo during the blinded follow up period with or without evidence of infection prior to 7 days after Dose 3."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1294"},{"groupId":"OG001","value":"612"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.960"},{"groupId":"OG001","value":"343.284"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Vaccine efficacy was estimated by 100\\*(1 - illness rate ratio \\[IRR\\]) in each of two age groups, where IRR=calculated ratio of confirmed COVID-19 illness per 1000 person-years of blinded follow-up in the active vaccine group to the corresponding illness rate in the placebo group.","nonInferiorityType":"OTHER","paramType":"Vaccine Efficacy","paramValue":"72.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"44.3","ciUpperLimit":"86.9"}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"Other AEs (non-SAEs): from Dose(D) 1 to 1 month after D2 and D3 to 1 month after D3. Local reactions/systemic events: Day 1 to 7 after each dose. SAEs: From D1 to 6 months after D2 and from D3 to 6 months after D3 (maximum up to 28.5 months for Phase 1, 30.5 months for Phase 2/3 during blinded follow-up period and 24.2 months for Phase 2/3 during OL period). 'OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D2)': SAEs: From D2 to 6 months after D2 and non-SAEs: from D1 to 1 month after D2","description":"Same event may appear as both non-SAE and SAE but are distinct events. An event may be categorised as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE. Safety population consisted of all participants who received at least 1 dose of study intervention. Participants were analyzed according to the treatment which they received.","eventGroups":[{"id":"EG000","title":"Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D1-D2)","description":"Participants aged 6 months to \\<2 years of age received 2 doses of 3 microgram (mcg) BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":16,"seriousNumAffected":0,"seriousNumAtRisk":16,"otherNumAffected":10,"otherNumAtRisk":16},{"id":"EG001","title":"Phase 1:BNT162b2 (3 mcg):6 Months to < 2 Years of Age (D3)","description":"Participants aged 6 months to \\<2 years received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.","deathsNumAffected":0,"deathsNumAtRisk":15,"seriousNumAffected":0,"seriousNumAtRisk":15,"otherNumAffected":7,"otherNumAtRisk":15},{"id":"EG002","title":"Phase 1: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2)","description":"Participants aged 2 to \\<5 years of age received 2 doses of 3 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":16,"seriousNumAffected":0,"seriousNumAtRisk":16,"otherNumAffected":10,"otherNumAtRisk":16},{"id":"EG003","title":"Phase 1: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2)","description":"Participants aged 2 to \\<5 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":32,"seriousNumAffected":0,"seriousNumAtRisk":32,"otherNumAffected":32,"otherNumAtRisk":32},{"id":"EG004","title":"Phase 1: BNT162b2 10 mcg: 2 to <5 Years of Age (D3)","description":"Participants aged 2 to \\<5 years of age who received dose 1 and 2 of either BNT162b2 3 mcg or 10 mcg, received third dose of 10 mcg BNT162b2 approximately 60 days after vaccination 2.","deathsNumAffected":0,"deathsNumAtRisk":13,"seriousNumAffected":0,"seriousNumAtRisk":13,"otherNumAffected":0,"otherNumAtRisk":13},{"id":"EG005","title":"Ph1:2-<5Y:D3: BNT162b2 3 mcg (D3)","description":"Participants aged 2 to \\<5 years of age who received dose 1 and 2 of either BNT162b2 3 mcg or 10 mcg, received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2.","deathsNumAffected":0,"deathsNumAtRisk":27,"seriousNumAffected":0,"seriousNumAtRisk":27,"otherNumAffected":17,"otherNumAtRisk":27},{"id":"EG006","title":"Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)","description":"Participants aged 5 to \\<12 years of age received 2 doses of 10 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":16,"seriousNumAffected":0,"seriousNumAtRisk":16,"otherNumAffected":16,"otherNumAtRisk":16},{"id":"EG007","title":"Phase 1: BNT162b2 (20 mcg): 5 to <12 Years of Age (D1-D2)","description":"Participants aged 5 to \\<12 years of age received 2 doses of 20 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":16,"seriousNumAffected":0,"seriousNumAtRisk":16,"otherNumAffected":16,"otherNumAtRisk":16},{"id":"EG008","title":"Phase 1:BNT162b2 (30/30 mcg): 5 to <12 Years of Age (D1-D2)","description":"Participants aged 5 to \\<12 years of age received 2 doses of 30 mcg BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":4,"seriousNumAffected":0,"seriousNumAtRisk":4,"otherNumAffected":4,"otherNumAtRisk":4},{"id":"EG009","title":"Phase 1:BNT162b2 (30/10 mcg): 5 to <12 Years of Age (D1-D2)","description":"Participants aged 5 to \\<12 years of age received 30 mcg in dose 1 and 10 mcg in dose 2 of BNT162b2 vaccine intramuscularly separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":11,"otherNumAtRisk":12},{"id":"EG010","title":"Phase 1: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)","description":"Participants aged 5 to \\<12 years who received dose 1 and 2 of either BNT162b2 10 mcg, 20 mcg or 30 mcg and received the third dose of 10 mcg BNT162b2 as part of this study were included.","deathsNumAffected":0,"deathsNumAtRisk":38,"seriousNumAffected":0,"seriousNumAtRisk":38,"otherNumAffected":35,"otherNumAtRisk":38},{"id":"EG011","title":"Phase 1:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3)","description":"Participants aged 5 to \\<12 years who received dose 1 and 2 of either BNT162b2 10 mcg, 20 mcg or 30 mcg and received the third dose of 30 mcg BNT162b2 as part of this study were included.","deathsNumAffected":0,"deathsNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"otherNumAffected":1,"otherNumAtRisk":2},{"id":"EG012","title":"Blinded Phase (BP): Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2)","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly in blinded placebo-controlled follow-up period separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":1458,"seriousNumAffected":24,"seriousNumAtRisk":1458,"otherNumAffected":1154,"otherNumAtRisk":1458},{"id":"EG013","title":"BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age (D1-D2)","description":"Participants aged 6 months to \\<2 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly in blinded placebo-controlled follow-up period separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":718,"seriousNumAffected":17,"seriousNumAtRisk":718,"otherNumAffected":550,"otherNumAtRisk":718},{"id":"EG014","title":"BP: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3)","description":"Participants aged 6 months to \\<2 years received third dose of 3 mcg BNT162b2 intramuscularly approximately 60 days after vaccination 2 in blinded placebo-controlled follow-up period.","deathsNumAffected":0,"deathsNumAtRisk":1324,"seriousNumAffected":1,"seriousNumAtRisk":1324,"otherNumAffected":267,"otherNumAtRisk":1324},{"id":"EG015","title":"BP: Phase 2/3: Placebo: 6 Months to <2 Years of Age(D3)","description":"Participants aged 6 months to \\<2 years were received placebo intramuscularly approximately 60 days after vaccination 2 in blinded placebo-controlled follow-up period.","deathsNumAffected":0,"deathsNumAtRisk":237,"seriousNumAffected":0,"seriousNumAtRisk":237,"otherNumAffected":119,"otherNumAtRisk":237},{"id":"EG016","title":"BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2)","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of 3 mcg BNT162b2 intramuscularly in blinded placebo-controlled follow-up period separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":2368,"seriousNumAffected":11,"seriousNumAtRisk":2368,"otherNumAffected":1661,"otherNumAtRisk":2368},{"id":"EG017","title":"BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D1-D2)","description":"Participants aged 2 to \\<5 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly in blinded placebo-controlled follow-up period separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":1173,"seriousNumAffected":10,"seriousNumAtRisk":1173,"otherNumAffected":778,"otherNumAtRisk":1173},{"id":"EG018","title":"BP: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3)","description":"Participants aged 2 to \\<5 years received third dose of 3 mcg BNT162b2 approximately 60 days after vaccination 2 in blinded placebo-controlled follow-up period.","deathsNumAffected":0,"deathsNumAtRisk":1889,"seriousNumAffected":3,"seriousNumAtRisk":1889,"otherNumAffected":398,"otherNumAtRisk":1889},{"id":"EG019","title":"BP: Phase 2/3: Placebo: 2 to <5 Years of Age (D3)","description":"Participants aged 2 to \\<5 years received third dose of placebo approximately 60 days after vaccination 2 in blinded placebo-controlled follow-up period.","deathsNumAffected":0,"deathsNumAtRisk":405,"seriousNumAffected":0,"seriousNumAtRisk":405,"otherNumAffected":152,"otherNumAtRisk":405},{"id":"EG020","title":"BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly in blinded placebo-controlled follow-up period separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":3109,"seriousNumAffected":8,"seriousNumAtRisk":3109,"otherNumAffected":2821,"otherNumAtRisk":3109},{"id":"EG021","title":"BP: Phase 2/3: Placebo: 5 to <12 Years of Age (D1-D2)","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly in blinded placebo-controlled follow-up period separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":1538,"seriousNumAffected":3,"seriousNumAtRisk":1538,"otherNumAffected":1083,"otherNumAtRisk":1538},{"id":"EG022","title":"BP: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)","description":"Participants aged 5 to \\<12 years received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.","deathsNumAffected":0,"deathsNumAtRisk":2410,"seriousNumAffected":10,"seriousNumAtRisk":2410,"otherNumAffected":1794,"otherNumAtRisk":2410},{"id":"EG023","title":"BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D1-D2)","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of 10 mcg BNT162b2 intramuscularly in blinded placebo-controlled follow-up period separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":518,"seriousNumAffected":1,"seriousNumAtRisk":518,"otherNumAffected":442,"otherNumAtRisk":518},{"id":"EG024","title":"BP: Phase 2/3:Troponin Group:Placebo:5 to <12 Years of Age (D1-D2)","description":"Participants aged 5 to \\<12 years were randomized to receive 2 doses of placebo (0.9% sodium chloride solution for Injection) intramuscularly in blinded placebo-controlled follow-up period separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":260,"seriousNumAffected":0,"seriousNumAtRisk":260,"otherNumAffected":163,"otherNumAtRisk":260},{"id":"EG025","title":"BP: Phase 2/3: Troponin Group:BNT162b2 (10 mcg):5 to <12 Years of Age (D3)","description":"Participants aged 5 to \\<12 years received third dose of 10 mcg BNT162b2 approximately 175 days after vaccination 2.","deathsNumAffected":0,"deathsNumAtRisk":418,"seriousNumAffected":2,"seriousNumAtRisk":418,"otherNumAffected":319,"otherNumAtRisk":418},{"id":"EG026","title":"BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D1-D2)","description":"Participants aged 12 to \\<16 years received 2 doses of 30 mcg BNT162b2 intramuscularly separated by 21 days interval as part of this study.","deathsNumAffected":0,"deathsNumAtRisk":487,"seriousNumAffected":2,"seriousNumAtRisk":487,"otherNumAffected":414,"otherNumAtRisk":487},{"id":"EG027","title":"BP: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 12 to <16 Years of Age (D3)","description":"Participants aged 12 to \\<16 years received third dose of 30 mcg BNT162b2 approximately 175 days after vaccination 2.","deathsNumAffected":0,"deathsNumAtRisk":433,"seriousNumAffected":0,"seriousNumAtRisk":433,"otherNumAffected":285,"otherNumAtRisk":433},{"id":"EG028","title":"OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D1-D2)","description":"Participants aged 6 months to \\<2 years who received placebo in blinded placebo controlled follow-up period received 2 doses of 3 mcg BNT162b2 intramuscularly after unblinding in the open-label (OL) period.","deathsNumAffected":0,"deathsNumAtRisk":581,"seriousNumAffected":5,"seriousNumAtRisk":581,"otherNumAffected":52,"otherNumAtRisk":581},{"id":"EG029","title":"OL: Phase 2/3: BNT162b2 (3 mcg): 6 Months to <2 Years of Age (D3)","description":"Participants aged 6 months to \\<2 years who received placebo in blinded placebo-controlled follow-up period. received third dose of 3 mcg BNT162b2 intramuscularly after unblinding in the open-label period.","deathsNumAffected":0,"deathsNumAtRisk":534,"seriousNumAffected":11,"seriousNumAtRisk":534,"otherNumAffected":6,"otherNumAtRisk":534},{"id":"EG030","title":"OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D1-D2)","description":"Participants aged 2 years to \\<5 years who received placebo in blinded placebo controlled follow-up period received 2 doses of 3 mcg BNT162b2 intramuscularly after unblinding in the open-label period.","deathsNumAffected":0,"deathsNumAtRisk":706,"seriousNumAffected":2,"seriousNumAtRisk":706,"otherNumAffected":31,"otherNumAtRisk":706},{"id":"EG031","title":"OL: Phase 2/3: BNT162b2 (3 mcg): 2 to <5 Years of Age (D3)","description":"Participants aged 2 to \\<5 years who received placebo in blinded placebo-controlled follow-up period, received third dose of 3 mcg BNT162b2 intramuscularly after unblinding in the open label period.","deathsNumAffected":0,"deathsNumAtRisk":581,"seriousNumAffected":6,"seriousNumAtRisk":581,"otherNumAffected":8,"otherNumAtRisk":581},{"id":"EG032","title":"OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)","description":"Participants aged 5 to \\<12 years who received placebo in blinded placebo-controlled follow-up period received 2 doses of 10 mcg BNT162b2 intramuscularly after unblinding in the open label period.","deathsNumAffected":0,"deathsNumAtRisk":1262,"seriousNumAffected":4,"seriousNumAtRisk":1262,"otherNumAffected":159,"otherNumAtRisk":1262},{"id":"EG033","title":"OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D1-D2)","description":"Participants aged 5 to \\<12 years who received placebo in blinded placebo-controlled follow-up period received 2 doses of 10 mcg BNT162b2 intramuscularly after unblinding in the open label period.","deathsNumAffected":0,"deathsNumAtRisk":243,"seriousNumAffected":2,"seriousNumAtRisk":243,"otherNumAffected":52,"otherNumAtRisk":243},{"id":"EG034","title":"OL: Phase 2/3: BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)","description":"Participants aged 5 to \\<12 years who received placebo in blinded placebo-controlled follow-up period received third dose of 10 mcg BNT162b2 intramuscularly after unblinding in the open label period.","deathsNumAffected":0,"deathsNumAtRisk":957,"seriousNumAffected":3,"seriousNumAtRisk":957,"otherNumAffected":75,"otherNumAtRisk":957},{"id":"EG035","title":"OL: Phase 2/3: BNT162b2 (30 mcg): 5 to <12 Years of Age (D3)","description":"Participants aged 5 to \\<12 years who received placebo in blinded placebo-controlled follow-up period received third dose of 30 mcg BNT162b2 intramuscularly after unblinding in the open label period.","deathsNumAffected":0,"deathsNumAtRisk":91,"seriousNumAffected":2,"seriousNumAtRisk":91,"otherNumAffected":0,"otherNumAtRisk":91},{"id":"EG036","title":"OL: Phase 2/3: Troponin Group:BNT162b2 (10 mcg): 5 to <12 Years of Age (D3)","description":"Participants aged 5 to \\<12 years who received placebo in blinded placebo-controlled follow-up period received third dose of 10 mcg BNT162b2 intramuscularly after unblinding in the open label period.","deathsNumAffected":0,"deathsNumAtRisk":202,"seriousNumAffected":0,"seriousNumAtRisk":202,"otherNumAffected":20,"otherNumAtRisk":202},{"id":"EG037","title":"OL: Phase 2/3: Troponin Group:BNT162b2 (30 mcg): 5 to <12 Years of Age (D3)","description":"Participants aged 5 to \\<12 years who received placebo in blinded placebo-controlled follow-up period received third dose of 30 mcg BNT162b2 intramuscularly after unblinding in the open label period.","deathsNumAffected":0,"deathsNumAtRisk":9,"seriousNumAffected":0,"seriousNumAtRisk":9,"otherNumAffected":0,"otherNumAtRisk":9},{"id":"EG038","title":"OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D3)","description":"Participants aged 2 to \\<5 years who received placebo in blinded placebo-controlled follow-up period, received third dose of 10 mcg BNT162b2 intramuscularly after unblinding in the open-label period.","deathsNumAffected":0,"deathsNumAtRisk":113,"seriousNumAffected":0,"seriousNumAtRisk":113,"otherNumAffected":3,"otherNumAtRisk":113},{"id":"EG039","title":"OL: Phase 2/3: BNT162b2 (10 mcg/30 mcg): 5 to <12 Years of Age (D3)","description":"Participants aged 5 to \\<12 years who received dose 1 and 2 of BNT162b2 10 mcg in the blinded placebo controlled follow-up period received third dose of 30 mcg BNT162b2 intramuscularly approximately 175 days after vaccination 2 in open-label period.","deathsNumAffected":0,"deathsNumAtRisk":145,"seriousNumAffected":2,"seriousNumAtRisk":145,"otherNumAffected":17,"otherNumAtRisk":145},{"id":"EG040","title":"BP: Phase 2/3: BNT162b2 (3 mcg/10 mcg): 2 to <5 Years of Age (D3)","description":"Participants aged 2 to \\<5 years who received dose 1 and dose 2 of BNT162b2 3 mcg received third dose of 10 mcg BNT162b2 intramuscularly approximately 60 days after vaccination 2 in blinded placebo-controlled follow-up period.","deathsNumAffected":0,"deathsNumAtRisk":204,"seriousNumAffected":1,"seriousNumAtRisk":204,"otherNumAffected":13,"otherNumAtRisk":204},{"id":"EG041","title":"OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D1-D2)","description":"Participants aged 2 years to \\<5 years who received placebo in blinded placebo controlled follow-up period received up to 2 doses (dose 1 and dose 2) of 10 mcg BNT162b2 intramuscularly after unblinding in the OL period.","deathsNumAffected":0,"deathsNumAtRisk":81,"seriousNumAffected":0,"seriousNumAtRisk":81,"otherNumAffected":10,"otherNumAtRisk":81},{"id":"EG042","title":"OL: Phase 2/3: BNT162b2 (10 mcg): 2 to <5 Years of Age (D2)","description":"Participants aged 2 years to \\<5 years who received placebo in blinded placebo controlled follow-up period and first dose of 3 mcg BNT162b2 intramuscularly after unblinding in the OL period received second dose of 10 mcg BNT162b2 intramuscularly in the OL period.","deathsNumAffected":0,"deathsNumAtRisk":13,"seriousNumAffected":0,"seriousNumAtRisk":13,"otherNumAffected":0,"otherNumAtRisk":13}],"seriousEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":1,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Sickle cell anaemia with crisis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":1,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":1,"numAtRisk":2368},{"groupId":"EG017","numAffected":1,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":1,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Febrile convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":1,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":1,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Narcolepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":1,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":1,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":1,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":1,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":1,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Status epilepticus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":1,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":1,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":1,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":1,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Papilloedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":1,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numEvents":0,"numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":1,"numAtRisk":2410},{"groupId":"EG023","numAffected":1,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":1,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Bronchial hyperreactivity","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":1,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pneumomediastinum","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Respiratory arrest","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":1,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":1,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":1,"numAtRisk":1538},{"groupId":"EG022","numAffected":1,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Colitis ulcerative","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":1,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":1,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":1,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":1,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Dermal cyst","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":1,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":1,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":2,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Feeding intolerance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Abdominal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":1,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Acute sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":1,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":2,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":1,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":1,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Arthritis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":1,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":3,"numAtRisk":1458},{"groupId":"EG013","numAffected":3,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":1,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":1,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Complicated appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":1,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Enterovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Exanthema subitum","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Focal peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":1,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":3,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":1,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":1,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Gastroenteritis adenovirus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":1,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Gastroenteritis norovirus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Gastroenteritis rotavirus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":1,"numAtRisk":2368},{"groupId":"EG017","numAffected":1,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":2,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":1,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":1,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"HCoV-NL63 infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Large intestine infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":1,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Lower respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":1,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Metapneumovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":1,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":1,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Otitis media acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Parainfluenzae virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":2,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":1,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":1,"numAtRisk":534},{"groupId":"EG030","numAffected":1,"numAtRisk":706},{"groupId":"EG031","numAffected":1,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pneumonia respiratory syncytial viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":1,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Respiratory syncytial virus bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":5,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":1,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":2,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Respiratory syncytial virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":1,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Rhinovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":1,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":1,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Burns second degree","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Epiphyseal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":1,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Eyelid injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":1,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":1,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":1,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Foreign body","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":1,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Foreign body ingestion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":1,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":1,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Cyanosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":2,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":1,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":1,"numAtRisk":581},{"groupId":"EG029","numAffected":1,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":1,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":1,"numAtRisk":1458},{"groupId":"EG013","numAffected":1,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":1,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":1,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Testicular appendage torsion","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":1,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Disruptive mood dysregulation disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":1,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Irritability (IRRITABILITY)","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":1,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Adenovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":1,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pneumonia influenzal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":1,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Lacrimal structure injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":1,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Bacterial disease carrier","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":1,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Scarlet fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":1,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Cerebral venous sinus thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":1,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Adenoidal hypertrophy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":1,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":1,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":1,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":1,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Phimosis","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":1,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":1,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Lower limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":1,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":1,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Balanoposthitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":1,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":1,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":1,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Conversion disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":1,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Addison's disease","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":1,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":1,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]}],"otherEvents":[{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":1,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":1,"numAtRisk":16},{"groupId":"EG008","numAffected":1,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":40,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":4,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":1,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":25,"numAtRisk":1262},{"groupId":"EG033","numAffected":8,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":2,"numAtRisk":145},{"groupId":"EG040","numAffected":1,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Headache (HEADACHE)","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":16},{"groupId":"EG003","numAffected":8,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":27},{"groupId":"EG006","numAffected":10,"numAtRisk":16},{"groupId":"EG007","numAffected":11,"numAtRisk":16},{"groupId":"EG008","numAffected":3,"numAtRisk":4},{"groupId":"EG009","numAffected":6,"numAtRisk":12},{"groupId":"EG010","numAffected":13,"numAtRisk":38},{"groupId":"EG011","numAffected":1,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":191,"numAtRisk":2368},{"groupId":"EG017","numAffected":86,"numAtRisk":1173},{"groupId":"EG018","numAffected":36,"numAtRisk":1889},{"groupId":"EG019","numAffected":15,"numAtRisk":405},{"groupId":"EG020","numAffected":1193,"numAtRisk":3109},{"groupId":"EG021","numAffected":506,"numAtRisk":1538},{"groupId":"EG022","numAffected":610,"numAtRisk":2410},{"groupId":"EG023","numAffected":163,"numAtRisk":518},{"groupId":"EG024","numAffected":77,"numAtRisk":260},{"groupId":"EG025","numAffected":93,"numAtRisk":418},{"groupId":"EG026","numAffected":228,"numAtRisk":487},{"groupId":"EG027","numAffected":143,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":1,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Somnolence (DROWSINESS)","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":560,"numAtRisk":1458},{"groupId":"EG013","numAffected":274,"numAtRisk":718},{"groupId":"EG014","numAffected":98,"numAtRisk":1324},{"groupId":"EG015","numAffected":27,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Speech disorder developmental","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":15,"numAtRisk":1458},{"groupId":"EG013","numAffected":5,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":22,"numAtRisk":2368},{"groupId":"EG017","numAffected":14,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":5,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":1,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":20,"numAtRisk":1458},{"groupId":"EG013","numAffected":5,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":3,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":1,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":1,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":2,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":1,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Diarrhea (DIARRHEA)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":16},{"groupId":"EG003","numAffected":5,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":27},{"groupId":"EG006","numAffected":1,"numAtRisk":16},{"groupId":"EG007","numAffected":1,"numAtRisk":16},{"groupId":"EG008","numAffected":2,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":305,"numAtRisk":2368},{"groupId":"EG017","numAffected":160,"numAtRisk":1173},{"groupId":"EG018","numAffected":39,"numAtRisk":1889},{"groupId":"EG019","numAffected":21,"numAtRisk":405},{"groupId":"EG020","numAffected":320,"numAtRisk":3109},{"groupId":"EG021","numAffected":138,"numAtRisk":1538},{"groupId":"EG022","numAffected":104,"numAtRisk":2410},{"groupId":"EG023","numAffected":40,"numAtRisk":518},{"groupId":"EG024","numAffected":26,"numAtRisk":260},{"groupId":"EG025","numAffected":19,"numAtRisk":418},{"groupId":"EG026","numAffected":66,"numAtRisk":487},{"groupId":"EG027","numAffected":18,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":31,"numAtRisk":1458},{"groupId":"EG013","numAffected":17,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":22,"numAtRisk":2368},{"groupId":"EG017","numAffected":13,"numAtRisk":1173},{"groupId":"EG018","numAffected":1,"numAtRisk":1889},{"groupId":"EG019","numAffected":5,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":1,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Teething","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":18,"numAtRisk":1458},{"groupId":"EG013","numAffected":7,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":2,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":27,"numAtRisk":1458},{"groupId":"EG013","numAffected":15,"numAtRisk":718},{"groupId":"EG014","numAffected":6,"numAtRisk":1324},{"groupId":"EG015","numAffected":7,"numAtRisk":237},{"groupId":"EG016","numAffected":41,"numAtRisk":2368},{"groupId":"EG017","numAffected":13,"numAtRisk":1173},{"groupId":"EG018","numAffected":2,"numAtRisk":1889},{"groupId":"EG019","numAffected":7,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":12,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":8,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":30,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":1,"numAtRisk":145},{"groupId":"EG040","numAffected":3,"numAtRisk":204},{"groupId":"EG041","numAffected":4,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Vomiting (VOMITING)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":16},{"groupId":"EG003","numAffected":2,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":1,"numAtRisk":16},{"groupId":"EG008","numAffected":1,"numAtRisk":4},{"groupId":"EG009","numAffected":2,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":144,"numAtRisk":2368},{"groupId":"EG017","numAffected":68,"numAtRisk":1173},{"groupId":"EG018","numAffected":16,"numAtRisk":1889},{"groupId":"EG019","numAffected":16,"numAtRisk":405},{"groupId":"EG020","numAffected":122,"numAtRisk":3109},{"groupId":"EG021","numAffected":55,"numAtRisk":1538},{"groupId":"EG022","numAffected":61,"numAtRisk":2410},{"groupId":"EG023","numAffected":13,"numAtRisk":518},{"groupId":"EG024","numAffected":8,"numAtRisk":260},{"groupId":"EG025","numAffected":7,"numAtRisk":418},{"groupId":"EG026","numAffected":22,"numAtRisk":487},{"groupId":"EG027","numAffected":11,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Dermatitis diaper","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":1,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":1,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":1,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":1,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":1,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":1,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":1,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":1,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Arthralgia (JOINT PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":16},{"groupId":"EG003","numAffected":1,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":1,"numAtRisk":16},{"groupId":"EG007","numAffected":1,"numAtRisk":16},{"groupId":"EG008","numAffected":1,"numAtRisk":4},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":53,"numAtRisk":2368},{"groupId":"EG017","numAffected":30,"numAtRisk":1173},{"groupId":"EG018","numAffected":9,"numAtRisk":1889},{"groupId":"EG019","numAffected":4,"numAtRisk":405},{"groupId":"EG020","numAffected":235,"numAtRisk":3109},{"groupId":"EG021","numAffected":110,"numAtRisk":1538},{"groupId":"EG022","numAffected":129,"numAtRisk":2410},{"groupId":"EG023","numAffected":35,"numAtRisk":518},{"groupId":"EG024","numAffected":22,"numAtRisk":260},{"groupId":"EG025","numAffected":23,"numAtRisk":418},{"groupId":"EG026","numAffected":69,"numAtRisk":487},{"groupId":"EG027","numAffected":26,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Costochondritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":1,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":1,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":3,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Myalgia (MUSCLE PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":4,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":2,"numAtRisk":16},{"groupId":"EG007","numAffected":5,"numAtRisk":16},{"groupId":"EG008","numAffected":4,"numAtRisk":4},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":3,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":106,"numAtRisk":2368},{"groupId":"EG017","numAffected":50,"numAtRisk":1173},{"groupId":"EG018","numAffected":15,"numAtRisk":1889},{"groupId":"EG019","numAffected":6,"numAtRisk":405},{"groupId":"EG020","numAffected":561,"numAtRisk":3109},{"groupId":"EG021","numAffected":192,"numAtRisk":1538},{"groupId":"EG022","numAffected":350,"numAtRisk":2410},{"groupId":"EG023","numAffected":81,"numAtRisk":518},{"groupId":"EG024","numAffected":31,"numAtRisk":260},{"groupId":"EG025","numAffected":73,"numAtRisk":418},{"groupId":"EG026","numAffected":167,"numAtRisk":487},{"groupId":"EG027","numAffected":76,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":1,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Decreased appetite (DECREASED APPETITE)","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":511,"numAtRisk":1458},{"groupId":"EG013","numAffected":236,"numAtRisk":718},{"groupId":"EG014","numAffected":89,"numAtRisk":1324},{"groupId":"EG015","numAffected":29,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":8,"numAtRisk":418},{"groupId":"EG026","numAffected":6,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":4,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numEvents":0,"numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":10,"numAtRisk":1458},{"groupId":"EG013","numAffected":8,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":7,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":1,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Enterobiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":2,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Hand-foot-and-mouth disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":16,"numAtRisk":1458},{"groupId":"EG013","numAffected":11,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":4,"numAtRisk":1324},{"groupId":"EG015","numAffected":4,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":8,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Periorbital cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":14,"numAtRisk":2368},{"groupId":"EG017","numAffected":12,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":1,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":4,"numAtRisk":518},{"groupId":"EG024","numAffected":3,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Animal bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Arthropod bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":16},{"groupId":"EG003","numAffected":1,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":1,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Foreign body ingestion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":1,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":1,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Axillary pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":5,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Chills (CHILLS)","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":16},{"groupId":"EG003","numAffected":3,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":5,"numAtRisk":16},{"groupId":"EG007","numAffected":7,"numAtRisk":16},{"groupId":"EG008","numAffected":3,"numAtRisk":4},{"groupId":"EG009","numAffected":5,"numAtRisk":12},{"groupId":"EG010","numAffected":6,"numAtRisk":38},{"groupId":"EG011","numAffected":1,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":125,"numAtRisk":2368},{"groupId":"EG017","numAffected":59,"numAtRisk":1173},{"groupId":"EG018","numAffected":22,"numAtRisk":1889},{"groupId":"EG019","numAffected":10,"numAtRisk":405},{"groupId":"EG020","numAffected":413,"numAtRisk":3109},{"groupId":"EG021","numAffected":129,"numAtRisk":1538},{"groupId":"EG022","numAffected":231,"numAtRisk":2410},{"groupId":"EG023","numAffected":50,"numAtRisk":518},{"groupId":"EG024","numAffected":31,"numAtRisk":260},{"groupId":"EG025","numAffected":35,"numAtRisk":418},{"groupId":"EG026","numAffected":88,"numAtRisk":487},{"groupId":"EG027","numAffected":52,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":38},{"groupId":"EG011","numAffected":1,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":14,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":40,"numAtRisk":1262},{"groupId":"EG033","numAffected":19,"numAtRisk":243},{"groupId":"EG034","numAffected":16,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":3,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":1,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":1,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Fatigue (FATIGUE)","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":5,"numAtRisk":16},{"groupId":"EG003","numAffected":23,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":8,"numAtRisk":27},{"groupId":"EG006","numAffected":14,"numAtRisk":16},{"groupId":"EG007","numAffected":13,"numAtRisk":16},{"groupId":"EG008","numAffected":4,"numAtRisk":4},{"groupId":"EG009","numAffected":10,"numAtRisk":12},{"groupId":"EG010","numAffected":15,"numAtRisk":38},{"groupId":"EG011","numAffected":1,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":977,"numAtRisk":2368},{"groupId":"EG017","numAffected":487,"numAtRisk":1173},{"groupId":"EG018","numAffected":202,"numAtRisk":1889},{"groupId":"EG019","numAffected":91,"numAtRisk":405},{"groupId":"EG020","numAffected":1614,"numAtRisk":3109},{"groupId":"EG021","numAffected":641,"numAtRisk":1538},{"groupId":"EG022","numAffected":897,"numAtRisk":2410},{"groupId":"EG023","numAffected":221,"numAtRisk":518},{"groupId":"EG024","numAffected":105,"numAtRisk":260},{"groupId":"EG025","numAffected":153,"numAtRisk":418},{"groupId":"EG026","numAffected":255,"numAtRisk":487},{"groupId":"EG027","numAffected":149,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Injection site bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":1,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Injection site discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":1,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":3,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":2,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":1,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Injection site erythema (REDNESS)","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":16},{"groupId":"EG001","numAffected":2,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":9,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":1,"numAtRisk":27},{"groupId":"EG006","numAffected":8,"numAtRisk":16},{"groupId":"EG007","numAffected":3,"numAtRisk":16},{"groupId":"EG008","numAffected":4,"numAtRisk":4},{"groupId":"EG009","numAffected":3,"numAtRisk":12},{"groupId":"EG010","numAffected":11,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":237,"numAtRisk":1458},{"groupId":"EG013","numAffected":83,"numAtRisk":718},{"groupId":"EG014","numAffected":33,"numAtRisk":1324},{"groupId":"EG015","numAffected":11,"numAtRisk":237},{"groupId":"EG016","numAffected":379,"numAtRisk":2368},{"groupId":"EG017","numAffected":136,"numAtRisk":1173},{"groupId":"EG018","numAffected":83,"numAtRisk":1889},{"groupId":"EG019","numAffected":18,"numAtRisk":405},{"groupId":"EG020","numAffected":806,"numAtRisk":3109},{"groupId":"EG021","numAffected":148,"numAtRisk":1538},{"groupId":"EG022","numAffected":354,"numAtRisk":2410},{"groupId":"EG023","numAffected":92,"numAtRisk":518},{"groupId":"EG024","numAffected":17,"numAtRisk":260},{"groupId":"EG025","numAffected":67,"numAtRisk":418},{"groupId":"EG026","numAffected":12,"numAtRisk":487},{"groupId":"EG027","numAffected":14,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":2,"numAtRisk":16},{"groupId":"EG003","numAffected":3,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":1,"numAtRisk":16},{"groupId":"EG007","numAffected":1,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":2,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":38},{"groupId":"EG011","numAffected":1,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":34,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":7,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":10,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":126,"numAtRisk":1262},{"groupId":"EG033","numAffected":37,"numAtRisk":243},{"groupId":"EG034","numAffected":60,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":17,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":3,"numAtRisk":113},{"groupId":"EG039","numAffected":2,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":3,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Injection site pain (PAIN)","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":7,"numAtRisk":16},{"groupId":"EG003","numAffected":21,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":9,"numAtRisk":27},{"groupId":"EG006","numAffected":14,"numAtRisk":16},{"groupId":"EG007","numAffected":15,"numAtRisk":16},{"groupId":"EG008","numAffected":4,"numAtRisk":4},{"groupId":"EG009","numAffected":11,"numAtRisk":12},{"groupId":"EG010","numAffected":33,"numAtRisk":38},{"groupId":"EG011","numAffected":1,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":998,"numAtRisk":2368},{"groupId":"EG017","numAffected":357,"numAtRisk":1173},{"groupId":"EG018","numAffected":222,"numAtRisk":1889},{"groupId":"EG019","numAffected":48,"numAtRisk":405},{"groupId":"EG020","numAffected":2603,"numAtRisk":3109},{"groupId":"EG021","numAffected":661,"numAtRisk":1538},{"groupId":"EG022","numAffected":1568,"numAtRisk":2410},{"groupId":"EG023","numAffected":397,"numAtRisk":518},{"groupId":"EG024","numAffected":79,"numAtRisk":260},{"groupId":"EG025","numAffected":273,"numAtRisk":418},{"groupId":"EG026","numAffected":384,"numAtRisk":487},{"groupId":"EG027","numAffected":257,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Injection site pain (TENDERNESS)","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":4,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":353,"numAtRisk":1458},{"groupId":"EG013","numAffected":126,"numAtRisk":718},{"groupId":"EG014","numAffected":67,"numAtRisk":1324},{"groupId":"EG015","numAffected":22,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Injection site swelling (SWELLING)","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":4,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":8,"numAtRisk":16},{"groupId":"EG007","numAffected":3,"numAtRisk":16},{"groupId":"EG008","numAffected":3,"numAtRisk":4},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":5,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":94,"numAtRisk":1458},{"groupId":"EG013","numAffected":26,"numAtRisk":718},{"groupId":"EG014","numAffected":15,"numAtRisk":1324},{"groupId":"EG015","numAffected":5,"numAtRisk":237},{"groupId":"EG016","numAffected":182,"numAtRisk":2368},{"groupId":"EG017","numAffected":53,"numAtRisk":1173},{"groupId":"EG018","numAffected":25,"numAtRisk":1889},{"groupId":"EG019","numAffected":6,"numAtRisk":405},{"groupId":"EG020","numAffected":622,"numAtRisk":3109},{"groupId":"EG021","numAffected":78,"numAtRisk":1538},{"groupId":"EG022","numAffected":286,"numAtRisk":2410},{"groupId":"EG023","numAffected":69,"numAtRisk":518},{"groupId":"EG024","numAffected":14,"numAtRisk":260},{"groupId":"EG025","numAffected":50,"numAtRisk":418},{"groupId":"EG026","numAffected":27,"numAtRisk":487},{"groupId":"EG027","numAffected":12,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":1,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":1,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":43,"numAtRisk":1458},{"groupId":"EG013","numAffected":14,"numAtRisk":718},{"groupId":"EG014","numAffected":12,"numAtRisk":1324},{"groupId":"EG015","numAffected":2,"numAtRisk":237},{"groupId":"EG016","numAffected":37,"numAtRisk":2368},{"groupId":"EG017","numAffected":23,"numAtRisk":1173},{"groupId":"EG018","numAffected":11,"numAtRisk":1889},{"groupId":"EG019","numAffected":6,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":13,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":2,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":27,"numAtRisk":581},{"groupId":"EG029","numAffected":6,"numAtRisk":534},{"groupId":"EG030","numAffected":15,"numAtRisk":706},{"groupId":"EG031","numAffected":8,"numAtRisk":581},{"groupId":"EG032","numAffected":21,"numAtRisk":1262},{"groupId":"EG033","numAffected":6,"numAtRisk":243},{"groupId":"EG034","numAffected":10,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":4,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":3,"numAtRisk":145},{"groupId":"EG040","numAffected":3,"numAtRisk":204},{"groupId":"EG041","numAffected":2,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pyrexia (FEVER)","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":16},{"groupId":"EG001","numAffected":1,"numAtRisk":15},{"groupId":"EG002","numAffected":1,"numAtRisk":16},{"groupId":"EG003","numAffected":9,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":3,"numAtRisk":16},{"groupId":"EG007","numAffected":4,"numAtRisk":16},{"groupId":"EG008","numAffected":4,"numAtRisk":4},{"groupId":"EG009","numAffected":4,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":184,"numAtRisk":1458},{"groupId":"EG013","numAffected":87,"numAtRisk":718},{"groupId":"EG014","numAffected":28,"numAtRisk":1324},{"groupId":"EG015","numAffected":13,"numAtRisk":237},{"groupId":"EG016","numAffected":224,"numAtRisk":2368},{"groupId":"EG017","numAffected":121,"numAtRisk":1173},{"groupId":"EG018","numAffected":41,"numAtRisk":1889},{"groupId":"EG019","numAffected":21,"numAtRisk":405},{"groupId":"EG020","numAffected":243,"numAtRisk":3109},{"groupId":"EG021","numAffected":40,"numAtRisk":1538},{"groupId":"EG022","numAffected":154,"numAtRisk":2410},{"groupId":"EG023","numAffected":16,"numAtRisk":518},{"groupId":"EG024","numAffected":8,"numAtRisk":260},{"groupId":"EG025","numAffected":18,"numAtRisk":418},{"groupId":"EG026","numAffected":33,"numAtRisk":487},{"groupId":"EG027","numAffected":14,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Menarche","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":1,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":1,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":1,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":1,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":15,"numAtRisk":1458},{"groupId":"EG013","numAffected":6,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Irritability (IRRITABILITY)","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":16},{"groupId":"EG001","numAffected":4,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":932,"numAtRisk":1458},{"groupId":"EG013","numAffected":431,"numAtRisk":718},{"groupId":"EG014","numAffected":191,"numAtRisk":1324},{"groupId":"EG015","numAffected":82,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":3,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Lymph node pain","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":1,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":1,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Lip injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":1,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":1,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":1,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":2,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Hand-foot-and-mouth disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":2,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":0,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Vaccination site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":1,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Vaccination site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":1,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Febrile convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":1,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":16},{"groupId":"EG001","numAffected":0,"numAtRisk":15},{"groupId":"EG002","numAffected":0,"numAtRisk":16},{"groupId":"EG003","numAffected":0,"numAtRisk":32},{"groupId":"EG004","numAffected":0,"numAtRisk":13},{"groupId":"EG005","numAffected":0,"numAtRisk":27},{"groupId":"EG006","numAffected":0,"numAtRisk":16},{"groupId":"EG007","numAffected":0,"numAtRisk":16},{"groupId":"EG008","numAffected":0,"numAtRisk":4},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":38},{"groupId":"EG011","numAffected":0,"numAtRisk":2},{"groupId":"EG012","numAffected":0,"numAtRisk":1458},{"groupId":"EG013","numAffected":0,"numAtRisk":718},{"groupId":"EG014","numAffected":0,"numAtRisk":1324},{"groupId":"EG015","numAffected":0,"numAtRisk":237},{"groupId":"EG016","numAffected":0,"numAtRisk":2368},{"groupId":"EG017","numAffected":0,"numAtRisk":1173},{"groupId":"EG018","numAffected":0,"numAtRisk":1889},{"groupId":"EG019","numAffected":0,"numAtRisk":405},{"groupId":"EG020","numAffected":0,"numAtRisk":3109},{"groupId":"EG021","numAffected":0,"numAtRisk":1538},{"groupId":"EG022","numAffected":0,"numAtRisk":2410},{"groupId":"EG023","numAffected":0,"numAtRisk":518},{"groupId":"EG024","numAffected":0,"numAtRisk":260},{"groupId":"EG025","numAffected":0,"numAtRisk":418},{"groupId":"EG026","numAffected":0,"numAtRisk":487},{"groupId":"EG027","numAffected":0,"numAtRisk":433},{"groupId":"EG028","numAffected":0,"numAtRisk":581},{"groupId":"EG029","numAffected":0,"numAtRisk":534},{"groupId":"EG030","numAffected":0,"numAtRisk":706},{"groupId":"EG031","numAffected":0,"numAtRisk":581},{"groupId":"EG032","numAffected":0,"numAtRisk":1262},{"groupId":"EG033","numAffected":0,"numAtRisk":243},{"groupId":"EG034","numAffected":0,"numAtRisk":957},{"groupId":"EG035","numAffected":0,"numAtRisk":91},{"groupId":"EG036","numAffected":0,"numAtRisk":202},{"groupId":"EG037","numAffected":0,"numAtRisk":9},{"groupId":"EG038","numAffected":0,"numAtRisk":113},{"groupId":"EG039","numAffected":0,"numAtRisk":145},{"groupId":"EG040","numAffected":0,"numAtRisk":204},{"groupId":"EG041","numAffected":1,"numAtRisk":81},{"groupId":"EG042","numAffected":0,"numAtRisk":13}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Sponsor (or its agents) has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"BioNTech clinical trials patient information","organization":"BioNTech SE","email":"patients@biontech.de","phone":"+49 6131 90840"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-04-28","uploadDate":"2024-10-02T10:42","filename":"Prot_000.pdf","size":1829428},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-07-11","uploadDate":"2024-10-02T10:43","filename":"SAP_001.pdf","size":556136}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-10-28","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D000086382","term":"COVID-19"}],"ancestors":[{"id":"D011024","term":"Pneumonia, Viral"},{"id":"D011014","term":"Pneumonia"},{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018352","term":"Coronavirus Infections"},{"id":"D003333","term":"Coronaviridae Infections"},{"id":"D030341","term":"Nidovirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D001688","term":"Biological Products"},{"id":"D000090982","term":"BNT162 Vaccine"}],"ancestors":[{"id":"D045424","term":"Complex Mixtures"},{"id":"D000087503","term":"mRNA Vaccines"},{"id":"D000087504","term":"Nucleic Acid-Based Vaccines"},{"id":"D014614","term":"Vaccines, Synthetic"},{"id":"D011994","term":"Recombinant Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014612","term":"Vaccines"},{"id":"D000086663","term":"COVID-19 Vaccines"},{"id":"D014765","term":"Viral Vaccines"},{"id":"D000941","term":"Antigens"},{"id":"D001685","term":"Biological Factors"}]}},"hasResults":true}